advanc
molecular
cytogenet
see
chapter
section
includ
arraycompar
genom
hybrid
chromosom
paint
current
appli
investig
chromosom
aberr
dog
lymphoma
public
canin
genom
commerci
avail
canin
gene
microarray
genechip
canin
genom
array
affymetrix
inc
led
advanc
understand
deregul
gene
express
occur
lymphoma
gain
canin
chromosom
loss
chromosom
document
common
aberr
group
case
analyz
chromosom
aberr
also
associ
prognosi
dog
lymphoma
studi
dog
lymphoma
demonstr
prognost
advantag
dog
trisomi
chromosom
dog
studi
evidenc
increas
durat
first
remiss
overal
surviv
time
st
germlin
somat
genet
mutat
alter
oncogenetumor
suppressor
gene
express
epigenet
chang
eg
dna
hypomethyl
signal
transduct
deathpathway
alter
eg
famili
common
human
lymphoma
report
dog
well
see
chapter
section
chapter
section
b
includ
nra
rb
cyclindepend
kinas
telomeras
among
other
somat
mutat
determin
exom
sequenc
shown
much
overlap
canin
breed
respect
bcell
lymphoma
specif
mutat
littl
overlap
somat
mutat
among
breed
tcell
lymphoma
addit
differ
preval
immunophenotyp
subtyp
lymphoma
among
differ
breed
indic
herit
risk
telomeras
activ
see
chapter
also
document
canin
lymphoma
tissu
somat
mutat
often
implic
surpris
alter
defici
dna
repair
mechan
would
also
implic
demonstr
golden
retriev
lymphoma
hypothesi
retroviru
may
involv
pathogenesi
canin
lymphoma
confirm
epsteinbarr
viru
gammaherpesviru
link
form
lymphoma
human
also
investig
canin
lymphoma
howev
associ
serolog
molecular
detect
gammaherpesviru
develop
lymphoma
human
direct
associ
helicobact
sp
infect
develop
gastric
lymphoma
made
although
definit
shown
dog
evid
helicobact
sp
infect
laboratori
beagl
dog
result
gastric
lymphoid
follicl
format
consid
precursor
mucosaassoci
lymphoid
tissu
malt
lymphoma
human
alter
gut
microbiom
implic
play
role
suscept
certain
tumor
fecal
microbiota
dog
lymphoma
shown
significantli
differ
control
dog
although
causeeffect
relationship
unclear
human
evid
accumul
implic
phenoxyacet
acid
herbicid
particular
acid
develop
nhl
epidemiolog
evid
also
implic
lawn
herbicid
use
occurr
lymphoma
incid
dog
one
casecontrol
studi
risk
canin
lymphoma
report
rise
twofold
odd
ratio
four
yearli
owner
applic
result
studi
come
critic
three
addit
followup
investig
valid
increas
risk
anoth
studi
dog
expos
lawn
treatment
within
day
applic
greater
time
like
urinari
level
higher
environment
casecontrol
studi
perform
europ
two
variabl
resid
industri
area
use
chemic
defin
paint
solvent
owner
modestli
increas
risk
develop
lymphoma
howev
link
found
pesticid
use
recent
epidemiolog
studi
investig
multipl
environment
factor
show
increas
risk
canin
lymphoma
use
lawn
care
product
particular
profession
appli
pesticid
studi
find
associ
flea
tick
control
product
weak
associ
lymphoma
dog
exposur
strong
magnet
field
observ
preliminari
epidemiolog
studi
hospitalbas
casecontrol
studi
risk
develop
lymphoma
high
high
exposur
increas
thorough
studi
necessari
evalu
associ
proxim
environment
wast
implic
two
european
studi
howev
felt
risk
indic
rather
risk
factor
would
requir
casecontrol
investig
exposur
tobacco
smoke
also
implic
one
studi
impair
immun
function
also
implic
dog
lymphoma
immun
system
alter
immunemedi
thrombocytopenia
independ
age
sex
associ
higher
risk
subsequ
develop
lymphoma
compar
normal
popul
addit
evid
come
observ
human
felin
transplant
patient
casecontrol
studi
cat
undergo
renal
transplant
case
develop
cancer
lymphoma
cyclosporin
immunosuppress
therapi
compar
control
cat
none
develop
lymphoma
p
case
lymphoma
develop
dog
treatment
cyclosporin
also
exist
one
report
suggest
associ
immunodysregul
observ
dog
atop
dermat
risk
develop
epitheliotrop
tcell
lymphoma
whether
lymphoma
associ
primari
diseas
immunomodulatori
treatment
commonli
appli
unknown
classif
malign
lymphoma
dog
base
anatom
locat
histolog
criteria
immunophenotyp
characterist
common
anatom
form
lymphoma
order
decreas
preval
multicentr
gastrointestin
gi
mediastin
cutan
form
primari
extranod
form
occur
locat
outsid
lymphat
system
includ
eye
skin
central
nervou
system
cn
bone
marrow
bladder
heart
nasal
caviti
patholog
characterist
variou
anatom
classif
discuss
section
clinic
characterist
describ
subsequ
section
dog
lymphoma
present
multicentr
form
usual
character
presenc
peripher
lymphadenopathi
fig
alimentari
form
lymphoma
much
less
common
account
canin
lymphoma
primari
gi
lymphoma
dog
may
occur
focal
often
affect
multipl
segment
thicken
wall
narrow
lumen
frequent
mucos
ulcer
histolog
infiltr
neoplast
lymphocyt
throughout
mucosa
submucosa
occasion
transmur
infiltr
liver
local
ln
often
secondarili
involv
lymphocyticplasmacyt
inflammatori
bowel
diseas
lpibd
seen
adjac
distant
primari
tumor
patholog
neoplasm
may
resembl
plasma
cell
tumor
aberr
product
immunoglobulin
may
occur
histolog
distinguish
gi
lymphoma
lpibd
difficult
suggest
lpibd
may
prelymphomat
chang
gi
tract
syndrom
immunoprolif
intestin
diseas
character
lpibd
describ
basenji
subsequ
develop
gi
lymphoma
addit
plasma
cellrich
area
heterogen
lymphomat
infiltr
may
resembl
lesion
lpibd
report
specif
identifi
immunophenotyp
lymphocyt
subpopul
gi
lymphoma
dog
histor
presum
like
origin
b
cell
howev
recent
evid
suggest
gi
lymphoma
dog
aris
cell
often
exhibit
epitheliotrop
boxer
sharpei
breed
may
overrepres
case
alimentari
lymphoma
mediastin
form
diseas
occur
approxim
case
form
character
enlarg
lymphoma
catchal
term
approxim
two
dozen
lymphocyt
cancer
subtyp
tabl
intermedi
high
grade
indol
form
exist
dog
lymphoma
commonli
peripher
lymphadenopathi
although
vari
anatom
locat
affect
box
nodal
diseas
needl
aspir
cytolog
good
first
screen
step
ancillari
diagnost
requir
subtyp
prognosi
confirm
diagnosi
equivoc
case
fig
mani
treatment
protocol
exist
involv
chopbas
combin
chemotherapi
tabl
initi
gratifi
treat
respons
rate
high
often
durabl
month
howev
cure
rare
ultim
uniformli
fatal
diseas
dog
indol
subtyp
may
live
year
often
without
therapeut
intervent
veterinari
oncolog
specialist
consult
individu
case
clinic
diagnost
therapeut
landscap
chang
rapidli
cranial
mediastin
ln
thymu
fig
hypercalcemia
report
occur
dog
lymphoma
common
mediastin
form
studi
dog
lymphoma
hypercalcemia
mediastin
lymphoma
mediastin
form
dog
commonli
associ
tcell
phenotyp
singl
case
mediastin
lymphoma
larg
granular
lymphocyt
morpholog
report
cutan
lymphoma
solitari
gener
usual
classifi
epitheliotrop
mycosi
fungoid
nonepitheliotrop
canin
epitheliotrop
cutan
lymphoma
origin
cell
similar
case
human
dog
commonli
repres
cell
wherea
human
typic
cell
rare
form
cutan
tcell
lymphoma
character
skin
involv
evid
peripher
circul
larg
diamet
malign
cell
fold
groov
nuclei
describ
human
refer
syndrom
report
dog
cat
nonepitheliotrop
cutan
lymphoma
form
singl
multipl
dermal
subcutan
nodul
plaqu
histolog
spare
epidermi
papillari
dermi
affect
middl
deep
portion
dermi
subcuti
inflam
form
nonepitheliotrop
cutan
tcell
lymphoma
nectcl
pleocellular
difficult
differenti
reactiv
histiocytosi
hepatosplen
lymphoma
rel
uncommon
distinct
present
dog
mark
lack
signific
peripher
lymphadenopathi
face
hepat
splenic
bone
marrow
infiltr
malign
lymphocyt
usual
tcell
origin
biolog
form
lymphoma
extrem
aggress
poorli
respons
therapi
human
dog
tumor
usual
compos
cell
ie
cell
express
receptor
intravascular
angiotrop
angioendotheliomatosi
lymphoma
distinct
form
lymphoma
defin
prolifer
neoplast
lymphocyt
within
lumen
wall
blood
vessel
absenc
primari
extravascular
mass
leukemia
report
sever
time
veterinari
literatur
often
involv
cn
peripher
nervou
system
pn
includ
eye
bcell
immunophenotyp
common
human
howev
report
case
dog
origin
either
cell
null
cell
neither
b
cell
although
one
case
bcell
phenotyp
report
pulmonari
lymphomatoid
granulomatosi
plg
also
term
angiocentr
bcell
lymphoma
rare
neoplasm
lung
occasion
tissu
character
heterogen
accumul
lymphocyt
b
cell
neutrophil
plasma
cell
macrophag
often
arrang
angiocentr
clinic
sign
relat
respiratori
compromis
variou
chemotherapeut
protocol
use
report
result
vari
rapid
progress
longterm
clinic
remiss
lymphoma
aris
clonal
expans
lymphocyt
distinct
morpholog
immunophenotyp
featur
mani
histolog
system
use
classifi
nhl
human
appli
lymphoma
dog
speci
histolog
classif
lymphoma
current
follow
revis
european
american
lymphomaworld
health
organ
realwho
system
incorpor
anatom
morpholog
cytolog
histolog
immunophenotyp
criteria
band
tcell
immunophenotyp
goal
enabl
accur
reproduc
diagnosi
specif
neoplast
entiti
fig
repres
overal
histolog
approach
classif
variou
subtyp
dog
review
seelig
et
al
theoret
assist
better
tailor
treatment
protocol
better
correl
prognosi
subtyp
better
compar
capabl
larger
data
set
correl
outcom
gener
less
common
categori
realwho
system
repres
list
canin
lymphoma
fall
follow
categori
decreas
frequenc
diffus
larg
bcell
lymphoma
dlbcl
peripher
tcell
lymphoma
otherwis
specifi
ptclno
tzone
lymphoma
tzl
tlymphoblast
lymphoma
also
call
precursor
tcell
neoplasia
margin
zone
lymphoma
mzl
realwho
system
provid
accur
consist
reproduc
diagnost
result
similar
system
use
human
patholog
agreement
among
group
pathologist
examin
case
accuraci
evalu
six
common
diagnos
case
clear
lymphoma
singl
diseas
classif
subtyp
becom
increasingli
import
clinic
studi
perform
correl
variou
categori
diseas
biolog
behavior
respons
treatment
prognosi
preliminari
result
indic
dog
indol
lymphoma
eg
mzl
follicular
lymphoma
bor
tcell
small
cell
lymphoma
tcellrich
bcell
lymphoma
tzl
maintain
normal
activ
appetit
level
even
advanc
stage
diseas
experi
longterm
surviv
even
limit
therapi
classif
system
use
includ
nation
cancer
institut
work
formul
wf
updat
kiel
system
wf
develop
allow
investig
translat
among
numer
classif
system
clinic
trial
could
compar
human
larger
compil
agre
canin
lymphoma
intermedi
high
grade
wf
categor
tumor
accord
pattern
diffus
follicular
cell
type
eg
small
cleav
cell
larg
cell
immunoblast
includ
inform
immunophenotyp
tumor
wf
subtyp
relat
biolog
tumor
patient
surviv
updat
kiel
classif
includ
architectur
pattern
morpholog
centroblast
centrocyt
immunoblast
immunophenotyp
b
cell
tumor
cell
system
tumor
categor
lowgrad
intermediategrad
highgrad
malign
lowgrad
lymphoma
compos
small
cell
low
mitot
rate
typic
progress
slowli
associ
long
st
ultim
incur
highgrad
lymphoma
high
mitot
rate
progress
rapidli
like
respond
initi
chemotherapi
human
potenti
curabl
realwho
system
subtyp
lymphoma
classifi
distinct
diseas
base
characterist
includ
biolog
behavior
indol
versu
aggress
respons
treatment
sever
featur
canin
lymphoma
becom
appar
classif
system
appli
strike
differ
canin
human
lymphoma
scarciti
follicular
lymphoma
dog
common
form
canin
lymphoma
dlbcl
highgrad
tumor
small
percentag
canin
lymphoma
consid
lowgrad
document
differ
exist
preval
variou
immunophenotyp
base
breed
exampl
cocker
spaniel
doberman
pinscher
like
develop
bcell
lymphoma
boxer
like
tcell
lymphoma
golden
retriev
appear
equal
likelihood
band
tcell
tumor
clinic
use
classif
system
end
must
yield
inform
respons
therapi
mainten
remiss
surviv
studi
highgrad
lymphoma
achiev
complet
respons
cr
chemotherapi
significantli
often
lowgrad
tumor
howev
dog
lowgrad
tumor
may
live
year
without
aggress
chemotherapi
dog
tcell
lymphoma
shown
lower
rate
cr
chemotherapi
shorter
remiss
st
dog
bcell
tumor
except
lowgrad
tcell
subtyp
furthermor
tcell
lymphoma
commonli
associ
hypercalcemia
veterinari
literatur
canin
lymphoma
bcell
origin
tcell
lymphoma
account
mix
band
tcell
lymphoma
account
mani
nullcel
tumor
repres
fewer
develop
monoclon
antibodi
detect
specif
marker
canin
lymphocyt
made
immunophenotyp
tumor
dog
routin
avail
mani
commerci
laboratori
techniqu
perform
paraffinembed
sampl
tissu
microarray
cytolog
specimen
obtain
fineneedl
aspir
fna
lesion
flow
cytometr
analysi
cellular
fluid
sampl
eg
peripher
blood
effus
lesion
aspir
one
critic
kiel
wf
classif
system
fail
includ
extranod
lymphoma
separ
categori
realwho
system
includ
anatom
locat
factor
determin
certain
categori
although
differ
nodal
extranod
tumor
biolog
behavior
prognosi
well
recogn
compar
inform
histogenesi
tumor
lack
exampl
human
smallcel
lymphoma
aris
malt
compos
cell
differ
immunophenotyp
smallcel
lymphoma
ie
malt
lymphoma
typic
neg
except
cutan
lymphoid
neoplasm
detail
character
extranod
lymphoma
dog
done
although
cutan
lymphoma
heterogen
group
neoplasm
includ
epitheliotrop
form
resembl
mycosi
fungoid
nonepitheliotrop
form
cutan
lymphoma
tcell
phenotyp
summar
import
determin
histolog
grade
canin
lymphoma
low
small
lymphocyt
centrocyt
lymphoma
intermedi
high
diffus
larg
cell
centroblast
immunoblast
lymphoma
architectur
diffus
nodularfollicular
furthermor
determin
immunophenotyp
tumor
provid
use
inform
essenti
accur
subtyp
lymphoma
respons
rate
chemotherapi
gener
better
anim
bcell
tumor
intermediateto
highgrad
lymphoma
dog
lowgrad
indol
lymphoma
long
st
without
aggress
therapi
clinic
sign
associ
canin
lymphoma
variabl
depend
extent
locat
tumor
multicentr
lymphoma
common
form
usual
distinguish
presenc
gener
peripher
lymphadenopathi
see
fig
enlarg
ln
usual
painless
rubberi
discret
addit
hepatosplenomegali
bone
marrow
involv
associ
gener
lymphadenopathi
dog
multicentr
lymphoma
present
without
dramat
sign
system
ill
substag
box
howev
divers
nonspecif
sign
anorexia
weight
loss
vomit
diarrhea
emaci
ascit
dyspnea
polydipsia
polyuria
fever
occur
substag
b
dog
tcell
lymphoma
like
constitut
ie
substag
b
sign
veterinari
oncologist
consid
mildmoder
sever
clinic
sign
suffici
substag
b
design
polydipsia
polyuria
often
evid
dog
hypercalcemia
malign
dog
may
also
present
clinic
sign
relat
blood
dyscrasia
secondari
mark
tumor
infiltr
bone
marrow
myelophthisi
paraneoplast
anemia
thrombocytopenia
neutropenia
could
includ
fever
sepsi
anemia
hemorrhag
diffus
pulmonari
infiltr
detect
radiograph
chang
seen
dog
multicentr
form
fig
base
bronchoalveolar
lavag
actual
incid
lung
involv
may
higher
involv
limit
singl
node
lymphoid
tissu
singl
organ
b
ii
involv
mani
lymph
node
region
area
tonsil
iii
gener
lymph
node
involv
iv
liver
andor
spleen
involv
stage
iii
v
manifest
blood
involv
bone
marrow
andor
organ
system
stage
iiv
stage
subclassifi
without
system
sign
b
system
sign
blood
bone
marrow
involv
b
exclud
bone
marrow
dog
gi
lymphoma
usual
present
nonspecif
gi
sign
vomit
diarrhea
weight
loss
malabsorpt
mesenter
ln
spleen
liver
may
involv
mediastin
form
lymphoma
character
enlarg
cranial
mediastin
structur
andor
thymu
see
fig
clinic
sign
associ
extent
diseas
result
respiratori
compromis
polydipsiapolyuria
hypercalcemia
advanc
case
dog
present
respiratori
distress
caus
spaceoccupi
mass
pleural
effus
exercis
intoler
possibl
regurgit
addit
dog
mediastin
lymphoma
may
precav
syndrom
character
pit
edema
head
neck
forelimb
secondari
tumor
compress
invas
cranial
vena
cava
fig
clinic
sign
dog
extranod
lymphoma
depend
specif
organ
involv
cutan
lymphoma
mucocutan
cutan
lesion
solitari
gener
multifoc
tumor
occur
nodul
plaqu
ulcer
erythem
exfoli
dermat
focal
hypopigment
alopecia
epitheliotrop
tcell
lymphoma
eg
mycosi
fungoid
typic
clinic
cours
three
appar
clinic
stage
initi
scale
alopecia
pruritu
fig
mimic
varieti
skin
condit
diseas
progress
skin
becom
erythemat
thicken
ulcer
exud
final
stage
character
prolif
plaqu
nodul
progress
ulcer
fig
oral
mucocutan
involv
may
also
occur
appear
multicentr
erythemat
plaquelik
hypopig
lesion
nodul
associ
gum
lip
fig
extracutan
involv
also
occur
often
ln
spleen
liver
bone
marrow
peripher
blood
nonepitheliotrop
cutan
lymphoma
also
quit
variabl
appear
form
singl
multipl
dermal
subcutan
nodul
plaqu
may
nonpurit
ulcer
alopec
crust
face
lip
nasal
planum
eyelid
lower
extrem
paw
interdigit
fold
neck
trunk
often
affect
dog
cn
lymphoma
may
present
either
multifoc
solitari
involv
major
case
involv
secondari
extens
cn
bcell
immunophenotyp
mening
perivascular
periventricular
locat
wherea
tcell
varieti
like
involv
peripher
nerv
seizur
paralysi
paresi
may
note
ocular
lymphoma
character
infiltr
thicken
iri
uveiti
hypopyon
hyphema
posterior
synechia
glaucoma
discuss
detail
chapter
although
often
secondari
multicentr
system
lymphoma
compil
case
presum
solitari
ocular
lymphoma
psol
without
system
involv
diagnosi
progress
postenucl
peripher
tcell
lymphoma
dlbcl
common
subtyp
importantli
dog
psol
median
surviv
time
mst
day
versu
day
dog
system
involv
diagnosi
one
studi
case
canin
multicentr
lymphoma
ocular
chang
consist
lymphoma
seri
case
uveiti
dog
secondari
lymphoma
anterior
uveiti
commonli
seen
advanc
stage
diseas
stage
v
dog
intravascular
lymphoma
usual
present
sign
relat
cn
pn
ocular
involv
includ
paraparesi
ataxia
hyperesthesia
seizur
blind
lethargi
anorexia
weight
loss
diarrhea
polyuria
polydipsia
intermitt
fever
final
dog
pure
hepatosplen
lymphoma
usual
present
nonspecif
sign
lethargi
inappet
weak
often
icter
canin
lymphoma
also
may
associ
paraneoplast
syndrom
see
chapter
anemia
common
lymphomarel
paraneoplast
syndrom
paraneoplast
hypercalcemia
also
common
character
clinic
anorexia
weight
loss
muscl
weak
lethargi
polyuria
polydipsia
rare
cn
depress
coma
lymphomainduc
hypercalcemia
case
result
parathyroid
hormonerel
peptid
pthrp
elabor
neoplast
cell
howev
also
relat
product
sever
humor
factor
includ
tumor
necrosi
factoralpha
transform
growth
factorbeta
vitamin
analog
eg
previous
discuss
hypercalcemia
commonli
associ
tcell
immunophenotyp
paraneoplast
syndrom
may
encount
includ
monoclon
gammopathi
neuropathi
cancer
cachexia
dog
suspect
lymphoma
diagnost
evalu
includ
thorough
physic
examin
complet
blood
count
cbc
includ
differenti
leukocyt
platelet
count
serum
biochem
profil
urinalysi
optim
plasma
ioniz
calcium
concentr
measur
ultim
obtain
tissu
cytolog
specimen
definit
diagnosi
essenti
differenti
diagnosi
lymphadenopathi
depend
travel
histori
dog
ie
rel
infecti
diseas
size
consist
locat
affect
ln
caus
lymphadenopathi
includ
infect
caus
bacteria
virus
protozoa
toxoplasma
sp
leishmania
sp
rickettsi
organ
salmon
poison
ehrlichia
sp
fungal
agent
blastomyc
histoplasma
sp
potenti
hypercalcemia
accompani
system
fungal
diseas
may
complic
differenti
lymphoma
discret
hard
asymmetr
ln
particularli
fix
underli
tissu
may
indic
metastat
tumor
mast
cell
tumor
carcinoma
immunemedi
diseas
eg
pemphigu
system
lupu
erythematosu
immunemedi
polyarthropathi
also
may
result
mildli
moder
enlarg
ln
variou
differenti
diseas
condit
resembl
canin
lymphoma
list
tabl
thorough
physic
examin
includ
palpat
assess
ln
rectal
examin
author
experi
signific
proport
dog
rectal
polyp
consist
aggreg
neoplast
lymphocyt
inspect
mucou
membran
pallor
icteru
petechia
ulcer
undertaken
sign
may
indic
anemia
thrombocytopenia
secondari
myelophthisi
immunemedi
diseas
may
evid
major
organ
failur
uremia
abdomin
palpat
may
reveal
organomegali
intestin
wall
thicken
mark
mesenter
lymphadenopathi
presenc
mediastin
mass
andor
pleural
effus
suspect
thorac
auscult
ocular
examin
includ
funduscop
assess
may
reveal
abnorm
eg
uveiti
retin
hemorrhag
ocular
infiltr
glaucoma
approxim
onethird
onehalf
dog
lymphoma
anemia
common
lymphomarel
hematolog
abnorm
usual
normochrom
normocyt
nonregen
consist
anemia
chronic
diseas
howev
hemorrhag
hemolyt
anemia
may
also
occur
regen
anemia
may
reflect
concomit
blood
loss
hemolysi
addit
signific
myelophthisi
present
anemia
may
accompani
thrombocytopenia
leukopenia
anim
anemia
evid
bleed
addit
platelet
count
reticulocyt
count
coagul
test
may
indic
thrombocytopenia
occur
case
bleed
seldom
clinic
problem
neutrophilia
occur
dog
lymphocytosi
occur
approxim
affect
dog
circul
atyp
lymphocyt
may
indic
bone
marrow
involv
leukemia
import
differenti
multicentr
lymphoma
bone
marrow
involv
ie
stage
v
diseas
primari
lymphocyt
leukemia
prognosi
may
differ
hypoproteinemia
observ
frequent
anim
alimentari
lymphoma
dog
high
total
protein
concentr
evid
increas
globulin
fraction
biochem
profil
serum
protein
may
evalu
serum
protein
electrophoresi
monoclon
gammopathi
report
occur
approxim
dog
lymphoma
serum
biochem
abnorm
often
reflect
anatom
site
involv
well
paraneoplast
syndrom
hypercalcemia
dog
lymphoma
ioniz
calcium
concentr
obtain
may
increas
even
total
calcium
concentr
within
refer
interv
case
hypercalcemia
unknown
origin
lymphoma
alway
consid
high
differenti
diseas
list
diagnost
test
direct
possibl
undertaken
see
chapter
addit
presenc
hypercalcemia
serv
biomark
respons
therapi
relaps
increas
urea
nitrogen
creatinin
concentr
occur
secondari
renal
infiltr
tumor
hypercalcem
nephrosi
preren
azotemia
dehydr
increas
liverspecif
enzym
activ
bilirubin
concentr
may
result
hepat
parenchym
infiltr
increas
serum
globulin
concentr
usual
monoclon
occur
infrequ
bcell
lymphoma
urinalysi
part
minimum
databas
use
assess
renal
function
urinari
tract
exampl
isosthenuria
proteinuria
absenc
activ
sediment
may
indic
renal
diseas
hematuria
may
result
hemostat
abnorm
import
note
isosthenuria
hypercalcem
dog
necessarili
indic
renal
diseas
high
calcium
concentr
interfer
tubular
concentr
capabl
impair
respons
antidiuret
hormon
howev
clinician
awar
risk
renal
calcif
subsequ
failur
sustain
high
calcium
concentr
morpholog
phenotyp
examin
tissu
cell
constitut
tumor
essenti
diagnosi
subtyp
lymphoma
human
combin
histolog
immunophenotyp
clinic
genet
featur
use
diagnosi
subtyp
nhl
excel
review
morpholog
immunophenotyp
diagnost
featur
canin
lymphoma
recent
publish
veterinari
medicin
care
taken
avoid
sampl
ln
reactiv
area
eg
mandibular
ln
unless
node
one
enlarg
prescapular
poplit
ln
prefer
also
involv
also
lymphocyt
fragil
prepar
smear
aspir
materi
gentl
pressur
appli
spread
materi
slide
major
dog
nodal
lymphoma
present
multicentr
effac
peripher
ln
intermedi
larg
lymphocyt
cytolog
examin
fna
affect
ln
tissu
highli
sensit
specif
firstlin
screen
diagnost
step
typic
cell
larg
lymphocyt
time
diamet
red
blood
cell
larger
neutrophil
may
visibl
nucleoli
basophil
cytoplasm
without
paranuclear
clear
zone
fig
fine
chromatin
indistinct
nucleoli
tissu
architectur
maintain
cytolog
specimen
effac
node
capsular
disrupt
detect
therefor
mark
reactiv
hyperplasia
character
increas
number
larg
lymphocyt
may
difficult
distinguish
lymphoma
form
lymphoma
intermedi
lymphocyt
similar
diamet
neutrophil
predomin
specimen
challeng
novic
cytopathologist
smallcel
lymphoma
may
cytolog
clue
point
malign
therefor
classif
lymphoma
subtyp
make
low
intermedi
highgrad
form
attempt
use
cytolog
appear
immunophenotyp
analysi
cytolog
specimen
fig
perform
accur
histolog
section
although
cytolog
find
identifi
experienc
cytopathologist
may
suggest
particular
subtyp
lymphoma
subsequ
analysi
may
includ
flow
cytometri
immunocytochemistri
biopsi
histolog
examin
clonal
assay
cytogenet
analysi
requir
subtyp
lymphoma
confirm
establish
diagnosi
equivoc
case
fig
present
diagnost
algorithm
assess
peripher
lymphadenopathi
dog
appli
techniqu
begin
initi
screen
cytolog
examin
accur
histopatholog
evalu
entir
ln
includ
capsul
remov
place
buffer
formalin
submit
pathologist
needlecor
biopsi
gener
inadequ
evalu
nodal
morpholog
effac
normal
nodal
architectur
neoplast
lymphocyt
capsular
disrupt
characterist
find
fig
diagnost
ultrasonographi
ultrasoundguid
fna
needl
biopsi
use
evalu
involv
liver
spleen
abdomin
ln
aspir
ultrasonograph
normal
splenic
tissu
rare
contributori
diagnosi
possibl
diagnosi
made
sampl
peripher
node
avoid
percutan
biopsi
liver
spleen
howev
peripher
node
involv
appropri
biopsi
affect
tissu
abdomin
caviti
gi
lymphoma
suspect
open
surgic
wedg
biopsi
intestin
prefer
case
differenti
lymphoma
lymphocyt
enter
associ
abdomin
ln
also
appear
involv
imageguid
biopsi
may
obtain
less
morbid
intestin
biopsi
multipl
sampl
may
necessari
accur
diagnos
segment
diseas
endoscop
biopsi
may
inadequ
superfici
specimen
obtain
howev
aggress
endoscop
biopsi
techniqu
combin
accur
histopatholog
immunophenotyp
molecular
assess
improv
diagnost
yield
less
invas
techniqu
mani
dog
primari
gi
lymphoma
inflammatori
nonneoplast
infiltr
ie
lpibd
may
misdiagnos
biopsi
specimen
superfici
applic
assay
clonal
expans
eg
receptor
gene
rearrang
parr
appear
yet
accur
endoscop
deriv
intestin
biopsi
solid
lymphoid
tumor
dog
cytolog
examin
cerebrospin
fluid
csf
thorac
fluid
mass
aspir
indic
anim
cn
diseas
pleural
effus
intrathorac
mass
respect
two
studi
csf
analysi
diagnost
lymphoma
sampl
characterist
csf
one
studi
includ
increas
nucleat
cell
count
seven
dog
cell
compris
atyp
lymphocyt
csf
protein
concentr
increas
five
dog
rang
mgdl
refer
interv
mgdl
flow
cytometr
molecular
diagnost
procedur
may
also
appli
csf
sampl
although
cell
count
may
limit
factor
assay
requir
least
cell
cutan
lymphoma
dermal
punch
biopsi
mm
taken
repres
infiltr
secondarili
infect
skin
lesion
applic
immunophenotyp
clonal
assess
cutan
biopsi
aid
differenti
lymphoma
benign
lymphocyt
lesion
molecular
techniqu
use
establish
diagnosi
lymphoma
best
use
character
tumor
initi
diagnosi
made
inde
peopl
genet
character
nhl
often
use
diagnosi
subtyp
tissu
cell
peripher
blood
ln
nonlymphoid
site
effus
analyz
variou
molecular
cytogenet
mean
aid
categor
subtyp
case
repres
difficult
diagnost
challeng
particularli
case
reactiv
lymphocytosi
lymphoma
possibl
base
standard
histolog
cytolog
assess
includ
histochem
cytochem
immunohistochem
ihc
immunocytochem
flow
cytometr
polymeras
chain
reaction
pcr
cytogenet
techniqu
exampl
immunophenotyp
b
vs
cell
prolifer
rate
eg
express
prolifer
cell
nuclear
antigen
express
argyrophil
nucleolar
organ
region
agnor
clonal
pcr
antigen
parr
tumor
determin
genet
character
canin
lymphoma
sampl
investig
show
potenti
diagnost
prognost
util
wide
appli
clinic
correl
current
preliminari
avail
molecular
genet
analys
increas
veterinari
oncolog
howev
present
immunophenotyp
parr
clonal
assay
routin
use
dog
inform
clinic
decis
make
immunophenotyp
use
determin
type
cell
compris
tumor
techniqu
also
help
make
initi
diagnosi
predict
outcom
heterogen
popul
lymphocyt
expect
tissu
document
homogen
popul
immunophenotyp
support
neoplast
process
immunophenotyp
lymphocyt
identifi
determin
express
molecul
specif
b
cell
eg
cell
eg
recent
review
although
tumor
cell
sometim
morpholog
characterist
typifi
particular
immunophenotyp
except
occur
morpholog
appear
use
sole
determin
immunophenotyp
exampl
seri
nine
highgrad
tcell
lymphoma
leukemia
dog
cell
plasmacytoid
appear
typic
associ
bcell
lymphoma
similarli
anatom
locat
alway
predict
immunophenotyp
accur
determin
immunophenotyp
antibodi
lymphocyt
marker
appli
tissu
section
ihc
cytolog
specimen
immunocytochemistri
individu
cell
fluid
medium
flow
cytometri
flow
cytometr
evalu
cell
obtain
needl
aspir
also
feasibl
cell
marker
includ
pan
helper
cytotox
b
cell
marker
see
fig
although
dog
indol
tzl
express
increasingli
aberr
express
cd
molecul
report
canin
lymphoma
studi
dog
lymphoma
tumor
cell
six
dog
posit
tand
bcell
marker
howev
clonal
assay
reveal
clonal
either
tcell
immunoglobulin
receptor
indic
case
malign
cell
may
coexpress
band
tcell
marker
antibodi
molecul
use
determin
immunophenotyp
howev
also
potenti
util
therapeut
modal
tumor
cell
could
target
use
antibodi
tabl
present
histolog
immunophenotyp
characterist
common
lymphoma
subtyp
dog
inform
clinic
present
morpholog
immunophenotyp
characterist
lymphocyt
obtain
ihc
flow
cytometr
analysi
must
integr
select
appropri
target
clonal
test
interpret
result
accur
occasion
diagnosi
lymphoma
differenti
malign
versu
benign
prolifer
lymphocyt
possibl
base
standard
histolog
cytolog
criteria
case
advanc
molecular
analys
may
help
confirm
diagnosi
clonal
hallmark
malign
malign
cell
popul
theoret
deriv
expans
singl
malign
clone
character
particular
dna
region
uniqu
tumor
exampl
dog
tcell
lymphoma
malign
cell
theoret
dna
sequenc
variabl
region
tcell
receptor
gene
likewis
dog
bcell
lymphoma
tumor
cell
ident
dna
sequenc
variabl
region
immunoglobulin
ig
receptor
gene
convers
reactiv
lymphocytosi
cell
polyclon
antigen
receptor
use
knowledg
investig
use
pcr
technolog
amplifi
variabl
region
tcell
immunoglobulin
receptor
gene
detect
presenc
clonal
lymphocyt
popul
dog
see
fig
chapter
techniqu
review
chapter
elsewher
physicianbas
medicin
assay
clonal
approxim
sensit
falseposit
rate
approxim
recent
studi
report
similar
rate
dog
falseneg
falseposit
result
occur
clonal
assay
exampl
cell
dog
lymphoma
may
neg
clonal
clonal
segment
dna
detect
pcr
primer
use
mutat
primer
site
occur
background
nonneoplast
lymphocyt
nois
within
tumor
malign
cell
natur
killer
nk
cell
rare
malign
cell
present
low
frequenc
detect
fals
posit
occur
rare
infecti
diseas
eg
ehrlichiosi
leishmaniasi
case
diagnosi
made
consid
result
diagnost
test
includ
histologiccytolog
evalu
immunophenotyp
clonal
studi
conjunct
signal
physic
examin
find
molecular
techniqu
although
help
diagnosi
could
also
util
detect
relaps
determin
accur
clinic
stage
socal
molecular
remiss
rate
sensit
standard
cytolog
assess
peripher
blood
bone
marrow
ln
assess
sever
marker
multidrug
resist
apoptot
pathway
eg
pglycoprotein
protein
evalu
dog
lymphoma
howev
clinic
signific
util
establish
proteom
compris
simplist
methodolog
analyz
entir
protein
compon
protein
signatur
cell
proteom
protein
compon
cell
normal
malign
chang
time
upregul
downregul
gene
express
respons
vari
stimuli
eg
growth
factor
environment
cue
may
therefor
possibl
use
field
proteom
identifi
serum
biomark
malign
ie
cancerspecif
protein
marker
analyz
respons
therapi
even
predict
therapi
appropri
individu
patient
tumor
although
infanc
veterinari
oncolog
preliminari
investig
proteom
dog
lymphoma
report
howev
yet
reach
level
sophist
use
output
would
signific
effect
clinic
decis
make
sever
analyt
serum
explor
biomark
lymphoma
dog
review
includ
tumor
metabol
product
cytokin
cellular
leakag
enzym
serum
protein
exampl
includ
thymidin
kinas
creactiv
protein
alphafetoprotein
glycoprotein
level
zinc
chromium
iron
endostatin
vascular
endotheli
growth
factor
vegf
lactat
dehydrogenas
haptoglobin
antioxidantsoxid
stress
marker
although
group
commerci
eg
tk
canin
cancer
panel
vdi
lab
simi
valley
ca
usa
canin
lymphoma
blood
test
clbt
avacta
anim
health
whetherbi
uk
clinic
biolog
prognost
signific
assay
yet
definit
character
intuit
use
biomark
detect
earli
relaps
would
clinic
util
meaning
therapeut
decis
option
identifi
would
result
enhanc
quantiti
qualiti
life
current
leadtim
provid
standard
clinic
diagnosi
relaps
rel
short
limit
routin
util
definit
studi
support
applic
larger
vari
gener
popul
dog
lymphoma
current
lack
diagnosi
establish
extent
diseas
determin
categor
clinic
stage
stage
system
routin
use
stage
dog
lymphoma
present
box
dog
present
advanc
stage
iiiiv
diagnost
imag
assess
bone
marrow
involv
may
indic
stage
degre
thorough
stage
implement
depend
whether
result
alter
treatment
plan
whether
relev
prognost
inform
glean
whether
client
need
know
stage
initi
declin
treatment
plan
addit
compar
differ
treatment
protocol
respect
efficaci
consist
similar
stage
diagnost
use
avoid
socal
stage
migrat
result
one
stage
methodolog
accur
anoth
effect
stage
migrat
prognosi
consid
compar
differ
publish
outcom
bone
marrow
aspir
core
biopsi
proxim
humeru
iliac
crest
recommend
complet
stage
prognost
may
indic
dog
anemia
lymphocytosi
circul
atyp
lymphocyt
peripher
cytopenia
one
studi
dog
lymphoma
circul
malign
cell
consid
leukem
wherea
bone
marrow
examin
indic
involv
dog
presenc
prolymphocyt
larg
lymphocyt
nucleoli
circul
dog
lymphoma
may
indic
bone
marrow
involv
import
rememb
cell
also
seen
immunemedi
inflammatoryinfecti
diseas
discuss
previous
tumor
cell
within
peripher
bone
marrow
compart
also
identifi
use
clonal
assay
parr
sensit
routin
microscop
examin
detect
malign
cell
howev
prognost
signific
knowledg
gain
sensit
stage
methodolog
yet
determin
although
bone
marrow
evalu
may
offer
prognost
valuabl
inform
necessari
perform
procedur
client
commit
treat
regardless
stage
evalu
thorac
abdomin
radiograph
may
import
determin
extent
intern
involv
fig
approxim
dog
multicentr
lymphoma
abnorm
thorac
radiograph
onethird
evid
pulmonari
infiltr
see
fig
twothird
thorac
lymphadenopathi
sternal
tracheobronchi
ln
see
fig
widen
cranial
mediastinum
see
fig
pulmonari
infiltr
usual
repres
interstiti
andor
alveolar
pattern
howev
nodul
rare
bronchial
infiltr
also
occur
pleural
effus
may
also
present
cranial
mediastin
lymphadenopathi
detect
dog
lymphoma
abdomin
radiograph
reveal
evid
involv
medial
iliac
sublumbar
andor
mesenter
ln
spleen
liver
approxim
case
author
practic
typic
case
canin
multicentr
lymphoma
imag
limit
thorac
radiograph
prognost
differ
dog
stage
iii
iv
diseas
ie
liverspleen
involv
howev
cranial
mediastin
lymphadenopathi
prognost
signific
clinic
sign
attribut
abdomin
diseas
complet
stage
necessari
eg
clinic
trial
inclus
peripher
lymphadenopathi
part
present
imag
abdomen
warrant
abdomin
ultrasonographi
import
obtain
ultrasoundguid
intraabdomin
sampl
diagnosi
peripher
lesion
evid
eg
gi
abdomin
nodal
hepatosplen
lymphoma
complet
clinic
stage
requir
ultrasonograph
includ
doppler
ultrasound
assess
peripher
ln
also
explor
howev
clinic
applic
question
cytolog
assess
peripher
node
easi
inexpens
higher
diagnost
util
advanc
imag
modal
includ
comput
tomographi
ct
magnet
reson
imag
mri
positron
emiss
tomographi
pet
petct
petmr
imag
becom
commonplac
veterinari
practic
util
determin
petct
imag
current
standard
care
follow
predict
durabl
treatment
respons
human
patient
lymphoma
f
fluorothymidin
flt
petct
f
fluorodglucos
fdg
pet
imag
report
dog
lymphoma
fltpetct
function
anatom
imag
show
promis
evalu
respons
cytotox
chemotherapi
dog
lymphoma
predict
relaps
standard
clinic
clinicopatholog
confirm
fig
therapeut
approach
particular
patient
lymphoma
determin
subtyp
stage
substag
diseas
presenc
absenc
paraneoplast
diseas
overal
physiolog
statu
patient
financi
time
commit
client
level
comfort
respect
likelihood
treatmentrel
success
andor
side
effect
without
treatment
dog
intermediateor
highgrad
lymphoma
die
diseas
within
week
diagnosi
although
signific
variabl
exist
except
canin
lymphoma
consid
system
diseas
therefor
requir
system
therapi
achiev
remiss
prolong
surviv
major
canin
multicentr
lymphoma
intermediateto
highgrad
current
histolog
immunophenotyp
character
play
signific
role
determin
initi
treatment
protocol
unless
diagnosi
indol
lowgrad
lymphoma
confirm
hope
near
futur
clinic
correl
inform
signific
variou
subclassif
lymphoma
dog
acquir
tailor
therapeut
approach
may
becom
avail
system
multiag
chemotherapi
continu
therapi
choic
canin
intermediateand
highgrad
lymphoma
gener
combin
chemotherapi
protocol
superior
efficaci
singleag
protocol
rare
case
lymphoma
limit
one
site
especi
extranod
site
anim
treat
local
modal
surgeri
radiat
therapi
rt
long
client
clinician
commit
dilig
reevalu
activ
surveil
document
subsequ
progress
system
involv
occur
mani
chemotherapeut
protocol
dog
lymphoma
develop
past
year
tabl
studi
includ
suffici
number
dog
adequ
statist
power
even
fewer
compar
treatment
protocol
random
prospect
fashion
addit
stage
inclus
respons
criteria
vari
consider
among
report
therefor
evalu
efficaci
among
variou
protocol
subject
substanti
bia
make
direct
comparison
difficult
inde
precari
recur
theme
conclud
statement
publish
protocol
variat
prospect
random
trial
requir
confirm
suggest
find
despit
plethora
avail
combin
protocol
modif
chop
protocol
initi
design
human
oncolog
use
current
random
prospect
evid
exist
dog
clearli
recommend
one
long
basic
chop
compon
present
chop
repres
combin
cyclophosphamid
c
doxorubicin
h
hydroxydaunorubicin
vincristin
oncovin
prednison
p
earli
physician
treat
human
patient
advanc
intermediateor
highgrad
lymphoma
face
similar
dilemma
mani
differ
variat
chop
exist
random
data
avail
determin
protocol
superior
eventu
nation
random
trial
involv
peopl
intermediatehigh
grade
nhl
conduct
compar
plethora
protocol
avail
result
indic
chop
effect
complic
protocol
safest
advers
event
profil
chop
subsequ
becam
remain
addit
monoclon
antibodi
therapi
standard
care
peopl
intermediatehighgrad
nhl
convent
chopbas
chemotherapi
induc
remiss
approxim
dog
overal
mst
month
approxim
treat
dog
aliv
year
initi
protocol
fig
respons
rate
durat
respons
vari
accord
presenc
absenc
prognost
factor
discuss
text
follow
rel
cost
variou
protocol
client
depend
drug
select
size
anim
frequenc
administr
laboratori
test
requir
monitor
advers
event
respons
attempt
better
standard
respons
criteria
outcom
report
futur
trial
veterinari
cooper
oncolog
group
vcog
publish
respons
evalu
criteria
appli
routin
practic
set
greatest
obstacl
perform
prospect
random
compar
lymphoma
trial
veterinari
oncolog
financi
clinic
trial
inher
costli
known
effect
drug
unregist
offlabel
human
gener
ie
offpat
drug
incent
pharmaceuticalfund
suffici
power
random
field
trial
low
result
gener
lack
compar
data
dog
respond
chemotherapi
undergo
complet
clinic
remiss
usual
free
clinic
sign
associ
lymphoma
subsequ
return
good
qualiti
life
make
treatment
dog
lymphoma
initi
gratifi
dog
toler
chemotherapi
well
although
dose
reduct
treatment
break
treatment
holiday
sometim
requir
individu
case
minor
dog
develop
signific
advers
event
requir
hospit
studi
assess
client
percept
medic
treatment
cancer
gener
lymphoma
particular
report
posit
experi
owner
feel
treatment
worthwhil
result
improv
wellb
pet
qualiti
life
treatment
good
client
express
regret
treat
lymphoma
use
multidrug
protocol
importantli
must
realiz
cure
rare
though
complet
clinic
remiss
norm
complet
molecular
remiss
icr
document
molecular
techniqu
rare
achiev
dog
thu
util
document
icr
absenc
meaning
therapeut
option
limit
investig
trial
strive
achiev
lymphoma
fundament
goal
chemotherapi
induc
complet
durabl
month
first
remiss
term
induct
reinduc
remiss
tumor
recrudesc
patient
relaps
achiev
remiss
term
reinduct
final
induc
remiss
cancer
fail
respond
induct
reinduct
use
drug
present
initi
protocol
term
rescu
unansw
question
treatment
lymphoma
whether
longterm
mainten
chemotherapi
use
initi
cours
aggress
induct
chemotherapi
last
month
less
longterm
mainten
chemotherapi
shown
signific
valu
human
aggress
form
nhl
howev
human
initi
induct
cours
chemotherapi
much
aggress
use
veterinari
patient
although
random
prospect
studi
perform
address
therapeut
benefit
longterm
mainten
chemotherapi
dog
comparison
dog
treat
chopbas
protocol
show
clear
advantag
mainten
consolid
phase
induct
therapi
inde
report
dog
receiv
shorter
less
costli
protocol
includ
prolong
mainten
phase
compar
remiss
progressionfre
surviv
pf
durat
appear
readili
achiev
second
remiss
relaps
complet
chemotherapi
counterpart
receiv
longterm
mainten
data
taken
togeth
suggest
mainten
therapi
benefici
dog
lymphoma
welldesign
random
prospect
trial
indic
otherwis
author
dmv
prefer
protocol
util
aggress
induct
without
mainten
effect
current
avail
chemotherapeut
agent
canin
lymphoma
includ
doxorubicin
dox
lasparaginas
vincristin
cyclophosphamid
prednison
repres
one
degre
anoth
firstlin
multiag
chemotherapi
protocol
drug
document
activ
often
consid
secondlin
agent
includ
rabacfosadin
lomustin
vinblastin
actinomycind
mitoxantron
mustargen
chlorambucil
methotrex
dacarbazin
dtic
ifosfamid
cytosin
arabinosid
procarbazin
bleomycin
gemcitabin
cytosin
arabinosid
ifosfamid
bleomycin
gemcitabin
appear
minim
activ
except
dox
singleag
induct
therapi
typic
result
durabl
remiss
durat
compar
standard
combin
protocol
incorpor
standard
cytotox
drug
singleag
activ
standard
chopbas
protocol
result
signific
gain
adequ
evalu
reserv
subsequ
rescu
set
use
rabacfosadin
warrant
brief
discuss
chemotherapi
agent
current
approv
albeit
condit
us
food
drug
administr
fda
treatment
dog
lymphoma
see
chapter
specif
discuss
rabacfosadin
rabacfosadin
evalu
hundr
dog
lymphoma
activ
document
singleag
treatment
cutan
lymphoma
multipl
myeloma
relaps
multicentr
lymphoma
well
combin
dox
lymphoma
current
rabacfosadin
commonli
use
rescu
agent
relaps
firstlin
treatment
combin
dox
owe
less
intens
treatment
protocol
maintain
similar
remiss
durat
compar
chop
nonrandom
fashion
sever
factor
consid
discuss
caregiv
casebycas
basi
choos
treatment
protocol
factor
includ
cost
time
commit
involv
efficaci
advers
event
profil
experi
clinician
protocol
consider
clearli
establish
standardofcar
combin
protocol
use
dog
intermediateand
highgrad
lymphoma
essenti
variat
chop
protocol
see
tabl
specif
detail
regard
dose
time
chop
protocol
current
prefer
author
dmv
outlin
box
protocol
mainten
compon
treatment
ceas
week
provid
anim
complet
clinic
remiss
although
sever
chopbas
protocol
includ
lasparaginas
either
initi
vari
time
throughout
protocol
sever
studi
suggest
result
clinic
relev
increas
remiss
rate
speed
attain
remiss
firstremiss
durat
therefor
author
reserv
use
rescu
situat
client
consider
preclud
chopbas
protocol
singleag
dox
mgm
intraven
iv
everi
week
five
total
treatment
offer
along
taper
oral
prednison
regimen
prednison
regimen
box
less
aggress
less
timeconsum
less
costli
approach
expect
cr
rate
singleag
dox
protocol
rang
anticip
mst
month
addit
oral
cyclophosphamid
mgm
daili
day
start
day
dox
singleag
dox
result
numer
statist
improv
outcom
random
trial
compar
dox
prednison
doxcyclophosphamideprednison
pf
month
vs
month
respect
trial
power
detect
threefold
differ
pf
therefor
larger
trial
undertaken
confirm
benefit
altern
less
timeintens
protocol
treatment
everi
week
involv
previous
mention
rabacfosadinedox
protocol
client
retic
includ
iv
medic
author
often
recommend
protocol
either
oral
lomustin
ccnu
mgm
mouth
po
everi
week
five
treatment
prednison
oral
cyclophosphamid
mgm
po
everi
week
prednison
ccnu
protocol
associ
short
median
remiss
day
one
small
case
seri
howev
author
experi
subset
dog
remain
remiss
sever
month
protocol
client
declin
iv
medic
financi
client
concern
preclud
use
system
chemotherapi
prednison
alon
mgkg
po
daili
often
result
shortliv
remiss
approxim
month
howev
occasion
durabl
remiss
result
case
import
educ
client
decid
pursu
aggress
therapi
later
date
dog
receiv
singleag
prednison
therapi
like
develop
multidrug
resist
mdr
experi
shorter
remiss
surviv
durat
subsequ
combin
protocol
especi
true
longterm
prednison
use
dog
experienc
relaps
receiv
prednison
therefor
earlier
client
opt
aggress
therapi
like
durabl
respons
result
cbc
perform
chemotherapi
treatment
dog
minimum
oncologist
use
cutoff
administr
myelosuppress
chemotherapi
neutrophil
count
lower
recommend
wait
day
repeat
cbc
neutrophil
count
increas
drug
safe
administ
caveat
restrict
dog
present
initi
chemotherapi
low
neutrophil
platelet
count
due
bone
marrow
effac
myelophthisi
myelosuppress
chemotherapi
institut
face
cytopenia
clear
bone
marrow
neoplast
cell
allow
hematopoiesi
normal
breed
like
homozyg
gene
mutat
eg
colli
see
chapter
therefor
risk
seriou
chemotherapi
toxic
author
dmv
initi
chop
protocol
sequenc
begin
drug
cyclophosphamid
ensur
treatment
lymphoma
allow
suffici
time
analysi
gene
mutat
initi
substrat
drug
specif
protocol
scrutin
treat
dog
doublemut
howev
use
drug
author
initi
treatment
use
dose
reduct
subsequ
dose
modif
increas
decreas
dosag
implement
depend
level
advers
event
observ
particularli
low
neutrophil
count
nadir
author
dosemodifi
heterozyg
gene
mutat
littl
document
clinic
signific
chemosensit
exist
anim
except
eg
tzl
multicentr
tcell
lymphoma
compar
multicentr
bcell
lymphoma
associ
similar
initi
respons
rate
significantli
lower
respons
durat
eg
pf
chemotherapi
includ
chopbas
protocol
addit
effect
singl
treatment
dox
treatment
lymphoma
one
retrospect
case
seri
suggest
lower
initi
respons
rate
tcell
compar
bcell
immunophenotyp
howev
studi
perform
singl
day
evalu
mani
question
whether
dog
diagnos
tcell
lymphoma
treat
standard
chopbas
protocol
altern
protocol
valid
question
howev
answer
remain
elus
adequ
power
random
control
trial
current
exist
demonstr
altern
protocol
better
immunophenotyp
sever
altern
protocol
mopp
lopp
velcaptsc
report
review
induct
therapi
dog
multicentr
tcell
lymphoma
altern
protocol
tend
add
substitut
alkyl
agent
eg
nitrogen
mustard
lomustin
procarbazin
dox
although
report
suggest
improv
remiss
durat
dog
either
confirm
tcell
lymphoma
lymphoma
hypercalcemia
immunophenotyp
classif
confid
interv
median
overlap
data
chopbas
protocol
differ
determin
pf
respons
evalu
studi
popul
particular
adequ
distinguish
indol
multicentr
lymphoma
report
preclud
confid
comparison
yet
control
random
trial
document
improv
approach
ultim
develop
better
protocol
treat
tcell
lymphoma
await
care
random
prospect
trial
assess
time
author
prefer
initi
chopbas
induct
switch
lomustinebas
rescu
first
sign
progress
enter
dog
clinic
trial
novel
agent
although
speci
differ
may
exist
peopl
aggress
tcell
nhl
altern
protocol
rich
alkyl
agent
shown
superior
chopbas
protocol
nation
comprehens
cancer
network
recommend
human
patient
particip
clinic
trial
gold
standard
aggress
nonindol
tcell
lymphoma
vcog
publish
criteria
evalu
treatment
respons
standard
report
outcom
result
comparison
among
protocol
peripher
nodal
diseas
use
criteria
readili
avail
practic
set
import
outcom
measur
prefer
tempor
outcom
criterion
assess
protocol
activ
consid
pf
defin
time
treatment
initi
tumor
progress
death
caus
bring
veterinari
outcom
report
line
human
standard
major
dog
lymphoma
eventu
experi
relaps
chemotherapyinduc
remiss
methodolog
differenti
complet
partial
respons
analysi
depend
respons
determin
pf
remov
mani
sourc
bia
overal
surviv
publish
report
invari
includ
patient
go
receiv
vari
rescu
protocol
bia
overal
result
make
less
compar
outcom
widespread
applic
standard
criteria
permit
suitabl
comparison
futur
true
icr
rare
occur
dog
lymphoma
document
icr
limit
investig
trial
strive
achiev
lack
meaning
therapeut
option
improv
method
detect
minim
residu
diseas
mrd
earli
recurr
investig
dog
lymphoma
includ
advanc
imag
detect
molecular
biolog
marker
mrd
advanc
function
anatom
imag
techniqu
ie
petct
current
standard
assess
treatment
respons
earli
relaps
lymphoma
human
also
investig
dog
see
fig
techniqu
becom
avail
broader
veterinari
popul
clinic
applic
sure
increas
molecular
detect
mrd
appli
clonal
pcr
techniqu
beyond
diagnost
applic
techniqu
appli
determin
cytoreduct
efficaci
variou
chemotherapeut
drug
document
predict
earli
relaps
patient
convent
method
regard
biomark
mrd
preliminari
investig
suggest
serum
lactat
dehydrogenas
activ
thymidin
kinas
activ
haptoglobin
serum
creactiv
protein
may
candid
dog
becom
profici
defin
mrd
press
clinic
question
becom
use
inform
theoret
inform
could
suggest
aggress
therapi
altern
therapi
institut
patient
achiev
molecular
remiss
undergo
earli
relaps
howev
determin
intervent
base
prospect
trial
assess
clinic
util
mrd
analyt
remain
theoret
eventu
vast
major
dog
achiev
remiss
relaps
experi
recrudesc
lymphoma
usual
repres
emerg
tumor
clone
tumor
stem
cell
see
chapter
inher
resist
chemotherapi
origin
tumor
socal
mdr
clone
either
initi
drug
resist
becam
exposur
select
chemotherapi
agent
evid
suggest
dog
relaps
lymphoma
tumor
cell
like
express
gene
eg
encod
abctransport
protein
transmembran
drug
pump
often
associ
mdr
repres
one
plethora
mechan
lead
drugresist
diseas
see
chapter
caus
relaps
chemotherapi
includ
inadequ
dose
andor
frequenc
administr
chemotherapi
failur
achiev
high
concentr
chemotherapeut
drug
certain
site
cn
initi
treatment
prednison
alon
first
recurr
lymphoma
recommend
reinduct
attempt
first
reintroduc
induct
protocol
initi
success
provid
recurr
occur
tempor
far
enough
conclus
initi
protocol
eg
month
make
reinduct
like
cumul
dose
dox
result
reinduct
baselin
cardiac
assess
use
cardioprotect
altern
drug
choic
client
educ
consid
gener
durat
reinduct
remiss
half
encount
initi
therapi
howev
subset
anim
enjoy
longterm
reinduct
especi
dog
complet
initi
induct
treatment
protocol
current
receiv
chemotherapi
sever
month
relaps
occur
reinduct
rate
nearli
expect
dog
complet
chopbas
protocol
relaps
receiv
therapi
durat
second
chopbas
remiss
one
report
predict
durat
interv
protocol
durat
first
remiss
reinduct
fail
dog
respond
initi
induct
use
socal
rescu
agent
rescu
protocol
may
attempt
singl
drug
drug
combin
typic
found
standard
chop
protocol
withheld
use
drugresist
set
common
rescu
protocol
use
dog
includ
singleag
use
combin
rabacfosadin
actinomycin
mitoxantron
dox
dox
part
origin
induct
protocol
dacarbazin
dtic
temozolomid
lomustin
ccnu
lasparaginas
mechlorethamin
vincristin
vinblastin
procarbazin
prednison
etoposid
rescu
protocol
rel
simpl
conveni
singleag
treatment
wherea
other
complic
expens
multiag
protocol
mopp
overal
rescu
respons
rate
report
howev
respons
usual
durabl
median
respons
durat
month
typic
regardless
complex
protocol
small
subset
anim
enjoy
longer
rescu
durat
tabl
provid
summari
canin
rescu
protocol
publish
result
current
publish
data
rescu
protocol
includ
suffici
number
adequ
statist
power
compar
protocol
control
random
prospect
fashion
therefor
compar
evalu
efficaci
among
variou
protocol
subject
substanti
bia
make
direct
comparison
difficult
choic
minimum
case
protocol
includ
suffici
number
adequ
statist
power
fewer
compar
treatment
protocol
random
prospect
fashion
addit
stage
inclus
respons
criteria
vari
consider
protocol
present
therefor
evalu
efficaci
variou
protocol
subject
bia
make
direct
comparison
difficult
inde
precari
b
prednison
often
use
concurr
c
variou
tempor
respons
endpoint
use
includ
diseasefre
interv
time
progress
progressionfre
surviv
time
discontinu
remiss
durat
particular
rescu
protocol
depend
sever
factor
includ
cost
time
commit
requir
efficaci
advers
event
profil
experi
clinician
protocol
question
complex
rescu
protocol
yet
appear
associ
signific
gain
rescu
durabl
author
dmv
tend
choos
simpler
less
costli
protocol
eg
ccnulasparaginaseprednison
tabl
howev
use
multipl
vari
rescu
protocol
switch
need
base
respons
continu
long
client
comfort
dog
qualiti
life
sequenti
applic
sever
differ
rescu
protocol
result
sever
month
extend
surviv
accept
qualiti
life
despit
plethora
publish
chemotherapeut
protocol
dog
lymphoma
appear
achiev
much
current
avail
cytotox
chemotherapeut
standard
set
median
surviv
wall
surviv
rate
improv
dramat
advanc
remiss
surviv
durat
await
develop
new
method
deliv
target
tradit
chemotherapeut
drug
new
gener
chemotherapeut
drug
novel
nonchemotherapeut
treatment
modal
particular
develop
target
immunotherapi
standard
care
physicianbas
oncolog
mechan
avoid
abrog
mdr
enhanc
tumor
apoptosi
program
cell
death
tumor
ablat
immunesystem
reconstitut
well
novel
immunomodulatori
therapi
lymphoma
activ
area
investig
human
veterinari
medicin
enhanc
durabl
first
remiss
human
bcell
nhl
achiev
primarili
institut
monoclon
antibodi
mab
base
therapi
socal
rchop
protocol
current
standardofcar
peopl
r
refer
rituximab
rituxan
recombin
chimer
murin
human
antibodi
direct
antigen
hydrophob
transmembran
protein
locat
normal
preb
matur
b
lymphocyt
bind
rituximab
trigger
host
cytotox
immun
respons
cell
unfortun
rituximab
therapeut
activ
dog
lack
extern
recognit
similar
antigen
canin
lymphoma
cell
inher
antigen
humanderiv
antibodi
dog
recent
canin
mab
design
target
either
bcell
blontuvetmab
blontress
tcell
tamtuvetmab
tactress
lymphoma
condit
approv
usda
use
dog
lymphoma
howev
assess
prospect
clinic
trial
involv
larg
number
dog
target
specif
found
inadequ
effect
clinic
efficaci
longer
avail
current
recommend
use
sever
laboratori
throughout
world
work
character
develop
specif
effect
mab
therapi
use
canin
lymphoma
practition
await
develop
sever
antitumor
vaccin
approach
investig
dog
lymphoma
includ
tumor
vaccin
extract
use
kill
lymphoma
cell
combin
freund
adjuv
autolog
kill
andor
gene
engin
lymphoma
tumor
cell
vaccin
howev
signific
gain
remiss
time
overal
surviv
document
exploratori
vaccin
target
telomeras
see
chapter
section
heat
shock
protein
rnaload
b
cell
dog
lymphoma
also
conduct
studi
involv
small
number
nonrandom
patient
lack
control
popul
comparison
xenogen
dna
vaccin
design
target
canin
current
undergo
clinic
trial
unit
state
although
preliminari
activ
suggest
mani
report
serv
enhanc
basic
understand
immunotherapeut
methodolog
develop
still
earli
complet
safeti
efficaci
trial
complet
date
much
excit
gener
physicianbas
medicin
adapt
immunotherapi
approach
particular
applic
chimer
antigen
receptor
cell
cart
see
chapter
approach
current
subject
sever
proofofconcept
trial
dog
nhl
dog
lymphoma
multicentr
diseas
therefor
requir
system
chemotherapi
effect
treat
diseas
week
week
prednison
mgkg
po
eod
treatment
discontinu
criteria
complet
protocol
two
treatment
beyond
complet
respons
cr
progress
diseas
increas
alt
activ
upper
limit
normal
baselin
higher
baselin
initi
institut
drug
discontinu
reinstitutiondos
reduct
depend
normal
alt
b
prophylact
liver
protect
recommend
eg
denamarin
alt
alanin
aminotransferas
howev
surgeri
use
treat
solitari
lymphoma
stage
solitari
extranod
diseas
care
stage
necessari
case
rule
multicentr
involv
treat
local
diseas
surgeri
also
occasion
appli
palli
remov
node
mechan
obstruct
drug
resist
set
benefit
surgic
remov
spleen
dog
massiv
splenomegali
remain
unclear
howev
indol
lymphoma
confin
spleen
longterm
surviv
splenectomi
norm
older
report
dog
lymphoma
underw
splenectomi
remov
massiv
enlarg
spleen
subsequ
treat
chemotherapi
within
week
splenectomi
five
dog
die
dissemin
intravascular
coagul
dic
sepsi
remain
dog
cr
seven
dog
mst
month
stage
histolog
inform
provid
inform
appear
limit
use
although
followup
live
approxim
year
two
report
indol
nodular
lymphoma
spleen
mzl
mantl
cell
lymphoma
mcl
outcom
avail
seven
mzl
case
includ
three
case
receiv
adjuv
chemotherapi
surgeri
one
die
lymphoma
splenectomi
recent
report
indol
lymphoma
four
splenic
lymphoma
three
mzl
one
mcl
underw
splenectomi
alon
surviv
year
none
die
primari
diseas
anoth
report
dog
undergo
splenectomi
lymphoma
dog
indol
form
enjoy
longterm
surviv
splenectomi
consid
lymphoma
document
site
thorough
stage
lymphoma
indol
form
splenic
ruptur
occur
note
control
popul
consist
dog
undergo
splenectomi
exist
natur
histori
indol
splenic
lymphoma
remain
uncertain
radiat
therapi
although
limit
routin
use
treatment
lymphoma
may
indic
select
case
potenti
indic
follow
cur
intent
therapi
stage
ln
solitari
extranod
diseas
ie
nasal
cutan
spinal
lymphoma
palliat
local
diseas
eg
mandibular
lymphadenopathi
rectal
lymphoma
mediastin
lymphoma
precav
syndrom
present
local
bone
involv
total
bodi
radiat
combin
bone
marrow
stem
cell
reconstitut
whole
stage
halfbodi
rt
chemotherapyinduc
remiss
latter
case
stage
halfbodi
irradi
sandwich
chemotherapi
cycl
attain
remiss
induct
chemotherapi
preliminarili
investig
form
consolid
mainten
rt
deliv
either
cranial
caudal
half
bodi
gy
fraction
rest
half
bodi
irradi
similar
fashion
although
preliminari
investig
random
suggest
rt
appli
dog
either
complet
partial
remiss
safe
warrant
investig
determin
whether
signific
therapeut
gain
realiz
pilot
studi
lowdos
gy
singlefract
total
bodi
irradi
seven
dog
relaps
drugresist
lymphoma
although
safe
appli
result
partial
nondur
week
remiss
total
bodi
irradi
andor
abl
chemotherapi
complet
partial
bone
marrow
ablat
follow
reconstitut
bone
marrow
stemcel
transplant
dog
although
recogn
model
compar
research
set
still
earli
phase
develop
applic
clinic
veterinari
practic
high
cost
limit
access
rel
sophist
equip
manag
requir
type
procedur
limit
preliminari
investig
center
current
longterm
result
document
significantli
enhanc
efficaci
suffici
number
treat
case
yet
present
gener
veterinari
literatur
contain
littl
inform
treat
variou
extranod
form
lymphoma
dog
abil
predict
outcom
thu
limit
gener
recommend
extens
stage
case
diseas
shown
local
solitari
site
local
therapi
eg
surgeri
local
rt
use
withhold
system
therapi
ie
chemotherapi
system
progress
recurr
document
contrast
multipl
extranod
site
involv
part
gener
process
system
chemotherapi
chosen
dog
alimentari
lymphoma
present
diffus
involv
intestin
tract
involv
local
ln
liver
common
chemotherapi
dog
diffus
intermediateor
highgrad
diseas
report
unreward
part
mst
month
chopbas
chemotherapi
howev
durabl
remiss
small
subset
case
report
smallcel
tcell
intestin
lymphoma
report
dog
appear
indol
cours
similar
smallcel
tcell
intestin
lymphoma
cat
report
dog
mst
receiv
conserv
treatment
prednison
chlorambucil
commonli
year
solitari
alimentari
lymphoma
rare
dog
howev
tumor
local
surgic
remov
result
without
followup
chemotherapi
encourag
colorect
lymphoma
gener
highgrad
bcell
phenotyp
also
associ
indol
outcom
median
progressionfre
overal
surviv
time
greater
year
initi
chemotherapi
primari
central
nervou
system
lymphoma
cn
lymphoma
dog
usual
result
extens
multicentr
lymphoma
howev
primari
cn
lymphoma
report
tumor
local
rare
local
rt
consid
studi
report
use
chemotherapi
one
studi
cytosin
arabinosid
arac
dosag
mgm
given
intrathec
treatment
combin
system
chemotherapi
cn
rt
overal
respons
rate
low
short
durat
sever
week
month
although
occasion
durabl
respons
encount
cutan
lymphoma
repres
assort
group
clinic
entiti
vari
consider
present
outcom
epitheliotrop
cutan
lymphoma
common
categor
two
clinic
separ
entiti
mucocutan
cutan
base
outcom
differ
mucocutan
form
appear
better
overal
outcom
treatment
cutan
mucocutan
lymphoma
depend
extent
diseas
solitari
lesion
better
prognosi
may
treat
surgic
excis
rt
although
thorough
stage
system
diseas
undertaken
local
therapi
activ
surveil
subsequ
develop
recurr
system
involv
implement
fraction
rt
associ
longterm
control
diffus
cutan
lymphoma
best
manag
system
therapi
although
rate
durabl
respons
gener
less
multicentr
lymphoma
wide
use
protocol
epitheliotrop
nonepitheliotrop
cutan
tcell
lymphoma
ctcl
includ
ccnu
without
lasparaginas
see
tabl
along
prednison
pegyl
lasparaginas
costli
oral
retino
acid
analog
limit
avail
acitretin
etretin
isotretinoin
multiag
protocol
gener
chopbas
may
also
use
gener
institut
singleag
therapi
fail
although
report
respons
rate
rang
median
remiss
durat
gener
short
approxim
month
occasion
durabl
remiss
encount
sporad
report
therapi
cutan
lymphoma
small
number
case
includ
use
coap
cyclophosphamid
vincristin
oncovin
arac
prednison
topic
mechlorethamin
mustargen
rabacfosadin
recombin
human
interferonalpha
masitinib
report
involv
small
number
case
result
rel
short
respons
durat
wholebodi
surfac
rt
also
explor
treatment
diffus
cutan
lymphoma
preliminari
trial
form
cutan
lymphocyt
infiltr
character
indol
tcell
lymphoma
base
clonal
associ
slow
progress
longterm
surviv
corticosteroid
manag
howev
potenti
progress
highgrad
lymphoma
prognosi
dog
lymphoma
highli
variabl
depend
wide
varieti
factor
document
presum
affect
respons
therapi
although
rare
curabl
case
cr
good
qualiti
life
extend
remiss
surviv
typic
factor
shown
influenc
treatment
respons
surviv
peripher
nodal
lymphoma
summar
tabl
hold
true
primarili
dog
multicentr
lymphoma
immunophenotyp
solitari
extranod
form
lymphoma
thoroughli
investig
respect
prognosi
addit
shown
dog
bcell
lymphoma
express
lower
normal
level
antigen
express
nonneoplast
lymphocyt
low
level
class
ii
mhc
express
experi
shorter
remiss
surviv
durat
dog
present
substag
b
diseas
ie
clinic
ill
also
poorli
compar
dog
substag
diseas
dog
stage
ii
diseas
better
prognosi
dog
advanc
stage
stage
iii
iv
v
prolif
assay
analysi
bromodeoxyuridin
brdu
uptak
antibodi
reactiv
agnor
indic
measur
prolif
activ
tumor
cell
shown
provid
prognost
inform
dog
treat
combin
chemotherapi
howev
differ
studi
contradictori
inform
rare
help
clinic
addit
one
report
proport
tumor
cell
undergo
apoptosi
modestli
predict
remiss
durat
anatom
site
diseas
also
consider
prognost
import
primari
diffus
cutan
diffus
gi
hepatosplen
primari
cn
lymphoma
tend
associ
poor
prognosi
dog
indol
cutan
tcell
lymphocyt
infiltr
experi
longterm
surviv
sex
shown
influenc
prognosi
studi
neuter
femal
tend
better
prognosi
male
dog
may
higher
incid
tcell
phenotyp
may
account
poorer
prognosi
report
biomark
prognosi
summar
tabl
includ
increas
circul
level
glutathionestransferas
thymidin
kinas
lactat
dehydrogenas
creactiv
protein
vegf
final
one
report
suggest
histori
chronic
inflammatori
diseas
sever
type
predict
likelihood
earli
relaps
put
prognost
indic
requir
confirm
larger
trial
particular
interest
capac
gene
express
analysi
predict
inde
subcategor
lymphoma
prognost
categori
although
type
analysi
current
wide
avail
veterinari
clinic
set
routin
use
prognost
therapeut
decis
make
peopl
like
becom
readili
avail
veterinari
clinician
next
decad
potenti
genet
molecular
profil
veterinari
oncolog
illustr
frant
et
al
abl
subcategor
dog
peripher
nodal
lymphoma
three
prognost
categori
base
benchtop
quantit
realtim
qrt
pcr
diagnost
analysi
express
four
gene
histolog
grade
subtyp
greatli
influenc
prognosi
dog
lymphoma
classifi
intermedi
high
grade
tend
respond
chemotherapi
relaps
earli
dog
lowgrad
indol
lymphoma
poorer
respons
chemotherapi
yet
surviv
advantag
dog
intermediateand
highgrad
lymphoma
see
fig
sever
case
compil
document
dog
indol
lymphoma
eg
mzl
mcl
tzl
experi
prolong
st
often
absenc
aggress
chemotherapi
often
enjoy
prolong
surviv
despit
intervent
rather
intervent
one
caveat
canin
nodal
margin
zone
lymphoma
design
indol
disord
gener
aggress
median
progressionfre
interv
month
overal
st
month
substanti
less
splenic
mzl
associ
longterm
surviv
cure
splenectomi
mani
dog
indol
lymphoma
live
near
normal
lifespan
ultim
die
nonlymphomarel
disord
gener
indol
lymphoma
unless
presenc
diseas
effect
qualiti
life
result
clinic
signific
cytopenia
myelophthisi
activ
surveil
absenc
treatment
recommend
treatment
deem
necessari
conserv
protocol
eg
chlorambucilprednison
cyclophosphamideprednison
initi
goal
therapi
control
diseas
stabl
diseas
partial
respons
cr
unusu
indol
lymphoma
lymphocyt
leukemia
typic
defin
prolifer
neoplast
lymphocyt
bone
marrow
neoplast
cell
usual
origin
bone
marrow
occasion
spleen
may
may
circul
peripher
blood
abil
diagnos
lymphocyt
leukemia
use
morpholog
flow
cytometr
immunophenotyp
cytochem
techniqu
increas
significantli
past
decad
although
littl
inform
treatment
prognosi
avail
acut
lymphocyt
leukemia
clinic
relev
inform
chronic
lymphocyt
leukemia
cll
prognosi
treatment
recent
come
light
differenti
true
leukemia
stage
v
lymphoma
difficult
arbitrari
often
base
lack
signific
lymphadenopathi
degre
blood
bone
marrow
involv
immunophenotyp
characterist
lymphocyt
leukemia
common
acut
myeloid
leukemia
myeloprolif
disord
true
incid
unknown
overal
cll
much
common
smaller
report
state
german
shepherd
dog
golden
retriev
may
overrepres
base
recent
compil
dog
bcell
cll
bcll
smallbre
dog
much
like
affect
lymphocyt
leukemia
occur
dog
age
typic
occur
middleag
older
dog
mean
year
age
cll
usual
occur
older
dog
mean
year
age
although
distinct
form
bcll
english
bulldog
occur
younger
dog
mean
year
age
signific
sex
predilect
report
lymphoma
etiolog
lymphocyt
leukemia
part
unknown
genet
factor
like
play
role
compar
dog
human
lymphocyt
leukemia
subdivid
base
cell
size
matur
genet
aberr
microrna
express
immunophenotyp
simplest
classif
divid
leukemia
two
group
chronic
small
cell
matur
cytolog
phenotyp
acut
larg
cell
immatur
cytolog
phenotyp
immunophenotyp
assess
use
flow
cytometr
molecular
assay
character
two
major
subtyp
cll
approxim
twothird
cell
tcll
onethird
bcll
three
primari
subtyp
cll
base
primarili
immunophenotyp
report
tcll
common
form
cell
major
case
granular
lymphocyt
bcll
next
common
subtyp
atyp
cll
repres
combin
immunophenotyp
contrast
cll
human
primarili
diseas
b
cell
cll
lymphocyt
often
indistinguish
morpholog
normal
small
lymphocyt
fig
low
rate
prolifer
accumul
lymphocyt
like
result
prolong
lifespan
also
classifi
lymphoid
precursor
neoplasm
deriv
either
b
cell
ball
cell
tall
major
ball
although
smaller
percentag
tall
gener
cell
tend
intermedi
larg
cell
moder
amount
basophil
cytoplasm
perhap
distinguish
featur
larg
lymphocyt
nuclear
chromatin
pattern
typic
less
condens
chromatin
small
lymphocyt
condens
chromatin
myeloblast
larg
lymphocyt
larger
neutrophil
high
nucleartocytoplasm
ratio
contain
basophil
cytoplasm
see
fig
nucleoli
although
present
less
promin
larg
lymphocyt
myeloblast
nevertheless
cell
distinguish
easili
immatur
cell
hematopoiet
lineag
identif
lineagespecif
marker
immunocytochem
flow
cytometr
molecular
genet
analysi
requir
ascertain
lineag
cell
express
stemcel
marker
acut
phenotyp
impli
howev
myeloid
lymphoid
lineag
express
abil
differenti
acut
myeloid
leukemia
reli
detect
marker
includ
tand
bcell
marker
myeloperoxidas
myeloid
marker
furthermor
tall
express
dog
cll
often
asymptomat
diagnosi
pursu
base
incident
find
increas
circul
matur
lymphocyt
routin
cbc
advanc
diseas
owner
report
lethargi
decreas
appetit
mild
lymphadenopathi
splenomegali
may
present
although
late
diseas
splenomegali
may
mark
compil
nearli
dog
bcll
degre
peripher
lymphadenopathi
splenomegali
hepatomegali
viscer
lymphadenopathi
mediastin
mass
white
blood
cell
wbc
count
usual
vari
normal
increas
circul
matur
lymphocyt
lymphocytosi
persist
granulocyt
usual
present
normal
number
lymphocytosi
hemogram
dog
cll
tend
abnorm
lymphocyt
less
mild
anemia
neutropenia
thrombocytopenia
common
may
becom
mark
diseas
progress
lymphocyt
count
increas
bcll
median
lymphocyt
count
neutropenia
thrombocytopenia
uncommon
respect
despit
welldifferenti
appear
lymphocyt
cll
cell
may
function
abnorm
paraneoplast
syndrom
includ
monoclon
gammopathi
immunemedi
hemolyt
anemia
pure
red
cell
aplasia
rare
hypercalcemia
dog
bcll
report
hyperglobulinem
hypercalcem
dog
cll
monoclon
gammopathi
usual
igm
iga
immunophenotyp
report
latter
report
monoclon
gammopathi
would
like
occur
bcll
dog
usual
present
clinic
sign
anorexia
weight
loss
lethargi
splenomegali
typic
physic
abnorm
may
includ
hemorrhag
lymphadenopathi
hepatomegali
infiltr
bone
marrow
neoplast
lymphocyt
may
extens
result
signific
depress
normal
hematopoiet
element
myelophthisi
anemia
neutropenia
thrombocytopenia
typic
much
sever
cll
may
becom
life
threaten
infiltr
extramedullari
site
cn
bone
gi
tract
may
also
occur
result
neuropathi
bone
pain
gi
sign
respect
consider
signal
histori
physic
find
morpholog
appear
immunophenotyp
cell
essenti
make
accur
diagnosi
help
know
profil
lymphocyt
subset
peripher
blood
normal
dog
determin
whether
particular
subset
expand
approxim
circul
lymphocyt
normal
dog
cell
b
cell
nk
cell
doubleneg
cell
constitut
remain
fraction
tcell
fraction
helper
cell
outnumb
cytotox
cell
lymphocyt
leukemia
consider
atyp
lymphocyt
circul
immunophenotyp
lymphocyt
circul
homogen
determin
flow
cytometr
analysi
phenotyp
typic
present
low
frequenc
increas
clonal
document
eg
parr
analysi
differenti
diagnos
lymphocytosi
includ
infecti
diseas
chronic
ehrlichiosi
postvaccin
respons
young
dog
administr
transient
physiolog
epinephrineinduc
lymphocytosi
case
reactiv
neoplast
lymphocytos
difficult
distinguish
expans
neoplast
lymphocyt
bone
marrow
hallmark
case
cll
care
examin
peripher
blood
bone
marrow
experienc
cytopathologist
import
establish
diagnosi
lymphocyt
leukemia
case
mark
lymphocytosi
atypia
peripher
blood
use
analysi
immunophenotyp
clonal
examin
bone
marrow
essenti
diagnost
bone
marrow
adequ
obtain
aspir
bone
marrow
core
biopsi
perform
larg
lymphocyt
predomin
bone
marrow
also
present
peripher
blood
lineag
decreas
band
tcell
cll
lymphocyt
small
matur
cell
occur
excess
number
bone
marrow
nucleat
cell
earli
diseas
tcll
lymphocyt
may
contain
pink
granul
infiltr
becom
extens
diseas
slowli
progress
eventu
neoplast
cell
replac
normal
marrow
separ
clinic
stage
system
develop
lymphocyt
leukemia
current
dog
leukemia
classifi
stage
v
base
stage
system
lymphoma
present
box
indol
often
asymptomat
natur
cll
decis
treat
often
base
clinic
laboratori
find
individu
dog
oncologist
recommend
activ
surveil
monthli
bimonthli
physic
examin
cbc
activ
therapi
cll
identifi
incident
accompani
clinic
sign
signific
hematolog
abnorm
identifi
dog
significantli
anem
thrombocytopen
show
evid
signific
lymphadenopathi
hepatosplenomegali
therapi
consid
consensu
degre
lymphocytosi
use
initi
therapi
definit
excess
high
vari
among
oncologist
standard
establish
veterinari
medicin
author
dmv
prefer
base
treatment
decis
presenc
signific
constitut
sign
peripher
cytopenia
rather
absolut
lymphocyt
count
current
effect
drug
avail
treatment
cll
therapi
deem
necessari
chlorambucil
chlorambucil
given
oral
dose
mgkg
mgm
po
daili
day
dose
reduc
mgkg
mgm
po
daili
longterm
mainten
dose
mgm
everi
day
use
dose
adjust
base
clinic
respons
bone
marrow
toler
pulsedos
chlorambucil
mgm
q
week
anecdot
use
cll
case
howev
compil
case
report
assess
effect
protocol
oral
prednison
use
concurr
chlorambucil
dose
mgkg
daili
week
mgkg
everi
day
thereaft
addit
vincristin
substitut
cyclophosphamid
chlorambucil
advoc
anim
respond
chlorambucil
treatment
cll
initi
primarili
palli
rare
complet
remiss
uniformli
fatal
cours
owe
indol
natur
diseas
howev
st
rang
year
good
qualiti
life
phenotyp
cll
usual
stabl
month
year
howev
diseas
may
evolv
acut
phase
dog
develop
form
lymphoma
rapidli
progress
character
presenc
pleomorph
larg
lymphocyt
human
term
richter
syndrom
base
data
set
case
tcll
bcll
progress
richterlik
acut
diseas
often
character
lymphadenopathi
cough
vomit
weight
loss
neurolog
sign
eight
dog
progress
acut
diseas
occur
month
initi
diagnosi
cll
mst
progress
day
despit
aggress
chopbas
chemotherapi
half
case
much
morbid
dog
result
effac
bone
marrow
myelophthisi
subsequ
lifethreaten
peripher
cytopenia
neutropenia
thrombocytopenia
anemia
may
sever
dog
often
requir
support
therapi
fresh
wholeblood
transfus
broadspectrum
antibiot
fluid
therapi
nutrit
support
care
monitor
sepsi
hemorrhag
dic
import
specif
treatment
would
requir
aggress
chemotherapi
howev
consist
efficaci
protocol
develop
veterinari
medicin
publish
report
chopbas
protocol
similar
use
lymphoma
see
tabl
use
author
dmv
other
dog
howev
respons
durabl
respons
gener
disappoint
standard
care
human
acut
leukemia
gener
involv
bone
marrow
abl
treatment
stem
cell
marrow
replac
technolog
wide
avail
often
pursu
veterinari
oncolog
gener
cll
indol
diseas
aforement
except
atyp
cll
mani
dog
requir
therapi
time
diagnosi
sever
dog
report
surviv
year
without
treatment
dog
treat
normal
lymphocyt
count
expect
case
one
report
dog
treat
vincristin
chlorambucil
prednison
mst
approxim
month
expect
surviv
year
larger
compil
case
includ
immunophenotyp
analysi
treatment
protocol
poorli
document
although
receiv
chlorambucil
prednison
immunophenotyp
cll
shown
prognost
report
case
mst
day
day
day
report
tcll
bcll
atyp
cll
respect
group
dog
young
age
anemia
also
associ
poor
prognosi
anoth
seri
limit
treatment
inform
dog
cll
immunophenotyp
present
less
greater
mst
day
respect
prognosi
dog
gener
poor
studi
dog
treat
vincristin
prednison
dog
achiev
complet
partial
remiss
mst
day
dog
surviv
longer
month
one
report
case
phenotyp
dog
mst
day
rang
day
even
though
major
receiv
chopbas
treatment
protocol
addit
dog
bcell
lymphocyt
larg
cell
forward
scatter
lymphocyteforward
scatter
neutrophil
ratio
greater
flow
cytometr
analysi
mst
day
independ
treatment
protocol
lymphoma
malign
lymphoma
lymphosarcoma
compris
divers
group
neoplasm
common
origin
lymphocyt
neoplasm
usual
aris
lymphoid
tissu
lymph
node
spleen
bone
marrow
howev
may
aris
almost
tissu
bodi
lymphoma
one
common
neoplasm
seen
cat
see
box
epidemiolog
report
suggest
lymphoma
account
hematopoiet
tumor
cat
hematopoiet
tumor
lymphoid
myeloid
repres
approxim
onethird
felin
tumor
estim
lymphoid
neoplasia
account
incid
per
cat
risk
one
seri
cat
hematopoiet
tumor
lymphoma
leukemia
myeloprolif
diseas
mpd
categor
undifferenti
leukemia
like
myeloid
origin
howev
signific
chang
epidemiolog
characterist
lymphoma
cat
coincid
widespread
integr
felin
leukemia
viru
felv
diagnost
assay
affect
anim
elimin
regimen
late
enhanc
commerci
avail
felv
vaccin
appear
late
declin
felvassoci
lymphoma
mirror
global
declin
overal
preval
per
year
felv
posit
cat
test
importantli
mani
studi
reveal
despit
sharp
drop
felvassoci
lymphoma
overal
preval
lymphoma
cat
increas
increas
preval
appear
increas
number
rel
frequenc
alimentari
particular
intestin
extranod
anatom
form
lymphoma
support
epidemiolog
survey
sever
hundr
case
felin
intestin
lymphoma
year
case
diagnos
year
chang
incid
also
observ
europ
true
annual
incid
rate
lymphoma
cat
current
unknown
respect
felin
pediatr
year
age
tumor
studi
unit
kingdom
n
patholog
specimen
found
repres
hematopoiet
tumor
lymphoma
note
felv
statu
unavail
compil
case
typic
signal
cat
lymphoma
uniformli
state
vari
wide
base
anatom
site
felv
statu
therefor
discuss
individu
sitespecif
discuss
gener
base
two
larg
compil
n
case
north
america
europ
domest
shorthair
dsh
cat
commonli
affect
siames
cat
appear
overrepres
report
maletofemal
ratio
observ
two
studi
associ
gender
neuter
statu
observ
one
larg
compil
australian
case
male
cat
siameseorient
breed
overrepres
similar
breed
find
observ
north
america
although
similar
gender
predilect
found
within
siameseorient
breed
appear
predisposit
mediastin
form
felvassoci
repres
younger
popul
median
year
felv
common
caus
hematopoiet
tumor
cat
socal
felv
era
approxim
twothird
lymphoma
case
associ
felv
antigenemia
sever
studi
document
potenti
molecular
mean
felv
result
lymphoid
neoplasia
see
chapter
section
c
one
would
predict
along
shift
away
felvassoci
tumor
came
shift
away
tradit
signal
rel
frequenc
anatom
site
also
support
outsid
north
america
similar
signal
anatom
frequenc
data
observ
australia
felv
infect
less
common
europ
felv
incid
declin
signal
anatom
site
preval
shift
accordingli
median
age
approxim
year
report
north
america
europ
consider
higher
median
age
year
report
felv
era
median
age
cat
within
variou
anatom
tumor
group
chang
anatom
form
tradit
associ
felv
mediastin
form
may
still
occur
younger
felv
antigenem
cat
similarli
alimentari
form
extranod
form
occur
often
older
felvneg
cat
tabl
present
overview
characterist
variou
anatom
site
lymphoma
cat
abil
interrog
felv
associ
molecular
basi
improv
eg
pcr
amplif
fluoresc
situ
hybrid
sever
report
exist
defin
role
potenti
role
felv
cat
without
felv
antigenemia
collect
studi
indic
felv
provir
insert
exist
proport
felin
lymphoma
tissu
common
tcell
origin
particularli
thymic
peripher
lymph
node
anatom
form
also
suggest
sever
common
felv
integr
site
exist
also
evid
felin
immunodefici
viru
fiv
infect
increas
incid
lymphoma
cat
contrast
direct
role
felv
tumorigenesi
evid
suggest
indirect
role
fiv
secondari
immunosuppress
effect
viru
shelton
et
al
determin
fiv
infect
alon
cat
associ
fivefold
increas
risk
develop
lymphoma
coinfect
felv
potenti
develop
lymphoprolif
disord
experiment
cat
infect
fiv
develop
lymphoma
kidney
alimentari
tract
liver
multicentr
site
fivassoci
lymphoma
like
bcell
immunophenotyp
oppos
tcell
predomin
associ
felv
suggest
fiv
infect
may
associ
commonli
alimentari
lymphoma
bcell
origin
may
relat
chronic
dysregul
immun
system
activ
oncogen
pathway
howev
vari
group
lymphoid
cancer
discuss
three
major
group
base
vari
present
diagnosi
manag
outcom
interrog
gammaherpesviru
cat
lymphoma
show
associ
howev
antigenemia
associ
overal
poorer
prognosi
cat
lymphoma
causal
specul
discuss
section
chapter
canin
lymphoma
recent
advanc
molecular
cytogenet
see
also
chapter
section
chapter
includ
gene
microarray
techniqu
current
appli
investig
chromosom
aberr
gene
express
chang
veterinari
speci
lymphoma
inde
predisposit
orient
cat
breed
develop
lymphoma
suggest
genet
predisposit
indic
herit
risk
alter
oncogenetumor
suppressor
gene
express
epigenet
chang
signal
transduct
cell
deathpathway
alter
common
lymphoma
human
like
also
involv
cat
sever
genet
factor
alreadi
discuss
relat
felv
associ
addit
nra
aberr
implic
although
rare
cat
furthermor
telomeras
activ
see
chapter
document
felin
lymphoma
tissu
alter
cellular
prolifer
cellcycl
death
apoptosi
pathway
particular
cyclindepend
kinas
cellcycl
regul
famili
proapoptot
antiapoptot
govern
molecul
also
implic
felin
lymphoma
evid
exposur
environment
tobacco
smoke
et
risk
factor
lymphoma
human
prompt
investig
cat
one
report
rel
risk
develop
lymphoma
cat
exposur
et
year
exposur
et
respect
larg
european
studi
document
associ
proxim
wast
manag
cancer
dog
fail
show
increas
risk
cat
immun
system
alter
cat
accompani
fiv
infect
implic
develop
lymphoma
case
immunosuppress
human
organ
transplant
patient
report
immunosuppress
felin
renal
transplant
recipi
document
increas
risk
lymphoma
transplant
associ
immunosuppress
therapi
studi
approxim
transplant
cat
develop
de
novo
malign
lymphoma
one
report
cat
intermediateor
highgrad
multicentr
b
cell
lymphoma
although
definit
proof
lack
grow
bodi
indirect
evid
suggest
lymphoma
associ
presenc
chronic
inflamm
theoret
could
case
intestin
nasal
lymphoma
particular
associ
suggest
intestin
lymphoma
inflammatori
bowel
diseas
howev
other
found
support
concept
addit
associ
gastric
helicobact
infect
gastric
mucosaassoci
lymphoid
tissu
malt
lymphoma
cat
suggest
one
studi
warrant
investig
recogn
syndrom
human
casecontrol
studi
investig
mucosainvad
intravascular
bacteria
felin
intestin
lymphoma
statist
signific
differ
found
preval
mucosainvad
bacteria
identifi
larg
cell
lymphoma
small
cell
lymphoma
lymphocyticplasmacyt
enter
biopsi
sampl
respect
furthermor
intravascular
bacteria
present
case
larg
cell
intestin
lymphoma
case
etiolog
signific
explor
also
warrant
final
suggest
chronic
inflamm
inject
site
may
involv
risk
develop
subcutan
lymphoma
cat
similar
document
associ
subcutan
soft
tissu
sarcoma
although
direct
evid
exist
link
diet
develop
intestin
lymphoma
cat
suggest
support
offer
rel
absolut
increas
alimentari
form
lymphoma
past
year
fact
sever
dietari
modif
cat
food
occur
similar
timefram
respons
diseas
urinari
tract
diseas
investig
warrant
prove
disprov
assert
lymphoma
classifi
base
anatom
locat
histolog
immunophenotyp
flow
cytometr
immunohistochem
criteria
often
two
intim
associ
certain
histolog
immunophenotyp
type
commonli
associ
specif
anatom
locat
see
tabl
interrog
lymphoma
subtyp
flow
cytometr
analysi
parr
clonal
analysi
genet
character
standard
practic
human
lymphoma
becom
canin
lymphoma
less
well
describ
appli
felin
lymphoma
partli
due
preval
intrabdomin
anatom
form
make
sampl
difficult
partli
due
variabl
pcr
primer
avail
sensit
largest
compil
felin
case
subject
rigor
histolog
classif
report
valli
other
use
nci
work
formul
also
publish
histolog
classif
system
use
real
system
basi
defin
histolog
categori
hematopoiet
tumor
domest
anim
system
incorpor
histolog
criteria
immunohistolog
criteria
eg
band
tcell
immunophenotyp
discuss
length
section
chapter
updat
kiel
classif
system
also
use
classifi
felin
lymphoma
regard
anatom
locat
profound
chang
present
signal
felv
antigenemia
immunophenotyp
frequenc
anatom
site
occur
cat
lymphoma
postfelv
era
see
tabl
shift
characterist
felin
lymphoma
discuss
chapter
primarili
limit
report
collect
case
present
sever
anatom
classif
exist
lymphoma
cat
categor
diseas
mediastin
alimentari
multicentr
nodal
leukem
individu
extranod
form
other
combin
variou
nodal
extranod
form
categori
atyp
unclassifi
mix
other
combin
intestin
splenic
hepat
mesenter
nodal
form
one
categori
term
intraabdomin
discrep
discuss
frequenc
inevit
result
variat
classif
use
literatur
rel
frequenc
anatom
form
associ
immunophenotyp
may
also
vari
geograph
distribut
may
relat
genet
felv
strain
differ
well
preval
felv
vaccin
use
purpos
chapter
felin
lymphoma
discuss
three
separ
section
alimentarygastrointestin
peripher
nodal
extranod
signal
clinic
present
diagnosi
treatment
prognosi
discuss
individu
three
section
lymphoma
common
tumor
type
found
gi
tract
cat
repres
case
epidemiolog
survey
intestin
tumor
speci
siames
breed
report
increas
risk
howev
major
case
occur
dsh
cat
although
lymphoma
may
occur
cat
age
primarili
diseas
age
cat
mean
year
tcell
alimentari
lymphoma
year
bcell
lymphoma
alimentarygi
lymphoma
confin
intestinalgastr
infiltr
combin
intestin
mesenter
lymph
node
hepatosplen
involv
uncommonli
cat
may
present
extraabdomin
coinvolv
tumor
solitari
commonli
diffus
throughout
intestin
consist
sex
bia
note
anatom
alimentari
lymphoma
nearli
four
time
like
occur
small
intestin
larg
intestin
seri
colon
neoplasia
cat
lymphoma
second
common
malign
second
adenocarcinoma
felin
gi
lymphoma
categor
one
three
type
base
histopatholog
immunohistopatholog
lowgrad
alimentari
lymphoma
lgal
intermediateor
highgrad
alimentari
lymphoma
ihgal
larg
granular
lymphoma
lgl
salient
generaliz
characterist
present
tabl
clear
vast
major
lgal
repres
mucos
epitheliotrop
small
tcell
immunophenotyp
aris
primarili
malt
thu
major
differenti
lgal
benign
lymphocyticplasmacyt
enter
lpe
commonli
refer
inflammatori
bowel
diseas
ibd
also
commonli
character
small
tcell
epitheliotrop
infiltr
largest
compil
lgal
n
classifi
gi
lymphoma
base
immunophenotyp
either
mucos
infiltr
confin
mucosa
lamina
propria
minim
submucos
extens
transmur
signific
extens
submucosa
musculari
propria
compar
infiltr
pattern
classif
scheme
well
document
anatom
locat
cell
size
presenc
epitheliotrop
clonal
outcom
data
inform
summar
tabl
case
none
test
serolog
posit
felv
three
cat
test
posit
fiv
four
cat
larg
bcell
lymphoma
gastric
cecal
colon
concurr
small
tcell
lymphoma
small
intestin
topograph
tcell
variant
much
like
occur
small
intestin
rare
stomach
larg
intestin
major
tcell
variant
mucos
equival
enteropathyassoci
tcell
lymphoma
eatcl
type
ii
major
bcell
tumor
transmur
equival
eatcl
type
classif
regard
cell
size
nearli
mucos
tcell
tumor
compos
small
lymphocyt
slightli
half
transmur
tcell
bcell
variant
compos
larger
cell
epitheliotrop
common
lgal
tcell
tumor
rare
bcell
tumor
abdomin
organ
involv
common
one
report
case
lowgrad
tcell
intestin
lymphoma
liver
mesenter
node
involv
document
case
respect
hepat
lymphoma
occur
concurr
gi
lymphoma
confin
sole
liver
tcell
clonal
oligoclon
base
pcr
analysi
unlik
lgal
major
ihgal
larg
intermedi
size
bcell
lymphoma
aris
organ
lymphoid
tissu
malt
stomach
peyer
patch
mucos
lymphoid
nodul
concentr
distal
small
intestin
cecum
colon
therefor
ihgal
common
stomach
distal
small
intestin
cecum
colon
see
tabl
bcell
variant
solitari
multipl
site
occur
simultan
within
stomach
small
intestin
ileocecocol
junction
major
transmur
equival
eatcl
type
classif
epitheliotrop
rare
observ
lgl
repres
less
common
distinct
form
alimentari
lymphoma
occur
older
median
age
year
cat
granul
round
cell
tumor
also
term
globul
leukocyt
tumor
although
like
variat
diseas
lgl
character
lymphocyt
describ
diamet
round
cleft
cerebriform
nucleu
variabl
distinct
nucleoli
fine
granular
lacey
chromatin
moder
amount
basophil
granular
cytoplasm
occasion
vacuol
promin
magenta
azurophil
granul
characterist
fig
chapter
usual
granzym
b
posit
immunohistochemistri
popul
cell
includ
cytotox
cell
occasion
nk
cell
tcell
receptor
gene
rearrang
one
report
nearli
express
integrin
alpha
e
lgl
confin
intestin
case
larg
compil
occur
extraabdomin
eg
nasal
approxim
express
neither
bor
tcell
marker
thu
classifi
nk
cell
nk
tumor
commonli
origin
small
intestin
especi
jejunum
transmur
often
exhibit
epitheliotrop
least
twothird
present
organ
involv
mesenter
lymph
node
involv
mani
liver
spleen
kidney
periton
malign
effus
bone
marrow
infiltr
also
thorac
involv
may
occur
malign
pleural
effus
mediastin
mass
present
peripher
blood
involv
present
report
often
anoth
report
affect
cat
gener
felvfiv
neg
lgal
commonli
associ
nonspecif
sign
associ
gi
tract
cat
present
weight
loss
vomit
andor
diarrhea
hyporexia
wherea
icteru
uncommon
abdomin
palpat
often
unremark
intestin
thicken
mesenter
lymphadenopathi
organomegali
occasion
appreci
clinic
sign
usual
present
sever
month
diagnosi
median
month
ihgal
tend
caus
similar
clinic
sign
lgal
howev
tend
progress
acut
like
present
palpabl
abdomin
mass
origin
gi
tract
enlarg
mesenter
lymph
node
liver
icteru
also
common
larg
cell
form
hematochezia
tenesmu
may
also
present
colon
involv
rare
cat
may
present
sign
consist
acut
abdomen
due
intestin
obstruct
perfor
concurr
periton
cat
intestin
lgl
typic
gi
clinic
sign
also
like
acut
present
palpabl
abdomin
mass
present
approxim
half
case
hepatomegali
splenomegali
renomegali
common
abdomin
pleural
effus
icteru
observ
nearli
case
cat
suspect
alimentarygi
lymphoma
diagnost
evalu
includ
baselin
assess
consist
cbc
differenti
cell
platelet
count
serum
biochemistri
profil
urinalysi
retrovir
felvfiv
screen
anemia
neutrophilia
common
find
form
alimentari
lymphoma
howev
tend
profound
ihgal
lgl
lgal
must
differenti
lpe
similar
clinic
present
histolog
cell
popul
lgal
commonli
associ
modest
palpabl
absent
intestin
thicken
without
mass
effect
similar
ident
present
lpe
key
element
necessari
diagnosi
lgal
differenti
ibd
includ
procur
tissu
histopatholog
necessari
assess
immunophenotyp
clonal
abdomin
ultrasound
mean
pathognomon
lgal
lpe
normal
ultrasound
appear
reveal
modest
intestin
wall
thicken
preserv
wall
layer
chang
present
predominantli
involv
musculari
propria
submucos
layer
although
mucos
thicken
also
occur
focal
mural
mass
uncommon
mesenter
lymphadenopathi
also
common
report
affect
cat
lgal
gener
involv
small
intestin
less
commonli
stomach
larg
intestin
cat
lgal
uncommonli
ultrasonograph
abnorm
abdomin
organ
stomach
liver
spleen
colon
pancrea
occasion
mild
effus
observ
cytolog
evalu
thicken
bowel
associ
mesenter
lymphadenopathi
alon
gener
suffici
differenti
lgal
lpe
therefor
tissu
procur
requir
diagnosi
differenti
lpe
debat
still
exist
whether
endoscop
obtain
tissu
suffici
diagnosi
fullthick
tissu
procur
laparotomi
laparoscopi
necessari
light
similar
lpe
although
histolog
morpholog
intestin
infiltr
pattern
eg
villou
nest
plaqu
highli
suggest
lymphoma
may
provid
definit
diagnosi
agre
although
full
thick
biopsi
prefer
less
invas
endoscop
biopsi
ancillari
immunophenotyp
molecular
ie
parr
see
chapter
assess
suffici
major
case
see
tabl
differenti
lymphoma
lpe
equivoc
standard
histopatholog
assess
addit
immunophenotyp
clonal
analysi
stepwis
fashion
propos
sever
report
enhanc
specif
sensit
usual
provid
definit
diagnosi
lgal
commonli
involv
jejunum
ilium
endoscop
biopsi
gastroduodenoscopi
ileocolonoscopi
may
necessari
procur
repres
sampl
diagnosi
ihgal
lgl
gener
less
complic
lgal
former
often
diagnos
physic
examin
abdomin
imag
eg
ultrasound
cytolog
histolog
assess
needl
aspir
needl
biopsi
sampl
intestin
mass
enlarg
mesenter
lymph
node
liver
mass
lesion
gross
lymphadenopathi
commonli
present
ultrasonograph
hgal
like
involv
stomach
colon
lgal
seri
cat
ihgal
stomach
either
ultrason
evid
wall
thicken
presenc
mass
abdomin
lymphadenopathi
less
commonli
abdomin
explor
necessari
lesion
subtl
amen
transabdomin
sampl
stage
via
thorac
imag
peripher
lymph
node
aspir
bone
marrow
assess
may
perform
rare
contribut
prognost
inform
alter
treatment
decis
diseas
alreadi
widespread
system
therapi
requir
gener
cat
toler
chemotherapi
lymphoma
quit
well
client
happi
choic
initi
treatment
qualiti
life
gener
improv
commenc
therapi
lgal
gratifi
diseas
treat
durabl
remiss
gener
achiev
welltoler
conserv
treatment
protocol
eg
oral
chlorambucil
prednisolon
chlorambucil
mgm
po
everi
week
prefer
author
mg
po
everi
day
prednisolon
initi
mgkg
po
daili
reduc
mgkg
everi
day
sever
week
result
respons
rate
ie
resolut
clinic
sign
greater
mst
approxim
year
clinic
oncologist
continu
conserv
protocol
year
longer
howev
one
report
discontinu
chlorambucilprednisolon
therapi
year
cat
relaps
receiv
protocol
often
subsequ
respond
altern
alkyl
agent
cyclophosphamid
mgm
po
week
lomustin
reintroduct
chlorambucil
discontinu
rescu
protocol
report
mst
rang
month
anecdot
mani
also
respond
vinblastin
chemotherapi
longer
respons
alkyl
agent
ultim
aggress
chopor
moppbas
protocol
may
util
conserv
protocol
longer
effect
prognost
factor
cat
lgal
welldefin
owe
indol
natur
diseas
typic
longterm
surviv
lack
respons
initi
induct
chemotherapi
consist
observ
neg
factor
although
transmur
extens
may
also
associ
shorter
st
aggress
multiag
combin
chemotherapi
recommend
ihgal
lgl
subtyp
lymphoma
agent
use
commonli
treat
intermediateor
highgrad
lymphoma
cat
similar
use
dog
lymphoma
see
section
chapter
induct
protocol
current
employ
cat
modif
chop
protocol
initi
design
human
chop
repres
combin
cyclophosphamid
c
doxorubicin
h
hydroxydaunorubicin
vincristin
oncovin
prednison
p
gener
chopbas
protocol
appropri
cat
intermediateand
highgrad
lymphoma
involv
anatom
site
eg
peripher
nodal
mediastin
extranod
form
firstlin
therapi
lowgrad
variant
lgal
dog
plethora
chopbas
protocol
report
use
cat
although
virtual
highqual
compar
data
exist
compar
outcom
protocol
use
base
cost
eas
clientveterinarian
prefer
level
comfort
one
report
found
cat
may
better
toler
chop
protocol
substitut
vinblastin
vincristin
gi
advers
event
less
frequent
lesser
grade
cat
receiv
vinblastin
current
chopbas
protocol
use
author
cat
present
tabl
protocol
use
mani
cat
variou
form
intermediateand
highgrad
lymphoma
gener
well
toler
present
canin
lymphoma
protocol
involv
induct
phase
whereupon
chemotherapi
discontinu
mainten
chemotherapi
use
although
data
exist
dog
maintenancefre
approach
similar
compar
data
current
exist
cat
dox
alon
mgm
everi
week
five
total
treatment
ccnu
lomustin
mgm
po
q
week
palli
prednison
therapi
offer
client
declin
aggress
chopbas
therapi
cat
gener
less
toler
dox
dog
therefor
lower
dosag
mgm
mgkg
iv
use
see
chapter
cardiac
toxic
appear
clinic
signific
problem
cat
although
renal
toxic
commonli
encount
renal
function
monitor
ie
serial
blood
urea
nitrogen
bun
creatinin
urin
specif
graviti
close
therapi
use
cop
ie
chop
without
addit
dox
often
use
cat
europ
one
compil
report
similar
result
chop
cop
cyclophosphamid
vincristin
prednisolon
protocol
commonli
employ
cat
present
tabl
howev
sever
studi
report
inclus
dox
import
predict
durabl
respons
use
intraperitonealdeliv
cop
small
number
cat
n
report
threequart
achiev
cr
mst
year
studi
includ
three
gi
case
histolog
immunophenotyp
subtyp
case
beyond
say
larg
cell
therefor
larger
control
studi
would
necessari
establishconfirm
efficaci
protocol
respons
rate
durabl
respons
cat
hgal
treat
combin
protocol
gener
good
dog
intermediateor
highgrad
peripher
nodal
lymphoma
remiss
rate
expect
approxim
onethird
achiev
cr
remiss
surviv
durabl
case
achiev
cr
mst
cat
cr
approxim
month
subset
live
year
longer
rescu
protocol
involv
altern
drug
eg
melphalan
lomustin
mechlorethamin
actinomycind
cytarabin
reinduct
chop
gener
result
durabl
subsequ
remiss
sever
prognost
factor
report
cat
hgal
howev
far
predict
whether
cr
achiev
neg
prognost
factor
identifi
ihgal
includ
transmur
extens
felv
antigenemia
weight
loss
elev
ldh
hypoalbuminemia
hypocobaliminemia
bicavitari
involv
stage
diseas
rare
associ
favor
prognosi
factor
found
prognost
immunophenotyp
variou
prolifer
indic
eg
pcna
agnor
cat
lgl
typic
lowest
report
respons
rate
shortest
respons
durat
gi
lymphoma
approxim
onethird
case
experi
respons
mst
larger
report
case
day
cat
receiv
chopbas
ccnubas
protocol
experienc
mst
day
said
small
subset
report
enjoy
durabl
month
surviv
respons
one
small
studi
n
mst
month
report
varieti
intervent
surgeri
primarili
reserv
ihgal
discret
lesion
cat
present
intestin
perfor
drug
dosag
rout
c
complet
remiss
week
therapi
discontinu
doxorubicin
cat
recheck
monthli
recurr
note
complet
blood
count
cbc
perform
chemotherapi
neutrophil
wait
day
repeat
cbc
administ
drug
neutrophil
risen
cutoff
obstruct
lesion
current
debat
whether
surgeri
perform
discret
lesion
perfor
obstruct
initi
system
chemotherapi
question
current
unansw
compar
trial
clearli
establish
benefit
detriment
approach
motiv
behind
perform
surgeri
chemotherapi
often
lie
concern
gi
perfor
result
robust
chemotherapi
respons
case
fullthick
involv
lymphoma
crous
report
cat
discret
hgal
undergo
chemotherapi
without
surgeri
although
four
cat
experienc
perfor
event
occur
day
initi
chemotherapi
rather
acut
postchemotherapi
period
associ
size
degre
hypoalbuminemia
progress
diseas
document
three
cat
partial
respons
cat
time
perfor
taken
togeth
impli
perfor
like
due
progress
diseas
rather
robust
respons
chemotherapi
addit
motiv
surgic
intervent
theoret
advantag
immedi
creation
minim
residu
diseas
state
stage
reveal
diseas
distant
larg
gi
primari
tumor
chemotherapi
gener
thought
result
favor
outcom
minim
diseas
state
rather
macroscop
diseas
state
author
gener
recommend
surgeri
albeit
absenc
convinc
support
literatur
lesion
larg
discret
minim
involv
document
outsid
primari
mass
complet
stage
multiag
chemotherapi
initi
sutur
remov
owe
highgrad
natur
overal
short
st
associ
ihgal
radiat
therapi
rt
gi
lymphoma
cat
thoroughli
explor
gener
reserv
consolid
therapi
chemotherapi
rescu
modal
one
report
cat
six
small
cell
four
larg
cell
one
lgl
progress
chemotherapi
receiv
abdomin
radiat
gy
two
fraction
day
experienc
mst
month
although
number
small
lost
followup
second
report
eight
cat
seven
hgal
underw
week
chopbas
combin
chemotherapi
follow
week
later
whole
abdomen
radiat
consist
daili
gy
fraction
although
three
cat
die
within
week
rt
five
experienc
durabl
remiss
preliminari
result
warrant
investig
rt
recommend
standard
care
intuit
gi
diseas
may
compromis
nutrit
statu
affect
cat
care
repeat
assess
nutrit
state
calor
intak
bodi
weight
undertaken
nutrit
support
see
chapter
section
b
institut
sooner
rather
later
affect
cat
good
plan
nutrit
help
maintain
improv
qualiti
life
immunolog
statu
toler
chemotherapi
cobalamin
supplement
institut
cat
document
hypocobalaminemia
involv
limit
peripher
lymph
node
unusu
cat
lymphoma
repres
approxim
case
contrast
approxim
onequart
anatom
form
lymphoma
compon
lymph
node
involv
onethird
cat
nodal
lymphoma
tcell
immunophenotyp
felv
antigenem
howev
complet
categor
occur
postfelv
era
may
longer
true
peripher
nodal
lymphoma
common
anatom
form
lymphoma
report
compil
case
cat
age
year
repres
onethird
case
age
group
lymphoma
progress
bone
marrow
hepat
infiltr
may
develop
clinic
stage
diagnost
approach
peripher
lymphadenopathi
peripher
nodal
lymphoma
similar
dog
see
section
chapter
cat
nodal
form
lymphoma
present
variabl
clinic
sign
depend
extent
diseas
howev
often
depress
letharg
peripher
lymphadenopathi
physic
find
uncommon
present
uncommon
distinct
form
nodal
lymphoma
cat
refer
hodgkinslik
lymphoma
report
form
typic
involv
solitari
region
lymph
node
head
neck
fig
histolog
resembl
hodgkin
lymphoma
human
affect
cat
gener
present
enlarg
one
two
mandibular
cervic
node
initi
tumor
immunophenotyp
classifi
tcellrich
bcell
lymphoma
histolog
lymph
node
effac
either
nodular
diffus
small
larg
lymphocyt
characterist
bizarr
multinucl
cell
reedsternberglik
cell
fig
associ
felv
fiv
document
cat
hodgkinslik
nodal
lymphoma
usual
present
without
overt
clinic
sign
inguin
node
multicentr
nodal
subcutan
conjunctiv
involv
report
interestingli
report
subcutan
hodgkin
lymphoma
cat
spontan
remiss
observ
suggest
may
true
lymphoid
neoplasia
clinic
cours
hodgkin
like
lymphoma
gener
indol
peripher
nodal
nonhodgkin
lymphoma
cat
treatment
choic
peripher
nodal
lymphoma
cat
depend
whether
individu
case
repres
lowgrad
eg
indol
rare
versu
intermediateor
highgrad
eg
intermediatelarg
cell
lymphoma
latter
fig
cat
present
mandibular
lymphadenopathi
confirm
hodgkinslik
lymphoma
histolog
assess
best
treat
chopor
copbas
protocol
discuss
ihgal
earlier
carri
less
favor
prognosi
wherea
former
gener
respond
less
aggress
chlorambucilcorticosteroid
protocol
enjoy
durabl
respons
less
known
regard
treatment
hodgkinslik
lymphoma
involv
solitari
region
node
head
neck
clinic
outcom
surgic
extirp
rt
affect
node
node
reason
number
often
associ
longterm
diseas
control
mst
approxim
year
suggest
indol
form
lymphoma
eventu
recurr
distal
node
surgic
excis
rt
common
author
current
offer
client
option
adjuv
chlorambucilcorticosteroid
surgeri
theoret
may
benefit
howev
insuffici
data
current
exist
document
surviv
advantag
approach
mediastin
form
involv
thymu
mediastin
sternal
lymph
node
pleural
effus
common
two
larg
compil
cat
thymic
diseas
cat
pleural
effus
document
lymphoma
hypercalcemia
occur
frequent
mediastin
lymphoma
dog
rare
cat
major
cat
mediastin
lymphoma
older
report
young
median
age
year
felv
posit
tcell
immunophenotyp
tumor
howev
mani
report
report
immunophenotyp
data
diseas
confin
mediastinum
case
form
mediastin
lymphoma
also
occur
primarili
young
felvneg
siames
cat
appear
less
biolog
aggress
respons
chemotherapi
felvassoci
form
recent
report
cat
mediastin
lymphoma
unit
kingdom
major
antigen
felvfiv
neg
young
median
age
year
male
maletofemal
ratio
nearli
onethird
siames
larg
cohort
immunophenotyp
report
clinic
sign
associ
mediastin
lymphoma
includ
dyspnea
tachypnea
noncompress
cranial
thorax
dull
heart
lung
sound
rare
horner
syndrom
precav
syndrom
may
observ
pleural
effus
observ
case
character
serohemorrhag
chylou
effus
case
neoplast
cell
lymphoblast
identifi
diagnost
suspicion
may
begin
noncompress
cranial
thorax
physic
examin
confirm
mediastin
masspleur
effus
thorac
radiograph
fineneedl
aspir
fna
cytolog
mass
cytolog
evalu
pleural
fluid
may
suffici
establish
diagnosi
cat
find
monoton
popul
intermedi
larg
lymphoid
cell
establish
diagnosi
howev
definit
diagnosi
lymphoma
cat
mediastin
mass
concurr
chylothorax
challeng
ct
appear
may
help
gener
contribut
definit
diagnosi
larg
lymphocyt
identifi
pleural
chylou
effus
cholesterol
triglycerid
concentr
measur
chylou
effus
pleural
fluid
triglycerid
concentr
greater
serum
howev
anorect
cat
may
lower
triglycerid
level
pleural
fluid
major
differenti
mediastin
lymphoma
thymoma
cytolog
featur
thymoma
distinct
lymphoma
mani
case
diagnosi
challeng
preponder
small
lymphocyt
thymoma
mast
cell
also
seen
aspir
thymoma
addit
immunophenotyp
clonal
assess
may
help
equivoc
case
largest
report
cat
mediastin
lymphoma
treat
either
copor
chopbas
protocol
experienc
overal
respons
rate
mst
day
day
cr
achiev
contrast
mediastin
lymphoma
young
felvposit
cat
gener
associ
poor
prognosi
mst
approxim
month
expect
treatment
chopor
copbas
protocol
collect
extranod
lymphoma
repres
second
common
site
lymphoma
gi
lymphoma
cat
common
extranod
site
lymphoma
cat
includ
nasal
includ
nasopharyng
sinonas
kidney
cn
laryng
tracheal
cutan
subcutan
ocular
clinic
sign
associ
felin
extranod
lymphoma
variabl
depend
anatom
locat
extent
diseas
mani
confin
primari
site
stage
appear
clinic
healthi
howev
cat
lymphoma
regardless
site
may
present
nonspecif
constitut
sign
includ
anorexia
weight
loss
lethargi
depress
secondari
bone
marrow
infiltr
although
uncommon
may
lead
anemia
sign
relat
paraneoplast
hypercalcemia
polyuriapolydipsia
pupd
occur
cat
howev
much
less
commonli
dog
one
survey
hypercalcemia
cat
approxim
diagnos
lymphoma
variou
anatom
type
cat
suspect
extranod
lymphoma
diagnost
evalu
includ
baselin
assess
consist
cbc
differenti
cell
count
platelet
count
serum
chemistri
profil
urinalysi
retrovir
felvfiv
screen
serum
biochemistri
profil
help
establish
overal
health
anim
well
case
suggest
sitespecif
tumor
involv
exampl
increas
liver
enzym
level
may
indic
hepat
infiltr
increas
bun
creatinin
may
indic
renal
lymphoma
hypoglycemia
report
approxim
onethird
cat
lymphoma
one
australian
studi
seri
cat
variou
anatom
form
lymphoma
serum
albumin
concentr
significantli
lower
concentr
measur
protein
electrophoresi
significantli
higher
healthi
control
popul
use
variou
imag
modal
cat
lymphoma
depend
anatom
site
discuss
sitespecif
discuss
follow
cytopatholog
histopatholog
evalu
involv
lymph
node
involv
organ
tissu
procur
via
fna
cytolog
see
chapter
surgic
endoscop
needlecor
biopsi
see
chapter
requir
definit
diagnosi
cytolog
alon
may
suffici
case
owe
difficulti
encount
distinguish
lymphoma
benign
hyperplast
reactiv
lymphoid
condit
case
incision
excision
biopsi
prefer
orient
inform
regard
invas
architectur
abnorm
may
necessari
diagnosi
addit
involv
tissu
needl
aspir
fluid
sampl
interrog
variou
histochem
immunohistochem
flow
cytometr
analysi
eg
size
immunophenotyp
assess
molecular
techniqu
eg
parr
assess
clonal
character
diseas
process
refin
diagnosi
equivoc
case
reader
refer
chapter
gener
discuss
flow
cytometr
analysi
molecular
diagnost
techniqu
well
section
chapter
specif
applic
lymphoma
parr
cat
approxim
sensit
diagnosi
lymphoma
howev
assess
specif
clearli
establish
clonal
assess
tool
eg
primer
ig
tcell
receptor
variabl
region
gene
develop
cat
assess
tumor
prolifer
rate
eg
pcna
agnor
telomeras
activ
serum
protein
electrophoresi
also
perform
involv
tissu
cat
howev
consist
prognost
valu
across
anatom
histopatholog
immunophenotyp
variant
lymphoma
cat
well
character
thorough
stage
includ
bone
marrow
aspir
biopsi
peripher
lymph
node
assess
clinic
normal
abnorm
node
thorac
andor
abdomin
imag
indic
solitari
site
diseas
suspect
stage
decis
locoregion
therapi
ie
surgeri
andor
rt
versu
system
therapi
ie
chemotherapi
consid
provid
prognost
inform
help
caregiv
make
treatment
decis
complet
stage
extent
diseas
requir
part
clinic
trial
bone
marrow
evalu
may
particular
interest
anemia
cellular
atypia
leukopenia
present
stage
system
exist
cat
similar
use
dog
see
box
howev
high
incid
visceralextranod
involv
cat
separ
stage
system
evalu
often
use
box
lymphoma
cat
vari
respect
anatom
locat
stage
system
gener
less
help
predict
respons
knowledg
base
treat
cat
extranod
lymphoma
well
establish
outcom
less
predict
dog
primarili
due
greater
variat
histolog
type
anatom
locat
observ
cat
complic
plethora
paper
includ
small
number
case
repres
multipl
anatomicimmunophenotyp
histolog
subtyp
eg
small
cell
vs
larg
cell
variant
togeth
report
surviv
analysi
chemotherapi
provid
gener
observ
rather
specif
outcom
inform
ie
respons
rate
durabl
respons
vari
significantli
respect
anatom
histolog
subtyp
treatment
decis
base
assess
whether
individu
case
repres
lowgrad
eg
indol
versu
intermediateor
highgrad
eg
larg
cell
lymphoma
whether
diseas
limit
local
extranod
site
chemotherapi
protocol
cat
previous
discuss
section
gi
lymphoma
lowgrad
tumor
gener
treat
chlorambucilprednisolon
protocol
intermediateor
highgrad
tumor
chopor
copbas
protocol
final
much
earli
work
chemotherapi
protocol
develop
cat
lymphoma
occur
felv
era
care
exercis
appli
inform
postfelv
era
nasal
lymphoma
common
extranod
lymphoma
cat
usual
local
diseas
howev
local
extens
distant
metastasi
necropsi
major
nonvir
nasalparanas
diseas
cat
neoplasia
lymphoma
repres
onethird
onehalf
case
occur
primarili
older
median
age
year
rang
year
felvfiv
antigenem
neg
cat
least
threequart
bcell
origin
although
tcell
mix
bcelltcel
immunophenotyp
report
case
italian
report
document
felv
antigen
express
nasal
lymphoma
tissu
immunohistochemistri
ihc
howev
felv
antigenemia
report
cohort
siames
cat
appear
overrepres
maletofemal
ratio
also
observ
intermediateor
highgrad
histolog
howev
smallcel
lowgrad
variant
report
cohort
epitheliotrop
common
epithelium
present
biopsi
singl
tumor
extranod
region
lymph
node
involv
two
nodal
area
side
diaphragm
two
singl
extranod
tumor
without
region
lymph
node
involv
side
diaphragm
resect
primari
gastrointestin
tract
tumor
usual
ileocec
area
without
involv
associ
mesenter
node
stage
two
singl
tumor
extranod
opposit
side
diaphragm
two
nodal
area
diaphragm
extens
primari
unresect
intraabdomin
diseas
paraspin
epidur
tumor
regardless
tumor
site
site
stage
liver
andor
spleen
involv
stage
initi
involv
cn
bone
marrow
cat
nasal
lymphoma
present
nasal
discharg
sneez
upper
respiratori
nois
stridor
stertor
wheez
facial
deform
hyporexia
epiphora
occasion
increas
respiratori
effort
cough
nasal
discharg
usual
mucopurul
although
epistaxi
present
onethird
case
region
lymphadenopathi
also
occur
median
durat
clinic
sign
diagnosi
month
rang
day
nasal
lymphoma
suspect
advanc
imag
ct
mri
rhinoscopi
biopsi
usual
necessari
diagnosi
see
chapter
section
b
ct
mri
use
determin
extent
involv
help
plan
biopsi
procur
rt
treatment
option
pursu
ct
characterist
includ
presenc
unilater
bilater
nasalsinu
mass
fluid
bulla
effus
lysi
associ
boni
structur
biopsi
procur
either
intranas
procur
without
rhinoscopi
flush
one
hemicav
bulb
syring
salin
occlud
contralater
caviti
collect
sampl
flush
nasopharynx
fig
thorough
stage
ie
region
node
assess
thorac
abdomin
stage
bone
marrow
assess
ensur
diseas
confin
nasal
passag
recommend
local
rt
without
system
chemotherapi
consid
ihc
may
necessari
differenti
nasal
carcinoma
nasal
lymphoma
subset
case
approxim
sampl
requir
ihc
differenti
carcinoma
lymphoma
one
larg
cohort
case
one
report
cat
nasal
lymphoma
treat
mst
day
howev
cat
treat
durabl
remiss
lengthi
mst
expect
major
case
diseas
document
confin
nasal
caviti
ie
stage
thorough
stage
rt
treatment
choic
cr
rate
report
mst
rt
year
cat
achiev
cr
rt
mst
approxim
month
total
radiat
dosag
affect
st
total
dose
greater
gy
recommend
addit
chemotherapi
rt
definit
shown
enhanc
st
cat
local
confin
diseas
combin
rt
chemotherapi
result
similar
respons
rate
st
chemotherapi
copor
chopbas
protocol
reason
altern
rt
cr
rate
approxim
mst
approxim
year
cat
achiev
cr
author
prefer
initi
system
chemotherapi
case
confirm
diseas
beyond
nasal
passag
case
relaps
rt
case
rt
unavail
declin
renal
lymphoma
second
common
form
extranod
lymphoma
occur
approxim
onethird
case
although
present
confin
kidney
commonli
present
concurr
alimentari
multicentr
lymphoma
median
age
present
year
although
occur
cat
year
age
major
case
associ
felv
although
associ
fiv
approxim
onehalf
cat
report
australian
studi
fiv
posit
littl
contemporari
inform
exist
immunohistolog
classif
renal
lymphoma
howev
major
highgrad
bcell
immunophenotyp
extens
cn
frequent
one
report
similarli
report
elsewher
cat
renal
lymphoma
present
sign
consist
renal
insuffici
hyporexia
weight
loss
polyuriapolydipsia
physic
examin
mark
renomegali
bilater
lumpi
irregular
although
smooth
variant
observ
palpat
major
case
fig
radiograph
appear
smoothtoirregular
renomegali
fig
ultrasonograph
imag
usual
reveal
bilater
irregular
renomegali
hypoecho
subcapsular
thicken
approxim
onethird
case
ultrasonograph
evid
abdomin
organ
involv
diseas
usual
diffus
throughout
renal
cortex
fig
transabdomin
fna
cytolog
core
biopsi
diagnost
case
treatment
outcom
appear
similar
highgrad
lymphoma
cat
approxim
twothird
experi
clinic
benefit
copor
chopbas
protocol
mst
report
month
owe
inabl
differenti
much
renal
insuffici
present
lymphomarel
versu
due
underli
renal
diseas
older
cat
oncologist
start
copbas
protocol
add
dox
renal
valu
normal
remiss
potenti
renal
toxic
dox
cat
cn
lymphoma
intracrani
extracrani
ie
spinal
cn
lymphoma
account
report
case
extranod
lymphoma
intracrani
tumor
spinal
cord
tumor
make
one
common
malign
encout
cn
cat
although
discord
exist
literatur
cat
cn
lymphoma
younger
median
age
year
case
felv
antigenem
report
older
data
may
longer
hold
true
current
era
approxim
twothird
intracrani
case
also
multicentr
extracrani
diseas
approxim
spinal
lymphoma
case
occur
multipl
spinal
cord
site
onethird
also
involv
intracrani
locat
compil
case
intracrani
tumor
cat
diffus
cerebr
brainstem
involv
common
lymphoid
malign
spinal
lesion
usual
extradur
intradur
although
limit
one
compart
felin
cn
lymphoma
may
primari
commonli
approxim
repres
multicentr
process
especi
renal
bone
marrow
involv
pauciti
inform
exist
immunophenotyp
cn
lymphoma
cat
cn
lymphoma
present
constitut
sign
hyporexia
lethargi
sign
refer
intracrani
lesion
spinal
lesion
intracrani
sign
may
includ
ataxia
alter
conscious
aggress
central
blind
vestibular
abnorm
studi
cat
seizur
diagnos
intracrani
lesion
due
lymphoma
clinic
sign
refer
spinal
cord
involv
may
includ
paresi
paraplegia
tetraparesi
ataxia
pain
constip
nonspecif
constitut
sign
eg
hyporexia
lethargi
weight
loss
neurolog
examin
may
reveal
lower
upper
motor
neuron
bladder
tail
flaccid
absent
deep
pain
approxim
onethird
cat
asymmetr
refer
thoracolumbar
involv
neurolog
dysfunct
may
insidi
progress
rapidli
cat
suspect
spinal
lymphoma
survey
radiograph
spine
rare
reveal
osseou
lesion
ct
mri
prefer
approxim
case
extradur
intradur
mass
detect
lesion
occur
thoracolumbar
lumbosacr
locat
often
multifoc
imageguid
fna
epidur
lesion
may
yield
cytolog
diagnosi
ct
mri
also
reveal
multifoc
diseas
major
cat
intracrani
lymphoma
csf
analysi
may
help
could
provid
definit
diagnosi
case
one
cat
confirm
spinal
lymphoma
one
studi
six
confirm
intracrani
lymphoma
anoth
studi
evid
neoplast
lymphocyt
cn
increas
protein
content
commonli
found
bone
marrow
renal
involv
often
present
cytolog
assess
access
involv
organ
gener
easili
attain
spinal
site
case
report
chemotherapi
treatment
outcom
cn
lymphoma
although
occasion
case
experienc
durabl
respons
system
chemotherapi
gener
fewer
respond
mst
month
expec
ted
rt
may
use
gener
brisk
respons
would
expect
owe
inher
radiosensit
lymphocyt
adjuv
chemotherapi
consid
mani
case
cn
lymphoma
document
bone
marrow
renal
involv
cutan
lymphoma
rare
encount
anatom
form
cat
usual
seen
older
cat
median
age
year
sex
breed
predomin
associ
felvfiv
diffus
vari
present
decreas
order
likelihood
lesion
may
includ
erythemat
patch
alopecia
scale
dermal
nodul
ulcer
plaqu
nasal
hypopigment
miliari
dermat
mucos
lesion
rare
observ
peripher
lymphadenopathi
may
also
present
cat
durat
sign
prolong
last
sever
month
cutan
lymphoma
often
affect
head
face
gener
indol
diseas
two
form
distinguish
histolog
immunohistochem
report
cat
epitheliotrop
consist
cell
although
unlik
dog
adnex
structur
often
spare
report
nonepitheliotrop
cutan
lymphoma
cat
also
found
case
tcell
deriv
cutan
lymphocytosi
uncommon
diseas
histolog
resembl
welldifferenti
lymphoma
character
cat
solitari
lesion
common
compos
primarili
cell
twothird
bcell
aggreg
cutan
lymphocytosi
character
slowli
progress
disord
howev
case
went
develop
intern
organ
infiltr
two
case
report
exist
cat
cutan
tcell
lymphoma
circul
atyp
lymphocyt
circul
cell
lymphocyt
larg
hyperchromat
groov
nuclei
one
case
immunophenotyp
popul
human
cutan
tcell
lymphoma
circul
malign
cell
term
syndrom
cat
suspect
cutan
lymphoma
dermal
punch
biopsi
mm
taken
repres
infiltr
site
avoid
overtli
infect
skin
lesion
immunophenotyp
parr
analysi
often
help
definit
diagnosi
complet
stage
rule
system
diseas
also
recommend
cat
cutan
lymphoma
local
therapi
may
appli
case
solitari
diseas
littl
publish
regard
treatment
cutan
lymphoma
cat
howev
report
cr
lomustin
exist
cat
solitari
diseas
could
theoret
treat
surgic
excis
rt
although
clinic
stage
necessari
rule
possibl
system
involv
multipl
site
combin
chemotherapi
consid
recent
sever
retrospect
compil
subcutan
form
lymphoma
scl
report
although
refer
cutan
lymphoma
report
clinic
histolog
characterist
impli
sc
local
affect
cat
older
dsh
cat
male
may
overrepres
overal
appear
uncommon
present
repres
cutaneoussc
mass
submit
report
case
retrovir
felvfiv
antigenemia
rare
although
one
report
cat
felv
andor
protein
express
major
tumor
tissu
cat
scl
present
firm
painless
sc
nodul
predilect
later
thorac
later
abdomin
wall
intrascapular
tarsal
locat
fig
histolog
character
deep
sc
invas
monomorph
round
cell
popul
extens
underli
tissu
overli
superfici
tissu
epitheliotrop
extens
central
necrosi
peripher
inflamm
collar
angiocentr
angioinvas
often
observ
mitot
index
rang
hpf
round
cell
popul
character
larg
highgrad
b
cell
approxim
twothird
case
highgrad
cell
onethird
occasion
nk
immunophenotyp
report
anim
otherwis
healthi
substag
diseas
gener
confin
local
site
present
stage
although
one
report
tarsal
locat
associ
region
poplit
lymph
node
involv
nearli
case
two
case
concurr
felin
injectionsit
sarcoma
fiss
found
site
scl
sever
similar
fiss
includ
clinic
present
site
occurr
poor
demarc
central
necrosi
peripher
inflamm
although
macrophag
phagocyt
vaccinelik
product
observ
within
inflammatori
compon
similar
suggest
possibl
injectionsit
inflamm
may
play
role
diseas
etiolog
howev
confirm
regardless
scl
remain
import
differenti
consider
fiss
treatment
scl
literatur
vari
standard
care
current
establish
although
diseas
initi
confin
local
primari
site
case
recurr
local
therapi
whether
surgic
excis
rt
occur
nearli
half
case
eventu
distant
metastasi
occur
onethird
case
approxim
affect
cat
go
die
lymphoma
therefor
scl
consid
aggress
biolog
behavior
largest
report
median
progressionfre
overal
st
primari
site
surgic
remov
day
day
respect
case
tarsal
scl
even
hindlimb
amput
three
cat
region
nodal
distant
involv
document
case
day
albeit
durabl
diseasefre
interv
observ
two
cat
limit
number
cat
treat
rt
respons
brisk
progress
beyond
radiat
field
efficaci
chemotherapi
current
well
known
small
number
case
receiv
varieti
chemotherapi
protocol
although
mani
respond
stabil
durabl
poor
mst
approxim
month
seven
case
tarsal
scl
receiv
chemotherapi
rt
mst
day
diseas
high
recurr
metastat
behavior
like
multimod
approach
involv
local
therapi
surgeri
andor
rt
system
chemotherapi
would
intuit
provid
best
outcom
laryng
lymphoma
compris
case
extranod
form
one
report
repres
laryng
diseas
speci
occur
older
cat
median
age
year
associ
felv
may
solitari
lesion
occur
presenc
multicentr
site
inform
immunophenotyp
current
avail
sign
associ
locat
affect
cat
includ
dyspnea
dysphonia
stridor
gag
retch
rare
cough
although
gener
local
primari
site
stage
approxim
region
nodal
involv
one
report
vast
major
cat
laryng
tracheal
lymphoma
respond
either
rt
local
system
chemotherapi
cr
copor
chopbas
protocol
fig
wherea
author
experi
durabl
respons
st
typic
approach
exceed
year
publish
report
mst
rang
month
achiev
cr
compil
case
intraocular
tumor
cat
lymphoma
seven
bcell
four
tcell
four
evalu
presum
prove
major
part
system
multicentr
process
inde
lymphoma
common
metastat
cancer
felin
eye
cat
survey
system
lymphoma
nearli
half
ocular
chang
uveiti
common
follow
exophthalmo
corneal
ulcer
chemosi
histolog
character
uveiti
cat
lymphoma
diagnos
approxim
onethird
case
howev
whether
part
system
process
limit
eye
unclear
nearli
half
case
document
nearli
half
felv
antigenem
cat
data
like
littl
bear
modern
incid
diseas
presum
solitari
ocular
lymphoma
psol
rare
cat
identifi
case
extranod
lymphoma
one
report
cat
ocular
lymphoma
present
uveiti
iridi
mass
well
sign
relat
system
involv
diseas
sporad
report
appear
literatur
major
approxim
bcell
immunophenotyp
one
case
lgl
psol
document
intraocular
retin
conjunctiv
locat
report
outcom
poorli
defin
report
case
underw
enucl
often
experienc
longterm
outcom
st
month
year
report
previous
discuss
predict
outcom
cat
lymphoma
generaliz
wide
spectrum
histolog
anatom
subtyp
encount
much
mention
previou
treatment
section
tabl
summar
prognost
paramet
lymphoma
cat
complet
discuss
leukemia
mpd
includ
gener
discuss
hematopoiesi
etiolog
lineag
classif
descript
see
section
c
chapter
classif
leukemia
cat
difficult
similar
clinic
patholog
featur
transit
overlap
mixtur
cell
type
involv
case
felv
era
gener
singl
case
report
exist
contemporari
postfelv
era
confus
understand
biolog
outcom
reason
simplist
discuss
primarili
relat
lymphoid
leukemia
present
interest
reader
refer
section
c
chapter
gener
discuss
nonlymphoid
leukemia
cat
suspect
leukemia
peripher
blood
assess
eg
cbc
differenti
flow
cytometr
analysi
size
immunophenotyp
parr
lymphoid
leukemia
bone
marrow
aspir
biopsi
may
contribut
diagnosi
cat
acut
leukemia
like
malign
cellular
infiltr
organ
bone
marrow
bone
marrow
aspir
greater
abnorm
blast
cell
suffici
make
diagnosi
acut
leukemia
cat
suspect
cll
infiltr
bone
marrow
matur
lymphocyt
help
support
diagnosi
cat
leukemia
test
felvfiv
determin
lineag
leukemia
challeng
distinguish
histolog
appear
histochem
stain
immunohistochem
flow
cytometr
analysi
leukem
cell
cellular
antigen
identifi
lineag
see
chapter
section
c
chapter
addit
examin
blast
cell
electron
microscopi
may
reveal
characterist
ultrastructur
featur
frenchamericanbritish
fab
classif
system
consid
use
cat
myelodysplast
syndrom
almost
report
case
felv
antigenem
lymphoid
leukemia
commonli
encount
type
leukemia
cat
felv
era
howev
much
less
common
today
character
poorli
differenti
lymphoblast
prolymphocyt
blood
bone
marrow
approxim
cat
felv
posit
malign
cell
tcell
immunophenotyp
howev
littl
inform
avail
contemporari
literatur
cll
rare
report
cat
character
welldifferenti
small
matur
lymphocyt
peripher
blood
bone
marrow
largest
compil
cat
older
half
present
incident
half
nonspecif
constitut
sign
weight
loss
hyporexia
specif
serum
biochem
abnorm
note
howev
anem
thrombocytopen
peripher
lymphocyt
count
greater
although
cutoff
requir
diagnosi
cat
test
n
neg
felvfiv
median
peripher
lymphocyt
count
rang
wherea
tcell
lineag
bcell
cll
also
report
cat
one
report
case
cll
cat
found
thelper
cell
use
chemotherapi
treat
disappoint
use
copbas
protocol
cr
rate
report
cll
treat
chlorambucil
mgkg
po
mg
cat
qod
altern
mgm
week
prednisolon
mgkg
po
daili
cat
treat
chlorambucil
prednisolon
approxim
respond
median
remiss
durat
month
howev
half
achiev
cr
median
remiss
durat
month
sever
cat
rescu
variou
protocol
recurr
mani
prolong
second
remiss
human
dog
signific
clinic
sign
profound
cytopenia
present
treatment
withheld
one
cat
cll
remain
stabl
without
chemotherapi
year
prognos
felin
all
gener
poor
although
except
exist
case
report
form
histor
literatur
myeloprolif
disord
mpd
group
neoplast
diseas
bone
marrow
clonal
disord
hematopoiet
stem
cell
aberr
prolifer
cell
defect
matur
function
lead
reduct
normal
hematopoiesi
invas
tissu
disord
classifi
base
biolog
behavior
degre
cellular
differenti
lineag
neoplast
cell
granulocyt
monocyt
erythroid
megakaryocyt
mix
newer
classif
system
human
incorpor
genet
molecular
genet
analysi
current
area
activ
investig
studi
anim
mpd
anim
leukemia
studi
group
made
recommend
classifi
nonlymphoid
leukemia
dog
cat
recent
oncolog
committe
american
colleg
veterinari
pathologist
acvp
reexamin
criteria
classif
system
spearhead
larg
multiinstitut
studi
valid
criteria
longterm
object
studi
defin
molecular
lesion
establish
prognost
marker
identifi
effect
therapeut
approach
see
box
myeloid
neoplasm
uncommon
rare
dog
occur
time
less
frequent
lymphoprolif
disord
accur
inform
incid
epidemiolog
inform
gener
lack
owe
lack
consist
use
uniform
classif
system
howev
sever
larger
compil
publish
recent
consist
breed
predilect
largebre
dog
median
age
year
although
acut
myeloid
leukemia
aml
occur
dog
young
month
age
aml
occur
frequent
male
femal
ratio
two
larg
compil
dog
etiolog
spontan
occur
leukemia
unknown
like
genet
environment
factor
includ
exposur
radiat
drug
toxic
chemic
play
role
human
acquir
chromosom
derang
lead
clonal
overgrowth
arrest
develop
chromosom
myeloid
leukemia
myeloprolif
disord
rare
neoplast
diseas
bone
marrow
clonal
disord
hematopoiet
stem
cell
tabl
clonal
disord
bone
marrow
includ
myeloaplasia
usual
refer
aplast
anemia
myelodysplasia
myeloprolifer
term
acut
chronic
refer
degre
cellular
differenti
leukem
cell
term
also
correl
biolog
behavior
neoplasm
acut
myeloid
leukemia
aml
aggress
leukemia
progress
rapidli
poorli
respons
treatment
associ
short
surviv
time
typic
month
aml
determin
leukem
lineag
ie
neutrophil
monocyt
erythroid
megakaryocyt
origin
requir
advanc
diagnost
test
cytochem
stain
flow
cytometr
analysi
clonal
test
genet
analysi
myeloprolif
neoplasm
mpn
previous
term
chronic
myeloprolif
disord
character
excess
product
differenti
bone
marrow
cell
result
accumul
erythrocyt
polycythemia
vera
granulocyt
andor
monocyt
chronic
myelogen
leukemia
variant
platelet
essenti
thrombocythemia
degre
differenti
cell
mpn
disord
must
distinguish
nonneoplast
caus
increas
cell
type
compar
aml
mpn
myelodysplasia
chronic
cours
may
better
respons
therapi
although
progress
ultim
result
mortal
abnorm
report
dog
aml
chronic
myelogen
leukemia
cml
lymphoid
leukemia
howev
karyotyp
difficult
perform
dog
larg
number
morpholog
similar
chromosom
resist
band
defin
genet
factor
canin
myeloid
neoplasm
await
applic
molecular
technolog
use
canin
genom
map
certain
form
leukemia
dog
produc
experiment
irradi
contrast
mpd
cat
caus
viral
agent
demonstr
dog
although
retroviruslik
bud
particl
observ
neoplast
cell
dog
granulocyt
leukemia
review
normal
hematopoiesi
aid
understand
variou
manifest
mpd
hematopoiesi
process
prolifer
differenti
matur
stem
cell
termin
differenti
blood
cell
simplifi
scheme
present
fig
pluripot
stem
cell
differenti
either
lymphopoiet
hematopoiet
multipot
stem
cell
influenc
specif
regulatori
microenvironment
factor
multipot
stem
cell
bone
marrow
differenti
progenitor
cell
commit
specif
hematopoiet
cell
line
exampl
erythroid
granulocyticmonocyt
megakaryocyt
matur
result
product
termin
differenti
blood
cell
erythrocyt
granulocyt
monocyt
platelet
deliv
circul
case
matur
reticulocyt
erythrocyt
final
develop
may
occur
spleen
prolifer
differenti
hematopoiet
cell
control
group
regulatori
growth
factor
erythropoietin
best
character
regul
erythroid
prolifer
differenti
produc
kidney
chang
oxygen
tension
detect
myeloid
compart
depend
group
factor
collect
refer
colonystimul
factor
csf
factor
act
level
commit
progenitor
cell
also
influenc
function
capabl
matur
cell
factor
broad
spectrum
activ
other
restrict
target
cell
action
csf
produc
vitro
multitud
cell
type
includ
monocyt
macrophag
lymphocyt
endotheli
cell
cell
like
play
role
product
regul
factor
vivo
gene
thrombopoietin
also
clone
appear
hormon
alon
induc
differenti
megakaryocyt
platelet
product
recombin
form
mani
growth
factor
increasingli
avail
clonal
disord
bone
marrow
includ
myeloaplasia
usual
refer
aplast
anemia
myelodysplasia
myeloprolifer
preleukem
syndrom
character
peripher
pancytopenia
bone
marrow
hyperplasia
matur
arrest
correctli
term
myelodysplasia
syndrom
alway
progress
overt
leukemia
syndrom
describ
cat
usual
associ
felv
infect
rare
recogn
dog
clonal
disord
may
manifest
abnorm
lineag
hematopoiet
cell
share
common
stem
cell
addit
transform
one
form
anoth
may
occur
myeloid
neoplasm
classifi
sever
way
term
acut
chronic
refer
degre
cellular
differenti
leukem
cell
term
also
correl
biolog
behavior
neoplasm
disord
result
uncontrol
prolifer
decreas
apoptosi
cell
incap
matur
lead
accumul
poorli
differenti
blast
cell
disord
includ
umbrella
term
aml
disord
result
unregul
prolifer
cell
exhibit
progress
albeit
incomplet
defect
matur
lead
accumul
differenti
cell
thu
call
chronic
disord
disord
term
myeloprolif
neoplasm
mpn
includ
polycythemia
vera
cml
variant
essenti
thrombocythemia
possibl
primari
myelofibrosi
myeloid
neoplasm
classifi
lineag
domin
cell
type
defin
romanowski
stain
special
cytochem
stain
ultrastructur
featur
flow
cytometr
analysi
molecular
genet
analysi
immunolog
cell
marker
classifi
subtyp
aml
sudden
onset
clinic
aggress
acut
chronic
disord
howev
abnorm
prolifer
matur
function
characterist
occur
hematopoiet
cell
line
addit
normal
hematopoiesi
advers
affect
anim
acut
leukemia
usual
decreas
number
circul
normal
cell
pathogenesi
cytopenia
complex
may
result
part
product
inhibitori
factor
eventu
neoplast
cell
displac
normal
hematopoiet
cell
term
myelophthisi
anemia
thrombocytopenia
particularli
common
neutropenia
thrombocytopenia
result
infect
hemorrhag
respect
may
deleteri
anim
primari
diseas
process
aml
rare
character
aberr
prolifer
decreas
apoptosi
clone
cell
without
matur
result
accumul
immatur
blast
cell
bone
marrow
peripher
blood
fig
white
blood
cell
wbc
count
variabl
rang
leukopenia
count
greater
spleen
liver
lymph
node
frequent
involv
tissu
includ
tonsil
kidney
heart
cn
may
infiltr
well
median
age
approxim
year
howev
young
dog
may
affect
clinic
cours
disord
tend
rapid
product
normal
peripher
blood
cell
usual
diminish
absent
anemia
neutropenia
thrombocytopenia
common
infect
hemorrhag
occur
frequent
sequela
occasion
neoplast
blast
present
bone
marrow
peripher
blood
term
aleukem
leukemia
wherea
subleukem
suggest
normal
decreas
wbc
count
neoplast
cell
circul
anim
leukemia
studi
group
form
auspic
american
societi
veterinari
clinic
patholog
develop
specif
morpholog
cytochem
criteria
classifi
acut
nonlymphocyt
leukemia
recognit
specif
subtyp
leukemia
requir
compil
accur
use
inform
prognosi
respons
treatment
well
compar
studi
differ
site
group
propos
classif
system
follow
adapt
fab
system
criteria
establish
nci
workshop
group
member
examin
blood
bone
marrow
dog
cat
myeloid
neoplasm
romanowskystain
specimen
examin
first
identifi
blast
cell
percentag
lineag
specif
determin
use
cytochem
marker
percentag
blast
inform
lineag
specif
use
combin
classifi
disord
acut
undifferenti
leukemia
aul
aml
subtyp
erythroleukemia
without
erythroid
predomin
descript
subtyp
present
tabl
modifi
fab
system
adopt
recent
name
given
disord
literatur
vari
consider
addit
absenc
cytochem
stain
immunophenotyp
electron
microscop
evalu
specif
subtyp
leukemia
often
uncertain
make
retrospect
analysi
epidemiolog
inform
prognosi
respons
therapi
confus
best
although
defin
specif
subtyp
may
seem
academ
exercis
owe
uniformli
poor
prognosi
acut
leukemia
inform
critic
improv
manag
low
incid
aml
nation
intern
cooper
effort
requir
accumul
inform
pathogenesi
respons
differ
treatment
modal
specif
subtyp
util
uniform
classif
system
essenti
first
step
differ
form
aml
demonstr
fig
except
acut
promyelocyt
leukemia
aml
subtyp
describ
dog
combin
three
recent
compil
dog
aml
rel
frequenc
subtyp
decreas
order
monocyt
leukemia
myelomonocyt
leukemia
myeloblast
leukemia
without
differenti
megakaryoblast
leukemia
one
myeloblast
leukemia
differenti
erythroleukemia
aml
mix
lineag
compris
case
mani
singl
case
small
case
seri
report
also
exist
describ
variou
subtyp
dog
monocyt
leukemia
like
includ
without
monocyt
differenti
case
diagnosi
may
chronic
myelomonocyt
chronic
monocyt
leukemia
report
dog
spontan
occur
erythroleukemia
leukem
cell
includ
myeloblast
monoblast
erythroid
element
aul
uncertain
lineag
neg
cytochem
marker
leukemia
distinguish
lymphoid
leukemia
flow
cytometr
analysi
leukem
cell
cellular
antigen
identifi
lineag
addit
examin
blast
cell
electron
microscopi
may
reveal
characterist
ultrastructur
featur
canin
karyotyp
difficult
advanc
molecular
cytogenet
analysi
chromosom
paint
genom
hybrid
aml
dog
analyz
basepair
level
missens
mutat
ckit
ra
sequenc
identifi
dog
aml
similar
found
human
aml
bcrabl
transloc
also
report
dog
acut
myeloblast
leukemia
recurr
dna
copi
number
abnorm
cna
interrog
dog
aml
potenti
cna
cluster
use
diagnost
model
addit
serv
diagnost
prognost
marker
cytogenet
lesion
may
therapeut
target
cytogenet
abnorm
continu
identifi
inform
need
incorpor
classif
scheme
myeloprolif
neoplasm
mpn
previous
term
chronic
myeloprolif
disord
character
excess
product
differenti
bone
marrow
cell
result
accumul
erythrocyt
polycythemia
vera
granulocyt
andor
monocyt
cml
variant
platelet
essenti
thrombocythemia
primari
myelofibrosi
clonal
disord
bone
marrow
stromal
cell
character
prolifer
megakaryocyt
granulocyt
precursor
accumul
collagen
bone
marrow
recogn
rare
anim
phenotypicdriv
mutat
calr
mpl
gene
identifi
peopl
polycythemia
vera
pv
essenti
thrombocythemia
et
primari
myelofibrosi
mutat
investig
dog
pv
ident
mutat
peopl
found
case
dog
myelofibrosi
consid
respons
injuri
may
occur
secondari
neoplasm
system
inflamm
drug
exposur
felv
infect
cat
polycythemia
vera
pv
clonal
disord
stem
cell
although
whether
defect
pluripot
stem
cell
hematopoiet
multipot
stem
cell
still
clear
diseas
rare
must
distinguish
common
caus
polycythemia
pv
neoplast
prolifer
erythroid
seri
termin
differenti
rbc
diseas
report
dog
tend
middleag
breed
sex
predilect
character
increas
rbc
mass
evidenc
increas
pack
cell
volum
pcv
rbc
count
hemoglobin
concentr
pcv
typic
rang
bone
marrow
hyperplast
although
myeloidtoerythroid
e
ratio
tend
normal
contrast
diseas
human
cell
line
appear
involv
transform
mpn
report
diseas
dog
may
appropri
term
primari
erythrocytosi
human
progenitor
cell
increas
sensit
insulinlik
growth
factor
stimul
hematopoiesi
known
whether
hypersensit
primari
defect
secondari
anoth
gene
mutat
case
result
overproduct
red
blood
cell
rbc
acquir
gene
mutat
identifi
human
pv
ident
mutat
gene
dog
pv
report
dog
cml
similar
chronic
neutrophil
leukemia
rare
form
mpn
human
cml
human
neoplast
prolifer
neutrophil
seri
although
concurr
eosinophil
basophil
differenti
occur
cml
occur
dog
age
neutrophil
neutrophil
precursor
accumul
bone
marrow
peripher
blood
well
organ
peripher
wbc
count
usual
alway
greater
immatur
matur
neutrophil
present
see
fig
matur
form
usual
numer
sometim
uneven
left
shift
present
sign
dysplasia
may
evid
includ
hypersegment
ring
nuclei
giant
form
eosinophil
basophil
may
also
increas
bone
marrow
character
granulocyt
hyperplasia
morpholog
abnorm
may
present
erythroid
megakaryocyt
line
may
affect
result
anemia
thrombocytopenia
less
commonli
thrombocytosi
disord
must
distinguish
sever
extrem
neutrophil
leukocytosi
leukemoid
reaction
caus
inflamm
immunemedi
diseas
extrem
neutrophilia
also
occur
paraneoplast
syndrom
human
cml
characterist
cytogenet
abnorm
present
bone
marrow
cell
signifi
lesion
level
earli
multipot
stem
cell
typic
individu
chromosom
transloc
result
philadelphia
chromosom
bcrabl
transloc
chromosom
analog
chromosom
dog
chromosom
bcrabl
transloc
term
raleigh
chromosom
report
sever
case
cml
dog
variant
cml
chronic
myelomonocyt
leukemia
chronic
monocyt
leukemia
cmol
cmol
also
associ
bcrabl
transloc
dog
diagnos
made
base
percentag
monocyt
leukem
cell
popul
infrequ
myeloprolif
neoplasm
atyp
chronic
myeloid
leukemia
report
dog
featur
myelodysplast
syndrom
chronic
leukemia
dog
bcrabl
transloc
present
fewer
cell
consid
neg
find
addit
accumul
bone
marrow
peripher
blood
leukem
cell
also
found
red
pulp
spleen
periport
sinusoid
area
liver
sometim
lymph
node
organ
kidney
heart
lung
less
commonli
affect
addit
extramedullari
hematopoiesi
may
present
liver
spleen
death
usual
due
complic
infect
hemorrhag
secondari
neutrophil
dysfunct
thrombocytopenia
respect
case
cml
may
termin
blast
crisi
transform
predomin
welldifferenti
granulocyt
excess
number
poorli
differenti
blast
cell
peripher
blood
bone
marrow
phenomenon
well
document
dog
basophil
leukemia
although
rare
report
dog
character
increas
wbc
count
high
proport
basophil
peripher
blood
bone
marrow
hepatosplenomegali
lymphadenopathi
thrombocytosi
may
present
dog
anem
basophil
leukemia
distinguish
mast
cell
leukemia
mastocytosi
whether
dog
develop
eosinophil
leukemia
remain
question
report
case
high
blood
eosinophil
count
eosinophil
infiltr
organ
one
dog
respond
well
treatment
corticosteroid
distinct
neoplast
prolifer
eosinophil
idiopath
hypereosinophil
syndrom
remain
elus
nonmyeloprolif
disord
associ
eosinophilia
parasit
skin
diseas
diseas
respiratori
gi
tract
consid
first
anim
eosinophilia
one
distinguish
featur
clonal
reactiv
eosinophilia
compris
polyclon
cell
neoplast
condit
aris
singl
clone
clonal
assay
becom
avail
discrep
may
resolv
human
et
primari
thrombocytosi
character
platelet
count
persist
greater
blast
cell
circul
mark
megakaryocyt
hyperplasia
bone
marrow
without
myelofibrosi
present
thrombosi
bleed
common
sequela
patient
splenomegali
mpd
especi
pv
rule
importantli
primari
disord
associ
reactiv
thrombocytosi
includ
inflamm
hemolyt
anemia
iron
defici
anemia
malign
recoveri
sever
hemorrhag
rebound
immunemedi
thrombocytopenia
splenectomi
addit
certain
drug
vincristin
induc
thrombocytosi
et
recogn
dog
one
dog
platelet
count
exceed
bizarr
giant
form
abnorm
granul
present
bone
marrow
contain
increas
number
megakaryocyt
megakaryoblast
circul
blast
cell
seen
find
includ
splenomegali
gi
bleed
increas
number
circul
basophil
caus
secondari
reactiv
thrombocytosi
rule
basophilia
also
report
recent
case
anoth
dog
et
diagnos
progress
cml
case
report
literatur
et
dog
microcyt
hypochrom
anemia
iron
defici
anemia
associ
reactiv
secondari
thrombocytosi
care
must
taken
rule
disord
howev
spuriou
microcytosi
may
report
dog
mani
giant
platelet
count
analyz
small
rbc
microscop
review
blood
film
may
help
case
myelofibrosi
primari
myelofibrosi
report
rare
dog
myelofibrosi
typic
secondari
reactiv
process
human
myelofibrosi
character
collagen
deposit
bone
marrow
increas
number
megakaryocyt
granulocyt
precursor
mani
exhibit
morpholog
abnorm
fact
breakdown
intramedullari
megakaryocyt
subsequ
releas
factor
promot
fibroblast
prolifer
inhibit
collagen
breakdown
may
underli
pathogenesi
fibrosi
focal
osteosclerosi
sometim
present
anemia
thrombocytopenia
splenomegali
myeloid
metaplasia
product
hematopoiet
cell
outsid
bone
marrow
consist
featur
dog
myelofibrosi
occur
secondari
mpd
radiat
damag
congenit
hemolyt
anemia
case
incit
caus
unknown
idiopath
myelofibrosi
may
concurr
marrow
necrosi
case
ehrlichiosi
septicemia
drug
toxic
estrogen
cephalosporin
specul
fibroblast
prolifer
respons
releas
inflammatori
mediat
associ
necrosi
myeloid
metaplasia
report
occur
liver
spleen
lung
extramedullari
hematopoiesi
ineffect
prevent
correct
pancytopenia
eventu
develop
dysfunct
hematopoiet
system
manifest
varieti
abnorm
constitut
myelodysplast
syndrom
md
dog
syndrom
rare
usual
cytopenia
two
three
line
peripher
blood
anemia
neutropenia
andor
thrombocytopenia
blood
abnorm
includ
macrocyt
erythrocyt
metarubricytosi
bone
marrow
typic
normocellular
hypercellular
dysplast
chang
evid
sever
cell
line
blast
cell
present
make
fewer
nucleat
cell
although
threshold
chang
less
myelodysplasia
sometim
refer
preleukemia
case
may
progress
acut
leukemia
base
report
case
poor
prognost
factor
includ
increas
percentag
blast
cell
cytopenia
involv
one
lineag
cellular
atypia
primari
mdss
clonal
disord
consid
neoplast
complex
classif
scheme
human
md
base
percentag
blast
bone
marrow
cytogenet
analysi
cytopenia
need
transfus
variabl
compris
least
nine
subtyp
applic
veterinari
medicin
unknown
three
subtyp
propos
dog
cat
includ
md
excess
blast
mdseb
blast
percentag
greater
less
progress
aml
may
occur
md
refractori
cytopenia
mdsrc
blast
percentag
less
cytopenia
one
lineag
md
erythroid
predomin
mdser
e
ratio
less
one
prognosi
poor
larger
studi
need
determin
util
classif
scheme
potenti
prognost
factor
sex
age
cat
felv
posit
addit
accumul
enough
case
anoth
confound
factor
studi
classifi
md
presenc
revers
mdss
occur
secondari
immunemedi
infecti
diseas
dog
cat
dog
myeloid
neoplasm
similar
present
regardless
specif
diseas
entiti
although
anim
aml
acut
onset
ill
rapid
clinic
cours
histori
constitut
sign
eg
lethargi
hyporexia
weight
loss
common
clinic
sign
includ
emaci
persist
fever
pallor
petechi
peripher
lymphadenopathi
report
case
hepatosplenomegali
approxim
case
shift
leg
lame
ocular
lesion
recurr
infect
also
seen
vomit
diarrhea
dyspnea
neurolog
sign
variabl
featur
serum
biochem
analyt
may
within
refer
interv
chang
signific
organ
infiltr
occur
anim
md
may
letharg
anorect
pallor
fever
hepatosplenomegali
pv
dog
often
erythema
mucou
membran
owe
increas
rbc
mass
dog
polydips
addit
neurolog
sign
disorient
ataxia
seizur
may
present
thought
result
hyperviscos
hypervolemia
hepatosplenomegali
usual
absent
peripher
blood
abnorm
consist
found
case
addit
presenc
neoplast
cell
abnorm
includ
biand
pancytopenia
may
present
low
number
nucleat
rbc
present
blood
half
dog
acut
nonlymphocyt
leukemia
nonregen
anemia
thrombocytopenia
present
case
anemia
usual
normocyt
normochrom
although
macrocyt
anemia
sometim
present
pathogen
mechan
includ
effect
inhibitori
factor
lead
ineffect
hematopoiesi
myelophthisi
immunemedi
anemia
secondari
neoplasia
hemorrhag
secondari
thrombocytopenia
platelet
dysfunct
dissemin
intravascular
coagul
anemia
sever
aml
although
anemia
thrombocytopenia
may
milder
anim
subtyp
acut
monocyt
leukemia
myelofibrosi
anemia
character
anisocytosi
poikilocytosi
addit
pancytopenia
leukoerythroblastosi
immatur
erythroid
myeloid
cell
circul
may
present
phenomena
probabl
result
replac
marrow
fibrou
tissu
result
shear
red
cell
escap
immatur
cell
normal
confin
bone
marrow
pv
pcv
increas
usual
rang
bone
marrow
hyperplast
e
ratio
usual
normal
rang
neoplast
cell
often
defect
function
platelet
dysfunct
report
dog
acut
megakaryoblast
leukemia
cml
neutrophil
decreas
phagocyt
capac
abnorm
one
except
report
cml
dog
neutrophil
enhanc
phagocyt
capac
superoxid
product
author
hypothes
increas
synthesi
granulocytemacrophag
gm
csf
result
lactoferrin
defici
neoplast
neutrophil
mediat
enhanc
function
cell
case
myeloid
neoplasm
diagnosi
depend
examin
peripher
blood
bone
marrow
aml
diagnos
basi
find
blast
cell
clearli
visibl
nucleoli
blood
bone
marrow
dog
acut
leukemia
circul
blast
cell
may
present
low
number
peripher
blood
care
examin
smear
especi
feather
edg
made
even
blast
detect
circul
indic
bone
marrow
diseas
nonregen
anemia
thrombocytopenia
usual
present
occasion
neoplast
cell
found
csf
anim
invas
cn
smear
aspir
tissu
lymph
node
spleen
liver
may
contain
blast
usual
contribut
littl
diagnost
workup
examin
blast
stain
standard
romanowski
stain
may
give
clue
lineag
cell
see
fig
e
myelomonocyt
leukemia
nuclei
blast
usual
pleomorph
round
lobul
form
cell
cytoplasm
may
contain
larg
azurophil
granul
vacuol
blast
megakaryocyt
leukemia
may
contain
vacuol
cytoplasm
bleb
addit
bizarr
macroplatelet
may
present
although
distinguish
morpholog
featur
may
suggest
definit
diagnosi
cytochem
stain
immunophenotyp
flow
cytometr
analysi
clonal
test
genet
analysi
usual
requir
definit
defin
lineag
blast
reader
refer
sever
larg
compil
methodolog
discuss
appli
dog
sever
investig
report
modif
diagnos
cytochem
stain
especi
import
distinguish
aml
lymphocyt
leukemia
provid
accur
prognost
inform
owner
institut
appropri
therapi
anim
leukemia
group
recommend
follow
diagnost
criteria
summar
fig
use
wellprepar
romanowskystain
blood
bone
marrow
film
minimum
cell
count
determin
leukocyt
differenti
blood
percentag
blast
cell
bone
marrow
andor
blood
bone
marrow
blast
cell
calcul
percentag
nucleat
cell
anc
nonerythroid
cell
character
use
cytochem
marker
neutrophil
differenti
identifi
posit
stain
blast
peroxidas
sudan
black
b
chloracet
esteras
nonspecif
esteras
acet
esteras
butyr
esteras
especi
inhibit
sodium
fluorid
mark
monocyt
canin
monocyt
may
also
contain
peroxidaseposit
granul
acetylcholinesteras
marker
megakaryocyt
dog
cat
addit
posit
immunostain
von
willebrand
factor
factor
viiirel
antigen
platelet
glycoprotein
surfac
blast
identifi
megakaryocyt
precursor
alkalin
phosphatas
alp
rare
mark
normal
cell
dog
cat
present
blast
cell
acut
myeloblast
myelomonocyt
leukemia
howev
owe
report
alp
activ
lymphoid
leukemia
dog
specif
marker
myeloid
cell
certain
recent
studi
indic
alp
use
marker
diagnosi
aml
neoplast
cell
express
omega
exonucleas
specif
marker
basophil
also
posit
chloracet
esteras
activ
blood
bone
marrow
differenti
count
cytochem
stain
perform
interpret
experienc
veterinari
cytopathologist
erythroid
cell
less
anc
blast
cell
greater
diagnosi
aml
aul
made
erythroid
cell
greater
anc
blast
cell
greater
diagnosi
erythroleukemia
made
rubriblast
signific
proport
blast
cell
diagnosi
erythroleukemia
erythroid
predomin
made
note
human
aml
classif
system
blast
threshold
lower
similar
recommend
made
aml
dog
cat
case
electron
microscopi
requir
identifi
lineag
blast
cell
exampl
megakaryocyt
precursor
posit
platelet
peroxidas
activ
contain
demarc
membran
alpha
granul
featur
detect
ultrastructur
level
increasingli
cytogenet
abnorm
identifi
anim
leukemia
cytogenet
analysi
may
yield
import
diagnost
prognost
inform
becom
valuabl
tool
identifi
target
therapeut
approach
although
morpholog
cytochem
analys
form
mainstay
cell
identif
newer
technolog
routin
use
classifi
leukemia
use
monoclon
antibodi
detect
antigen
associ
certain
cell
type
cell
immunophenotyp
use
flow
cytometr
analysi
immunocytochemistri
cell
acut
lymphoid
leukemia
aml
posit
mani
lymphocyt
marker
includ
igg
avail
dog
use
rule
lymphoblast
leukemia
dog
acut
leukemia
marker
includ
myeloperoxidas
mpo
myeloid
cell
megakaryoblast
overlap
express
cellular
antigen
exampl
canin
human
granulocyt
express
highli
recommend
use
panel
antibodi
similar
use
batteri
cytochem
stain
antigen
often
express
multipl
lineag
lineag
infidel
occur
test
becom
valuabl
avail
canin
reagent
current
acvp
oncolog
committe
recommend
follow
immunophenotyp
panel
done
bone
marrow
andor
blood
smear
character
anim
leukemia
b
lymphocyt
lymphocyt
myeloid
cell
mpo
megakaryoblast
dendrit
cell
acut
leukemia
larg
report
case
aml
dog
posit
one
report
clonal
biclon
rearrang
either
tor
bcell
receptor
degre
differenti
cell
mpn
disord
must
distinguish
nonneoplast
caus
increas
cell
type
make
diagnosi
pv
must
first
establish
polycythemia
absolut
rather
rel
rel
polycythemia
plasma
volum
decreas
hemoconcentr
dehydr
hypovolemia
absolut
rbc
mass
increas
splenic
contract
also
result
rel
polycythemia
absolut
polycythemia
rbc
mass
increas
usual
secondari
tissu
hypoxia
caus
appropri
increas
product
erythropoietin
rare
erythropoietin
may
produc
inappropri
tumor
eg
renal
cell
carcinoma
renal
diseas
pyelonephr
local
renal
hypoxia
caus
polycythemia
elimin
appropri
laboratori
work
thorac
radiograph
arteri
blood
ga
analysi
renal
ultrasonographi
human
pv
plasma
erythropoietin
epo
concentr
low
epo
concentr
dog
pv
tend
low
lownorm
wherea
anim
secondari
absolut
polycythemia
level
high
sampl
determin
epo
concentr
taken
therapeut
phlebotomi
use
treat
hyperviscos
owe
fluctuat
epo
concentr
repeat
result
incongru
inform
pathognomon
featur
cml
dog
common
caus
mark
leukocytosi
left
shift
extrem
neutrophilia
granulocyt
hyperplasia
bone
marrow
must
elimin
includ
infect
especi
pyogen
infect
immunemedi
diseas
neoplasm
caus
neutrophilia
elabor
csf
cml
matur
sometim
appear
disorderli
may
variat
size
shape
neutrophil
level
matur
addit
neoplast
leukocyt
may
disintegr
rapidli
appear
vacuol
invas
natur
cml
biopsi
liver
spleen
may
also
help
distinguish
true
leukemia
leukemoid
reaction
assum
anim
toler
procedur
fluoresc
situ
hybrid
analysi
avail
identifi
chromosom
rearrang
includ
transloc
eg
raleigh
chromosom
invers
delet
dog
aberr
associ
certain
form
leukemia
continu
investig
like
yield
larger
databas
cytogenet
abnorm
link
hematolog
malign
basophil
leukemia
diagnos
find
excess
number
basophil
circul
bone
marrow
basophil
leukemia
must
differenti
mastocytosi
base
morpholog
cell
type
present
basophil
segment
ribbonlik
nucleu
variabl
size
granul
wherea
mast
cell
roundtoov
nucleu
may
partial
total
obscur
small
round
metachromaticstain
granul
distinct
usual
easi
make
howev
basophil
leukemia
chang
morpholog
nucleu
granul
make
distinct
less
clear
et
diagnos
base
find
persist
excess
thrombocytosi
without
circul
blast
cell
absenc
anoth
mpd
eg
pv
myelofibrosi
disord
known
caus
secondari
thrombocytosi
includ
iron
defici
anemia
chronic
inflammatori
diseas
recoveri
sever
hemorrhag
rebound
immunemedi
thrombocytopenia
absenc
spleen
thrombocytosi
transient
disord
abat
resolut
primari
diseas
et
platelet
morpholog
may
abnorm
bizarr
giant
form
abnorm
granul
bone
marrow
megakaryocyt
hyperplasia
consist
featur
dysplast
chang
may
evid
megakaryocyt
spuriou
hyperkalemia
may
present
serum
sampl
dog
thrombocytosi
caus
due
releas
potassium
platelet
clot
format
measur
potassium
plasma
recommend
case
usual
demonstr
potassium
concentr
within
refer
interv
platelet
aggreg
variabl
report
impair
enhanc
one
dog
measur
plasma
thrombopoietin
tpo
concentr
normal
unclear
whether
tpo
play
role
et
suppress
high
platelet
mass
md
abnorm
two
three
cell
line
usual
manifest
peripher
blood
neutropenia
without
left
shift
nonregen
anemia
thrombocytopenia
chang
includ
macrocytosi
metarubricytosi
bone
marrow
typic
normocellular
hypercellular
increas
e
ratio
blast
cell
although
increas
constitut
less
nucleat
cell
report
dog
primari
secondari
md
one
dog
blast
cell
percentag
less
dysplast
chang
detect
cell
line
dyserythropoiesi
character
asynchron
matur
erythroid
cell
typifi
larg
hemoglobin
cell
immatur
nuclei
megaloblast
chang
erythroid
compon
domin
md
call
mdser
see
tabl
dysgranulopoiesi
giant
neutrophil
precursor
abnorm
nuclear
segment
cytoplasm
granul
seen
final
dysthrombopoiesi
character
giant
platelet
micromegakaryocyt
myelofibrosi
suspect
anim
nonregen
anemia
pancytopenia
abnorm
erythrocyt
morpholog
especi
shape
leukoerythroblastosi
bone
marrow
aspir
usual
unsuccess
result
dri
tap
necessit
bone
marrow
biopsi
obtain
jamshidi
needl
specimen
process
routin
histopatholog
examin
necessari
special
stain
fibrou
tissu
use
myelofibrosi
occur
secondari
diseas
bone
marrow
chronic
hemolyt
anemia
bone
marrow
necrosi
clinician
look
primari
diseas
process
concept
clinic
stage
patient
aml
mpd
md
obvious
much
differ
patient
solid
tumor
hematolog
tumor
liquid
involv
primarili
peripher
blood
bone
marrow
compart
clinic
stage
gener
perform
beyond
two
compart
certainli
infiltr
peripher
node
organ
occur
howev
document
involv
advanc
imag
tissu
aspir
alter
treatment
prognosi
signific
way
two
studi
document
proofofconcept
use
bodi
mri
distinguish
diffus
versu
focal
bone
marrow
andor
parenchym
involv
hematopoet
neoplasia
howev
clinic
util
methodolog
current
unknown
treatment
treatment
acut
nonlymphocyt
leukemia
unreward
date
limit
inform
respons
specif
subtyp
leukemia
uniform
chemotherapeut
protocol
part
owe
rariti
diseas
pauciti
case
literatur
veterinarian
advis
contact
veterinari
oncologist
discuss
new
protocol
appropri
manag
case
novel
agent
current
develop
may
becom
avail
futur
overrid
therapeut
goal
erad
leukem
cell
reestablish
normal
hematopoiesi
current
best
accomplish
cytoreduct
chemotherapi
agent
commonli
util
includ
combin
anthracyclin
doxorubicin
cyclophosphamid
vincristin
prednison
dog
cytosin
arabinosid
arac
mgm
given
slow
infus
hour
daili
day
repeat
weekli
use
well
sever
variat
use
subcutan
inject
arac
see
chapter
sever
variat
chopor
copbas
protocol
see
section
chapter
without
arac
use
well
overal
prognosi
current
avail
treatment
poor
although
respons
rate
multiag
protocol
rel
high
respons
durabl
mst
despit
aggress
protocol
gener
month
obvious
effect
therapi
aml
dog
await
investig
regardless
chemotherapi
protocol
use
signific
cytopenia
either
persist
sequela
chemotherapi
intens
support
care
necessari
transfus
whole
blood
plateletrich
plasma
may
requir
treat
anemia
thrombocytopenia
infect
manag
aggress
antibiot
therapi
gener
poor
respons
mani
client
choos
palli
support
care
howev
acut
progress
diseas
allow
prolong
palliat
case
mst
support
care
gener
week
treat
pv
therapi
direct
reduc
rbc
mass
pcv
reduc
onesixth
start
valu
phlebotomi
perform
need
administ
appropri
colloid
crystalloid
solut
replac
lost
electrolyt
ml
whole
bloodkg
bodi
weight
remov
regular
interv
human
phlebotomi
continu
therapeut
approach
use
frequent
chemotherapeut
drug
choic
hydroxyurea
inhibitor
dna
synthesi
drug
administ
initi
dose
mgkg
day
reduc
mg
kg
po
daili
major
goal
treatment
maintain
pcv
close
normal
possibl
radiophosphoru
p
shown
provid
longterm
control
peopl
pv
et
seen
limit
use
veterinari
medicin
inhibitor
ruxolitinib
jakafi
approv
secondlin
use
peopl
pv
mutat
gene
ident
observ
peopl
document
one
five
dog
pv
therefor
one
could
specul
oclacitinib
apoquel
inhibitori
activ
fdaapprov
use
dog
atopi
could
therapeut
potenti
pv
dog
potenti
applic
oclacitinib
yet
investig
document
subset
cml
dog
associ
bcrabl
chromosom
abnorm
raleigh
chromosom
similar
philadelphia
chromosom
transloc
respons
larg
major
cml
human
imatinib
mesyl
gleevec
tyrosin
kinas
inhibitor
known
effect
therapi
cml
human
dog
cml
raleigh
chromosom
abnorm
intuit
type
drug
may
activ
inde
tyrosin
kinas
inhibitor
investig
dog
bcrabl
transloc
cml
one
dog
chronic
monocyt
leukemia
treat
toceranib
palladia
prednison
therapi
achiev
clinic
remiss
develop
progress
diseas
partial
cytogenet
respons
addit
molecular
techniqu
may
use
monitor
cytogenet
aberr
dna
copi
number
aberr
bcrabl
transloc
treatment
gaug
cytogenet
respons
therapi
author
dmv
other
anecdot
use
toceranib
imatinib
hand
cml
case
respons
last
sever
month
true
activ
durabl
respons
agent
dog
await
investig
cml
also
manag
chemotherapi
control
prolifer
abnorm
cell
line
improv
qualiti
life
hydroxyurea
effect
agent
treat
cml
chronic
phase
initi
dosag
mgkg
twice
daili
treatment
hydroxyurea
continu
leukocyt
count
fall
dosag
hydroxyurea
reduc
daili
basi
mgkg
given
biweekli
triweekli
human
alkyl
agent
busulfan
use
altern
effect
dosag
establish
dog
follow
human
protocol
mgkgday
po
given
leukocyt
count
reduc
vincristin
prednison
therapi
result
short
remiss
one
dog
cml
despit
respons
chemotherapi
control
mani
month
dog
cml
eventu
enter
termin
phase
diseas
one
studi
seven
dog
cml
dog
underw
termin
phase
blast
crisi
human
blast
crisi
may
lymphoid
myeloid
dog
blast
crisi
poor
prognosi
despit
rescu
aggress
multiag
chemotherapi
case
report
one
dog
treat
success
combin
chemotherapi
protocol
includ
vincristin
arac
cyclophosphamid
prednison
treatment
controversi
human
lack
evid
asymptomat
patient
benefit
chemotherapi
patient
thrombosi
bleed
given
cytoreduct
therapi
hydroxyurea
drug
choic
initi
control
thrombocytosi
small
molecul
inhibitor
use
peopl
et
although
studi
investig
mutat
dog
et
one
could
specul
use
oclacitinib
apoquel
dog
radiophosphoru
treatment
also
occasion
use
peopl
et
standard
therapeut
regim
md
often
human
receiv
treatment
cytopenia
caus
clinic
sign
transfus
given
necessari
patient
fever
evalu
aggress
detect
infect
growth
factor
epo
gmcsf
gcsf
sometim
use
patient
requir
frequent
transfus
increas
blood
cell
count
enhanc
neutrophil
function
one
case
report
human
epo
administ
ukg
sq
hour
dog
md
profound
anemia
rational
use
epo
promot
termin
differenti
dysplast
erythrocyt
human
recombin
epo
use
caution
anim
antiepo
antibodi
may
induc
target
endogen
epo
pcv
increas
day
epo
treatment
dog
remain
remiss
month
factor
induc
differenti
hematopoiet
cell
includ
retino
acid
analog
dihydroxyvitamin
convent
chemotherapeut
agent
arac
propens
factor
enhanc
progress
leukemia
known
mani
case
potenti
risk
exist
gener
prognosi
anim
mpn
better
dog
aml
grave
prognosi
pv
cml
guard
signific
remiss
achiev
certain
therapeut
regim
care
monitor
anim
commonli
surviv
year
macroglobulinemia
solitari
osseou
plasmacytoma
sop
igsecret
lymphoma
leukemia
includ
plasma
cell
leukemia
mm
import
mrd
base
clinic
incid
sever
appear
discord
blur
distinct
mm
multicentr
noncutan
emp
cat
two
mrd
discuss
togeth
speci
see
box
although
mm
repres
fewer
malign
tumor
anim
respons
approxim
hematopoiet
tumor
primari
secondari
tumor
affect
bone
dog
compil
bone
marrow
disord
dog
n
mm
repres
abnorm
sampl
neoplast
process
respect
furthermor
compil
serum
protein
electrophoret
sampl
n
dog
mm
account
abnorm
neoplast
process
encount
respect
sever
compil
suggest
male
predisposit
wherea
other
observ
older
dog
affect
averag
age
year
rang
year
one
larg
case
seri
german
shepherd
dog
overrepres
base
hospit
popul
true
incid
mm
cat
unknown
howev
rare
diagnosi
dog
repres
tumor
two
larg
compil
felin
malign
malign
hematolog
malign
anoth
report
mm
repres
abnorm
malign
serum
protein
electrophoret
sampl
respect
compil
felin
sampl
mm
occur
age
cat
median
age
year
commonli
domest
short
hair
cat
sex
predilect
consist
report
although
male
preponder
may
exist
mm
associ
coronaviru
felv
fiv
infect
etiolog
mm
part
unknown
genet
predisposit
molecular
aberr
eg
ckit
viral
infect
chronic
immun
stimul
carcinogen
exposur
suggest
contribut
factor
suggest
famili
associ
cat
follow
case
report
among
sibl
evid
exist
molecular
mechan
cellular
control
includ
overexpress
cell
cycl
control
compon
like
cyclin
see
chapter
receptor
tyrosin
kinas
dysregul
may
involv
canin
mm
plasma
cell
tumor
rodent
model
chronic
immun
stimul
exposur
implant
silicon
gel
associ
develop
mm
chronic
infect
prolong
hyposensit
therapi
human
viral
aleutian
diseas
mink
result
monoclon
gammopathi
small
percentag
case
exposur
agricultur
industri
petroleum
product
irradi
known
risk
factor
develop
human
addit
progress
solitari
plasma
cell
tumor
mm
report
dog
cat
singl
case
bcell
lymphoma
progress
mm
exist
dog
patholog
natur
behavior
mm
system
prolifer
malign
plasma
cell
precursor
aris
clone
singl
cell
usual
involv
multipl
bone
marrow
site
dog
cat
previous
state
blur
distinct
mm
multicentr
noncutan
emp
within
mrd
occur
widespread
abdomin
organ
involv
without
signific
bone
marrow
infiltr
describ
proport
case
european
compil
mm
multicentr
noncutan
emp
similar
clinic
cours
widespread
system
involv
hyperglobulinemia
cat
discuss
mm
chapter
malign
plasma
cell
vari
appear
histolog
section
cytolog
prepar
degre
differenti
rang
resembl
normal
plasma
cell
late
stage
differenti
fig
larg
anaplast
round
cell
often
refer
plasmablast
high
mitot
index
repres
earli
stage
differenti
binucl
multinucl
cell
often
present
see
fig
chapter
cat
mm
one
case
seri
major
plasma
cell
immatur
mark
atypia
includ
increas
size
multipl
nuclei
cleft
nuclei
anisocytosi
anisokaryosi
variabl
nuclear
cytoplasm
ratio
decreas
chromatin
densiti
variabl
nucleoli
nearli
one
quarter
flame
cell
morpholog
character
peripher
eosinophil
cytoplasm
process
howev
european
compil
felin
multicentr
noncutan
mrd
case
n
welldifferenti
morpholog
author
latter
case
seri
develop
grade
system
depend
percentag
plasmablast
within
neoplast
cell
welldifferenti
intermediategrad
poorli
differenti
mm
less
plasmablast
respect
malign
plasma
cell
typic
produc
overabund
singl
type
compon
immunoglobulin
refer
compon
sever
case
nonsecretori
mm
report
dog
rare
cryoglobulinemia
occur
dog
mm
igm
macroglobulinemia
also
report
cat
igg
myeloma
cryoglobulin
paraprotein
insolubl
temperatur
requir
blood
collect
clot
perform
serum
separ
whole
blood
allow
clot
temperatur
protein
precipit
clot
lost
pure
lightchain
compon
rare
report
dog
cat
patholog
associ
mm
result
either
high
level
circul
compon
organ
bone
infiltr
neoplast
cell
associ
patholog
condit
includ
bone
diseas
bleed
diathesi
hyperviscos
syndrom
hv
renal
diseas
hypercalcemia
immunodefici
subsequ
suscept
infect
cytopenia
secondari
myelophthisi
cardiac
failur
bone
lesion
isol
discret
osteolyt
lesion
includ
patholog
fractur
fig
diffus
osteopenia
fig
approxim
onequart
twothird
dog
mm
radiograph
evid
boni
lysi
diffus
osteoporosi
incid
radiograph
skelet
lesion
cat
vari
tremend
within
report
case
seri
high
other
bone
engag
activ
hematopoiesi
commonli
affect
includ
vertebra
rib
pelvi
skull
metaphys
long
bone
skelet
lesion
rare
igm
macroglobulinemia
malign
cell
often
infiltr
spleen
liver
lymphoid
tissu
rather
bone
bleed
diathesi
result
one
combin
event
compon
may
interfer
coagul
inhibit
platelet
aggreg
releas
platelet
caus
adsorpt
minor
clot
protein
gener
abnorm
fibrin
polymer
produc
function
decreas
calcium
approxim
dog
onequart
cat
clinic
evid
hemorrhag
dog
nearli
half
abnorm
prothrombin
pt
partial
thromboplastin
ptt
time
thrombocytopenia
may
also
play
role
bone
marrow
infiltr
signific
ie
myelophthisi
hv
repres
one
constel
clinicopatholog
abnorm
result
greatli
increas
serum
viscos
magnitud
viscos
chang
relat
type
size
shape
concentr
compon
blood
hv
common
igm
macroglobulinemia
high
molecular
weight
class
immunoglobulin
igasecret
myeloma
iga
usual
present
dimer
dog
may
undergo
polymer
result
increas
serum
viscos
iggassoci
hv
also
occur
albeit
less
frequent
high
serum
viscos
occur
approxim
dog
mm
result
bleed
diathesi
neurolog
sign
eg
dementia
depress
seizur
activ
coma
ophthalm
abnorm
eg
dilat
tortuou
retin
vessel
retin
hemorrhag
fig
retin
detach
increas
cardiac
workload
potenti
subsequ
develop
cardiomyopathi
retrospect
compil
dog
retin
hemorrhag
due
mm
consequ
hv
thought
result
sludg
blood
small
vessel
ineffect
deliveri
oxygen
nutrient
coagul
abnorm
hv
report
cat
igg
iga
igmsecret
tumor
sever
case
rel
serum
viscos
increas
control
rang
renal
diseas
present
approxim
onequart
onehalf
dog
mm
azotemia
observ
cat
pathogenesi
renal
failur
often
multifactori
ensu
result
benc
jone
lightchain
proteinuria
tumor
infiltr
renal
tissu
hypercalcemia
amyloidosi
diminish
perfus
secondari
hv
dehydr
ascend
urinari
tract
infect
normal
heavyand
lightchain
synthesi
well
balanc
nonneoplast
immunoglobulin
product
case
mm
unbalanc
excess
lightchain
product
may
produc
light
chain
low
molecular
weight
normal
filter
renal
glomerulu
presenc
urin
result
protein
precipit
subsequ
renal
tubular
injuri
presenc
light
chain
urin
without
concomit
monoclon
spike
serum
although
rare
indic
pure
lightchain
diseas
tubul
becom
obstruct
larg
lamin
cast
contain
albumin
immunoglobulin
light
chain
benc
jone
proteinuria
occur
approxim
dog
mm
benc
jone
proteinuria
report
occur
approxim
cat
mm
mrd
hypercalcemia
report
dog
mm
thought
result
primarili
product
osteoclastactiv
factor
neoplast
cell
factor
includ
increas
level
variou
cytokin
implic
human
mm
two
dog
mm
hypercalcemia
serum
elev
circul
ntermin
parathyroid
hormonerel
peptid
note
hypercalcemia
may
also
exacerb
associ
renal
diseas
hypercalcemia
initi
thought
rare
event
cat
mm
occur
recent
report
case
suscept
infect
immunodefici
long
associ
mm
often
ultim
caus
death
affect
anim
infect
rate
human
mm
time
higher
normal
usual
present
pneumonia
urinari
tract
infect
respons
vaccin
also
shown
suppress
human
mm
normal
immunoglobulin
concentr
often
sever
depress
affect
anim
addit
leukopenia
may
present
secondari
myelophthisi
report
multipl
concurr
infect
dog
cat
affect
mm
exist
one
dog
sever
concurr
infect
polyclon
monoclon
gammopathi
exist
pretreat
former
persist
success
treatment
myeloma
variabl
cytopenia
may
observ
associ
mm
normocyt
normochrom
nonregen
anemia
encount
approxim
onehalf
twothird
dog
mm
result
marrow
infiltr
myelophthisi
blood
loss
coagul
disord
anemia
chronic
diseas
increas
erythrocyt
destruct
secondari
high
serum
viscos
rare
erythrophagocyt
form
mm
also
report
dog
cat
may
contribut
anemia
similar
factor
lead
thrombocytopenia
leukopenia
dog
mm
respect
cat
approxim
twothird
onehalf
onethird
anem
thrombocytopen
neutropen
respect
cardiac
diseas
present
usual
result
excess
cardiac
workload
myocardi
hypoxia
secondari
hyperviscos
myocardi
infiltr
amyloid
anemia
may
complic
factor
nearli
onehalf
cat
mm
two
report
present
cardiac
murmur
etiolog
establish
three
cat
hv
present
congest
heart
failur
murmur
echocardiograph
sign
consist
hypertroph
cardiomyopathi
clinic
sign
mm
may
present
year
diagnosi
median
durat
month
report
dog
one
cat
mcompon
elev
detect
year
clinic
present
latter
case
mcompon
elev
consist
monoclon
gammopathi
unknown
signific
mgu
mgu
ie
benign
essenti
idiopath
monoclon
gammopathi
benign
monoclon
gammopathi
associ
osteolysi
bone
marrow
infiltr
benc
jone
proteinuria
mgu
also
report
dog
sign
mm
variabl
base
wide
rang
patholog
effect
possibl
tabl
list
rel
frequenc
clinic
sign
observ
dog
cat
respect
base
compil
sever
rep
ort
bleed
diathesi
usual
repres
epistaxi
gingiv
bleed
funduscop
abnorm
may
includ
retin
hemorrhag
see
fig
venou
dilat
saccul
tortuos
retin
detach
blind
cn
sign
may
includ
dementia
seizur
activ
tremor
defici
midbrain
brainstem
local
reflex
secondari
hv
extrem
hypercalcemia
sign
reflect
transvers
myelopathi
secondari
vertebr
column
infiltr
patholog
fractur
extradur
mass
compress
also
occur
one
case
ataxia
seizur
activ
dog
emp
secondari
tumorassoci
hypoglycemia
report
addit
paraneoplast
polyneuropathi
report
dog
mm
histori
chronic
respiratori
infect
persist
fever
may
also
present
cat
hepatosplenomegali
renomegali
occur
due
organ
infiltr
bleed
diathesi
due
hv
less
common
cat
howev
epistaxi
pleural
periton
hemorrhag
effus
retin
hemorrhag
central
neurolog
sign
report
dog
cat
diagnosi
mm
dog
usual
follow
demonstr
bone
marrow
plasmacytosi
see
fig
fig
absenc
osteolyt
bone
lesion
diagnosi
also
made
marrow
plasmacytosi
associ
progress
increas
mcompon
plasma
cell
clonal
eg
parr
document
cat
degre
bone
marrow
infiltr
may
mark
suggest
consider
plasma
cell
morpholog
viscer
organ
infiltr
fig
given
case
demonstr
mcompon
diseas
absenc
mark
marrow
plasmacytosi
anim
suspect
plasma
cell
tumor
receiv
minim
diagnost
evalu
includ
cbc
platelet
count
ioniz
calcium
serum
biochemistri
profil
urinalysi
particular
attent
paid
renal
function
serum
calcium
level
clinic
hemorrhag
present
coagul
assess
eg
platelet
count
pt
ptt
serum
viscos
measur
indic
anim
undergo
care
funduscop
examin
serum
electrophoresi
immunoelectrophoresi
perform
determin
presenc
monoclon
mcompon
see
fig
categor
immunoglobulin
class
involv
heat
precipit
electrophoresi
urin
may
perform
determin
presenc
benc
jone
proteinuria
commerci
urin
dipstick
method
capabl
determin
definit
diagnosi
usual
follow
perform
bone
marrow
aspir
dog
bone
marrow
core
biopsi
multipl
aspir
may
necessari
possibl
uneven
cluster
infiltr
plasma
cell
bone
marrow
normal
marrow
contain
less
plasma
cell
wherea
myelomat
marrow
often
greatli
exce
level
current
recommend
requir
marrow
plasmacytosi
present
although
cutoff
cat
recent
recommend
special
attent
cellular
atypia
even
threshold
may
problemat
cat
cellular
atypia
viscer
organ
involv
assess
needl
aspir
cytolog
tissu
biopsi
consid
equal
import
speci
rare
biopsi
osteolyt
lesion
ie
jamshidi
core
biopsi
see
chapter
necessari
diagnosi
dog
one
case
mm
dog
splenic
aspir
diagnost
help
overal
frequenc
clinic
diagnost
abnorm
dog
cat
mm
compil
publish
seri
least
five
case
list
tabl
histochem
ihc
analys
cell
tissu
suspect
mrd
often
appli
case
solitari
plasmacytoma
routin
thorac
abdomin
radiograph
recommend
suspect
case
occasion
boni
lesion
observ
skelet
area
standard
film
organomegali
liver
spleen
kidney
observ
major
cat
abdomin
ultrasound
recommend
cat
suspect
mm
modal
reveal
involv
one
abdomin
organ
major
case
includ
splenomegali
without
nodul
diffus
hyperecho
hepatomegali
without
nodul
renomegali
iliac
lymph
node
enlarg
one
case
seri
cat
mm
organ
ultrasonograph
abnorm
subsequ
confirm
plasma
cell
infiltr
skelet
survey
radiograph
recommend
determin
presenc
extent
osteolyt
lesion
may
diagnost
prognost
therapeut
implic
although
nuclear
scintigraphi
bone
scan
clinic
stage
dog
mm
perform
predomin
osteolyt
activ
osteoblast
inact
present
scan
seldom
give
posit
result
therefor
use
routin
diagnosi
physicianbas
oncolog
bone
miner
densiti
analysi
dualenergi
xray
absorptiometri
dexa
scan
document
osteoporosi
mri
bone
marrow
pet
ct
commonli
use
stage
howev
modal
appli
consist
veterinari
literatur
clinic
stage
system
canin
mm
suggest
howev
present
prognost
signific
attribut
therapi
mm
direct
tumor
cell
mass
secondari
system
effect
elicit
except
treat
lifethreaten
sequela
eg
mark
hypercalcemia
infect
renal
failur
diagnost
procedur
confirm
mm
complet
initi
primari
therapi
ensur
diagnosi
confirm
baselin
valu
procur
monitor
respons
chemotherapi
effect
reduc
malign
cell
burden
reliev
bone
pain
allow
skelet
heal
reduc
level
serum
immunoglobulin
major
dog
mm
greatli
extend
qualiti
quantiti
patient
live
mm
dog
initi
gratifi
diseas
treat
clinician
companion
anim
caregiv
durabl
remiss
norm
although
complet
elimin
neoplast
myeloma
cell
rare
achiev
eventu
relaps
expect
although
cat
mm
also
initi
respond
chemotherapi
overal
respons
rate
durabl
respons
overal
surviv
time
gener
high
durabl
dog
although
recent
compil
cat
favor
respons
chemotherapi
see
prognosi
section
follow
melphalan
alkyl
agent
chemotherapeut
choic
treatment
multipl
myeloma
dog
two
differ
melphalan
protocol
use
continu
daili
dose
regimen
histor
use
dog
initi
start
dose
mgkg
po
daili
day
reduc
mgkg
po
daili
continu
author
prefer
pulsedos
protocol
recent
shown
result
statist
similar
albeit
numer
superior
efficaci
similar
advers
event
profil
pulsedos
regimen
use
melphalan
mgm
po
daili
consecut
day
everi
week
protocol
also
advantag
requir
caregiv
administ
fewer
treatment
less
overal
exposur
chemotherapi
deliveri
bodi
fluid
protocol
use
success
author
small
number
case
myelosuppress
limit
tradit
continu
lowdos
therapi
addit
prednison
prednisolon
thought
increas
efficaci
melphalan
therapi
prednison
initi
dosag
mgkg
po
daili
day
reduc
mgkg
everi
day
discontinu
day
therapi
although
continu
everi
day
prednison
continu
melphalan
continu
indefinit
clinic
relaps
occur
myelosuppress
necessit
dose
reduct
discontinu
vast
major
dog
melphalan
prednison
combin
therapi
toler
regimen
well
clinic
signific
toxic
melphalan
myelosuppress
particular
delay
thrombocytopenia
slow
recov
case
irrevers
cbc
includ
platelet
count
perform
biweekli
month
therapi
monthli
thereaft
dog
continu
protocol
pulsedos
use
altern
protocol
signific
myelosuppress
occur
usual
thrombocytopenia
neutropenia
drug
holiday
institut
reintroduct
lesser
dose
marrow
recoveri
altern
differ
alkyl
agent
eg
cyclophosphamid
lomustin
may
substitut
although
melphalan
prednisolon
therapi
also
use
cat
multipl
myeloma
appear
protocol
myelosuppress
dog
mani
clinician
prefer
use
cyclophosphamid
mgm
po
iv
everi
week
prednisolon
mgkg
po
daili
week
everi
day
protocol
cop
protocol
see
section
b
chapter
speci
altern
use
cyclophosphamid
dose
mgcat
twice
weekli
use
melphalan
cat
dose
schedul
similar
dog
report
mgkg
daili
day
everi
day
clinic
improv
leukopenia
develop
longterm
continu
mainten
mgkg
everi
day
advoc
altern
protocol
advoc
cat
use
melphalan
mgm
everi
day
continu
appear
well
toler
cyclophosphamid
use
altern
alkyl
agent
combin
melphalan
dog
cat
mm
evid
suggest
superior
melphalan
dog
author
practic
cyclophosphamid
dog
mm
limit
case
present
sever
hypercalcemia
widespread
system
involv
faster
act
alkyl
agent
may
quickli
allevi
system
effect
diseas
cyclophosphamid
initi
dosag
mgm
iv
po
time
oral
melphalan
start
cyclophosphamid
less
like
affect
platelet
may
substitut
patient
thrombocytopenia
develop
secondari
longterm
melphalan
use
chlorambucil
anoth
alkyl
agent
use
success
treatment
igm
macroglobulinemia
dog
dosag
mgkg
po
daili
littl
clinic
sign
toxic
result
dose
schedul
chlorambucil
also
use
cat
mrd
lomustin
ccnu
yet
anoth
alkyl
agent
use
limit
number
cat
mm
partial
respons
report
dose
mgm
po
everi
day
evalu
respons
system
therapi
mm
base
improv
clinic
sign
clinicopatholog
paramet
radiograph
improv
skelet
lesion
ultrasonograph
improv
organ
involv
case
bone
marrow
reassess
molecular
analysi
clonal
subject
improv
clinic
sign
bone
pain
lame
lethargi
hyporexia
evid
within
week
initi
therapi
object
laboratori
improv
includ
reduct
serum
total
globulin
compon
calcium
along
normal
hemogram
usual
note
within
week
fig
radiograph
improv
osteolyt
bone
lesion
may
take
month
resolut
may
partial
ophthalm
complic
includ
longstand
retin
detach
paraneoplast
neuropathi
often
resolv
along
tumor
mass
cat
respond
chemotherapi
clinic
improv
note
week
serum
protein
radiograph
bone
abnorm
greatli
improv
week
previous
discuss
complet
resolut
mm
gener
occur
good
respons
defin
reduct
measur
mcompon
ie
immunoglobulin
benc
jone
protein
least
pretreat
valu
reduct
serum
immunoglobulin
level
may
lag
behind
reduct
benc
jone
proteinuria
halfliv
day
hour
respect
routin
followup
quantif
increas
serum
globulin
immunoglobulin
urin
benc
jone
protein
perform
monthli
good
respons
note
everi
month
thereaft
repeat
bone
marrow
aspir
imag
case
viscer
diseas
evalu
plasma
cell
infiltr
may
occasion
necessari
bone
marrow
reevalu
particularli
prudent
cytopenia
develop
chemotherapi
druginduc
myelosuppress
must
differenti
myelophthisi
due
neoplast
marrow
recurr
longterm
control
complic
includ
hypercalcemia
hv
bleed
diathesi
renal
diseas
immunosuppress
infect
ophthalm
complic
patholog
skelet
fractur
depend
control
primari
tumor
mass
howev
therapi
direct
specif
complic
may
indic
short
term
hypercalcemia
mark
signific
clinic
sign
exist
standard
therapi
includ
fluid
diuresi
without
pharmacolog
agent
eg
zoledron
calcitonin
may
indic
see
chapter
moder
hypercalcemia
typic
begin
improv
within
day
initi
melphalanprednison
chemotherapi
without
addit
therapi
direct
hypercalcemia
specif
hv
best
treat
short
term
plasmapheresi
whole
blood
collect
patient
centrifug
separ
plasma
pack
cell
pack
red
cell
resuspend
normal
salin
anoth
crystalloid
reinfus
patient
advanc
plasmapheresi
method
also
use
dog
hv
bleed
diathesi
usual
resolv
along
hv
howev
plateletrich
plasma
transfus
may
necessari
face
thrombocytopenia
renal
impair
may
necessit
aggress
fluid
therapi
short
term
mainten
adequ
hydrat
long
term
care
attent
secondari
urinari
tract
infect
appropri
antimicrobi
therapi
indic
ensur
adequ
water
intak
home
import
occasion
educ
owner
subcutan
fluid
administr
indic
continu
monitor
renal
function
recommend
along
followup
direct
tumor
respons
patient
mm
thought
immunolog
impair
recommend
prophylact
antibiot
therapi
dog
mm
howev
human
benefit
approach
dilig
monitor
aggress
antimicrobi
manag
indic
observ
cidal
antimicrobi
prefer
static
drug
avoid
nephrotox
antimicrobi
recommend
patholog
fractur
weightbear
long
bone
vertebra
result
spinal
cord
compress
may
requir
immedi
surgic
intervent
conjunct
system
chemotherapi
orthoped
stabil
fractur
undertaken
may
follow
rt
see
fig
inhibit
osteoclast
activ
bisphosphon
drug
particular
zoledron
shown
sever
metaanalys
reduc
incid
sever
skelet
complic
eg
bone
pain
patholog
fractur
mm
human
result
prolong
overal
surviv
class
drug
may
hold
promis
use
dog
cat
variou
skelet
tumor
howev
adequ
evalu
timetoev
efficaci
mrd
companion
speci
mm
eventu
relaps
dog
cat
undergo
initi
melphalan
altern
alkyl
therapi
uncommon
case
initi
resist
alkyl
agent
rescu
therapi
may
attempt
switch
altern
alkyl
agent
eg
cyclophosphamid
lomustin
chlorambucil
may
effect
author
also
limit
success
vad
combin
doxorubicin
mgm
iv
everi
day
vincristin
mgm
iv
day
dexamethason
sodium
phosphat
mgkg
iv
week
day
given
cycl
wherea
dog
initi
respond
rescu
protocol
durat
respons
tend
short
last
month
liposom
doxorubicin
produc
longterm
remiss
dog
mm
previous
resist
nativ
doxorubicin
mm
ultim
uniformli
fatal
diseas
speci
thu
signific
effort
place
investig
therapi
diseas
current
bone
marrow
abl
therapi
marrow
stem
cell
rescu
thalidomid
antiangiogen
therapi
bortezomib
proteasom
inhibitor
arsen
trioxid
bisphosphon
sever
molecular
target
therapi
investig
howev
use
veterinari
speci
limit
complet
absent
present
bortezomib
shown
activ
canin
melanoma
cell
cultur
mous
xenograft
model
bortezomib
protocol
welltoler
dog
use
success
treatment
golden
retriev
muscular
dystrophi
yet
report
dog
mm
one
case
report
exist
dog
mm
resist
melphalan
prednison
doxorubicin
subsequ
achiev
partial
respons
tyrosin
kinas
inhibitor
therapi
toceranib
maintain
month
rabacfosadin
use
investig
dog
mm
either
induct
therapi
rescu
melphalanresist
diseas
signific
efficaci
includ
durabl
molecular
complet
respons
note
howev
rabacfosadin
current
condit
approv
use
dog
lymphoma
prognosi
dog
mm
good
initi
control
tumor
return
good
qualiti
life
group
dog
mm
approxim
achiev
complet
remiss
ie
serum
immunoglobulin
normal
achiev
partial
remiss
ie
immunoglobulin
pretreat
valu
respond
melphalan
prednison
chemotherapi
longterm
surviv
norm
median
surviv
time
day
report
fig
recent
dog
treat
melphalanprednison
object
respons
pulsedos
protocol
continu
daili
protocol
median
progressionfre
overal
surviv
time
mst
day
respect
surviv
rate
respect
presenc
hypercalcemia
benc
jone
proteinuria
extens
boni
lysi
found
neg
prognost
factor
dog
one
larg
cohort
anoth
presenc
renal
diseas
high
peripher
neutrophil
lymphocyt
ratio
diagnosi
neg
indic
latter
report
despit
longterm
durabl
respons
treat
dog
mm
gener
uniformli
fatal
disord
drugresist
recurr
tumor
mass
associ
clinic
sign
expect
eventu
tumor
longer
respons
avail
chemotherapeut
death
follow
infect
renal
failur
euthanasia
intract
bone
spinal
pain
prognosi
mm
cat
favor
dog
said
approxim
cat
mm
respond
chemotherapi
although
older
compil
report
mst
approxim
month
sever
longterm
respons
ie
year
report
recent
compil
document
mst
month
treatment
one
investig
group
mm
cat
two
prognost
categori
tabl
base
criteria
known
predict
behavior
dog
although
rigor
statist
analysi
perform
small
group
nine
cat
mst
cat
aggress
nonaggress
categori
day
day
respect
experi
dog
igm
macroglobulinemia
limit
respons
chlorambucil
expect
nine
treat
dog
achiev
remiss
mst
month
solitari
collect
monoclon
plasmacyt
tumor
origin
soft
tissu
bone
refer
extramedullari
plasmacytoma
emp
solitari
osseou
plasmacytoma
sop
respect
system
multicentr
biolog
aggress
emp
syndrom
encount
cat
discuss
mm
section
receiv
limit
discuss
section
number
larg
case
compil
cutan
plasmacytoma
report
dog
common
locat
emp
dog
cutan
fig
mucou
membran
oral
caviti
lip
fig
gastrointestin
tract
skin
limb
head
includ
ear
frequent
report
cutan
site
oral
plasmacytoma
repres
oral
tumor
lingual
tumor
approxim
emp
emp
site
uncommonli
encount
includ
spleen
genitalia
eye
uteru
liver
larynx
trachea
third
eyelid
sinonas
caviti
one
case
report
cat
intracrani
site
american
cocker
spaniel
english
cocker
spaniel
west
highland
white
terrier
perhap
yorkshir
terrier
boxer
german
shepherd
airedal
terrier
report
inconsist
increas
risk
develop
plasmacytoma
median
age
affect
dog
year
age
aggress
hypercalcemia
presenc
boni
lesion
patholog
fractur
low
pack
cell
volum
pcv
presenc
lightchain
benc
jone
protein
urin
azotemia
hypercreatinemia
persist
high
serum
protein
level
week
treatment
littl
clinic
improv
less
aggress
normal
serum
calcium
normal
creatinin
blood
urea
nitrogen
pcv
level
presenc
boni
lesion
without
patholog
fractur
absenc
lightchain
benc
jone
protein
normal
serum
protein
level
week
treatment
cutan
oral
emp
dog
typic
benign
tumor
highli
amen
local
therapi
exist
howev
uncommon
form
multipl
cutan
plasmacytoma
absenc
mm
refer
cutan
plasmacytosi
dog
biolog
aggress
diseas
treatment
outcom
like
mm
three
dog
multipl
oral
plasmacytoma
report
local
aggress
metastas
dog
enjoy
longterm
surviv
surgic
excis
natur
behavior
noncutaneousnonor
emp
appear
somewhat
aggress
dog
gastrointestin
emp
report
number
occas
veterinari
literatur
includ
esophagu
stomach
small
larg
intestin
metastasi
associ
lymph
node
common
case
howev
bone
marrow
involv
monoclon
gammopathi
less
commonli
encount
colorect
emp
tend
low
biolog
aggress
recur
surgic
excis
convers
major
sop
eventu
progress
system
mm
howev
time
cours
local
tumor
develop
system
mm
may
mani
month
year
sop
report
dog
involv
appendicular
skeleton
well
zygomat
arch
rib
sop
less
common
cat
fewer
report
exist
literatur
occur
older
cat
mean
age
year
signific
sex
predilect
skin
common
site
howev
site
includ
oral
caviti
eye
gi
tract
liver
subcutan
tissu
brain
report
exist
cutan
emp
cat
progress
system
mrd
clinic
sign
associ
emp
sop
relat
locat
involv
rare
case
high
level
compon
hv
may
occur
cutan
plasmacytoma
solitari
smooth
rais
pink
variabl
alopec
nodul
cm
diamet
see
fig
although
tumor
larg
cm
report
combin
larg
seri
greater
occur
solitari
mass
less
occur
part
system
mm
process
cutan
oral
emp
usual
benign
cours
relat
clinic
sign
cutan
plasmacytosi
howev
associ
multipl
lesion
often
hundr
lesion
ulcer
present
asymptomat
present
gastrointestin
emp
typic
nonspecif
sign
may
suggest
alimentari
involv
one
dog
gi
emp
present
intussuscept
colorect
plasmacytoma
often
caus
rectal
bleed
hematochezia
tenesmu
rectal
prolaps
one
case
ataxia
seizur
activ
dog
emp
secondari
tumorassoci
hypoglycemia
report
sop
usual
associ
pain
lame
appendicular
skeleton
affect
neurolog
sign
vertebr
bodi
involv
diagnosi
sop
emp
usual
requir
tissu
biopsi
needl
aspir
cytolog
diagnosi
cell
make
solitari
plasmacyt
tumor
cat
dog
histolog
classifi
matur
hyalin
cleav
asynchron
monomorph
blastic
polymorph
blastic
cell
type
howev
prognost
signific
observ
classif
although
suggest
polymorphousblast
type
may
act
aggress
dog
diverg
pseudoglandular
histolog
subtyp
report
small
number
dog
may
confus
epitheli
neoplasia
intravascular
tumor
cell
observ
cutan
plasmacytoma
sampl
one
report
found
correl
outcom
behavior
benign
differ
classif
propos
emp
cat
base
percentag
plasmablast
prognost
import
document
case
poorli
differenti
plasmacyt
tumor
ihc
studi
direct
detect
immunoglobulin
light
heavi
chain
regulatori
thioflavin
may
help
differenti
round
cell
tumor
note
canin
cutan
histiocytoma
histiocyt
sarcoma
immunoreact
therefor
consid
differenti
immunoreact
demonstr
canin
igg
f
ab
vimentin
variant
character
iggreact
amyloid
interspers
neoplast
cell
also
describ
panel
monoclon
antibodi
recogn
tryptas
chymas
serotonin
mhc
class
ii
associ
histochem
stain
naphthol
asd
chloroacet
advoc
use
formalinfix
paraffinembed
section
cutan
round
cell
tumor
help
classifi
poorli
differenti
round
cell
tumor
mast
cell
tumor
histiocytoma
lymphoma
plasmacytoma
addit
clonal
immunoglobulin
heavi
chain
variabl
region
gene
perform
plasmacytoma
myeloma
use
pcr
technolog
may
diagnost
util
difficult
case
import
thoroughli
stage
dog
cat
plasmacytoma
higher
risk
system
spread
contempl
local
locoregion
therapi
without
system
therapi
includ
bone
marrow
aspir
cytolog
serum
electrophoresi
abdomin
ultrasound
skelet
survey
radiograph
ensur
diseas
confin
local
site
initi
therapi
sever
albeit
rare
instanc
monoclon
gammopathi
plasma
cell
leukemia
report
dog
cutan
plasmacytoma
cutan
plasmacytosi
gastrointestin
emp
stage
like
import
case
cutan
plasmacytosi
sop
gi
emp
due
rel
high
metastat
rate
less
import
cutan
oral
colorect
plasmacytoma
typic
benign
behavior
cutan
plasmacytosi
associ
lymph
node
abdomin
viscera
involv
approxim
case
howev
case
larg
compil
posit
bone
marrow
aspir
one
dog
monoclon
gammopathi
gi
emp
includ
colorect
emp
endoscop
evalu
entir
gi
tract
recommend
singl
case
report
use
petct
imag
extramedullari
splenic
plasmacytoma
dog
exist
howev
util
remain
unknown
cutan
oral
plasma
cell
tumor
dog
almost
alway
benign
carri
excel
prognosi
conserv
surgic
excis
except
cutan
plasmacytosi
excis
possibl
due
number
lesion
fact
case
document
system
diseas
system
chemotherapi
therefor
indic
dog
cutan
plasmacytosi
approxim
threequart
case
experienc
object
respons
either
melphalan
lomustin
median
progressionfre
overal
st
day
respect
emp
trachea
liver
uteru
also
report
dog
benign
cours
local
resect
success
therapi
melphalan
prednison
rare
appli
local
recurr
incomplet
margin
dog
cat
rt
use
infrequ
case
surgic
candid
includ
applic
plesiotherapi
lingual
plasmacytoma
dog
surgeri
recommend
combin
rt
case
sop
lesion
result
unstabl
long
bone
fractur
see
fig
patient
nonambulatori
neurolog
compromis
result
vertebr
bodi
sop
latter
case
spinal
cord
decompress
mass
excis
possibl
spinal
stabil
may
necessari
rt
use
alon
ie
without
surgeri
case
fractur
stabl
palli
measur
bone
pain
case
vertebr
sop
patient
ambulatori
stabl
good
local
control
usual
achiev
howev
progress
system
mm
sop
axial
skeleton
manag
excis
rt
alon
controversi
whether
system
chemotherapi
initi
time
local
therapi
sop
system
involv
document
system
spread
may
occur
mani
month
even
year
beyond
primari
sop
diagnosi
human
dog
studi
human
reveal
benefit
initi
system
chemotherapi
progress
system
diseas
two
case
sop
cat
recent
report
one
treat
externalbeam
rt
one
manag
melphalan
chemotherapi
enjoy
durabl
remiss
greater
year
similarli
emp
gi
tract
human
treat
commonli
surgic
excis
thorough
stage
diseas
system
therapi
initi
unless
system
involv
document
system
chemotherapi
use
gastric
emp
cat
howev
util
adjuv
therapi
speci
unknown
longterm
followup
patient
sop
indic
recogn
recurr
diseas
system
spread
care
attent
given
serum
globulin
level
bone
pain
radiograph
appear
bone
heal
case
sop
restag
diseas
includ
bone
marrow
evalu
indic
system
spread
suspect
prognosi
solitari
plasma
cell
tumor
gener
good
cutan
mucocutan
plasmacytoma
usual
cure
surgic
excis
larg
compil
case
dog
local
recurr
rate
approxim
nodal
distant
metastasi
occur
case
new
cutan
plasmacytoma
site
distant
primari
develop
fewer
case
neither
tumor
cell
prolifer
rate
measur
ihc
intravascular
tumor
infiltrationemboli
dog
histopatholog
grade
dog
cat
prognost
larg
compil
case
although
suggest
polymorphousblast
plasmablast
type
may
act
aggress
dog
cat
presenc
amyloid
overexpress
cyclin
prognost
human
plasmacytoma
shown
prognost
valu
dog
dog
emp
alimentari
tract
abdomin
organ
eg
liver
uteru
treat
surgic
excis
alon
combin
system
chemotherapi
metastasi
present
enjoy
longterm
surviv
major
case
compil
nine
dog
colorect
plasmacytoma
two
dog
local
recurr
month
surgeri
overal
mst
month
surgeri
alon
dna
ploidi
myc
oncoprotein
express
biopsi
sampl
determin
prognost
emp
dog
howev
malign
noncutan
site
ie
lymph
node
colon
spleen
therefor
locat
appear
predict
previous
discuss
major
case
sop
eventu
develop
system
diseas
howev
long
diseasefre
period
usual
preced
event
prognosi
cat
less
welldefin
pauciti
report
case
diseas
confin
local
site
region
node
surgic
excis
chemotherapi
result
longterm
control
howev
earli
widespread
metastasi
progress
mm
also
report
cat
